<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Topical microbicides for preventing sexually transmitted infections - Obiero, J - 2021 | Cochrane Library</title> <meta content="Topical microbicides for preventing sexually transmitted infections - Obiero, J - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007961.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Topical microbicides for preventing sexually transmitted infections - Obiero, J - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007961.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD007961.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Topical microbicides for preventing sexually transmitted infections" name="citation_title"/> <meta content="Jael Obiero" name="citation_author"/> <meta content="Institute of Primate Research" name="citation_author_institution"/> <meta content="obierojatina@yahoo.com" name="citation_author_email"/> <meta content="Paul Ogongo" name="citation_author"/> <meta content="Institute of Primate Research" name="citation_author_institution"/> <meta content="Peter G Mwethera" name="citation_author"/> <meta content="Institute of Primate Research" name="citation_author_institution"/> <meta content="Charles S Wiysonge" name="citation_author"/> <meta content="South African Medical Research Council" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD007961.pub3" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/03/13" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007961.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007961.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007961.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acrylic Resins [administration &amp; dosage]; Adenine [administration &amp; dosage, analogs &amp; derivatives]; Administration, Intravaginal; Agaricales [chemistry]; Anti-HIV Agents [administration &amp; dosage, adverse effects]; Anti-Infective Agents, Local [*administration &amp; dosage]; Bias; Cellulose [administration &amp; dosage, adverse effects, analogs &amp; derivatives]; HIV Infections [prevention &amp; control]; Naphthalenesulfonates [administration &amp; dosage]; Placebos [administration &amp; dosage]; Polymers [administration &amp; dosage]; Pyrimidines [administration &amp; dosage, adverse effects]; Seaweed [chemistry]; Sexually Transmitted Diseases [*prevention &amp; control]; Tenofovir [administration &amp; dosage, adverse effects]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007961.pub3&amp;doi=10.1002/14651858.CD007961.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007961.pub3&amp;doi=10.1002/14651858.CD007961.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007961.pub3&amp;doi=10.1002/14651858.CD007961.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007961.pub3&amp;doi=10.1002/14651858.CD007961.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007961.pub3&amp;doi=10.1002/14651858.CD007961.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007961.pub3&amp;doi=10.1002/14651858.CD007961.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007961.pub3&amp;doi=10.1002/14651858.CD007961.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007961.pub3&amp;doi=10.1002/14651858.CD007961.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007961.pub3&amp;doi=10.1002/14651858.CD007961.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007961.pub3&amp;doi=10.1002/14651858.CD007961.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007961.pub3&amp;doi=10.1002/14651858.CD007961.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007961.pub3&amp;doi=10.1002/14651858.CD007961.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007961.pub3&amp;doi=10.1002/14651858.CD007961.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007961.pub3&amp;doi=10.1002/14651858.CD007961.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007961.pub3&amp;doi=10.1002/14651858.CD007961.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007961.pub3&amp;doi=10.1002/14651858.CD007961.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007961.pub3&amp;doi=10.1002/14651858.CD007961.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007961.pub3&amp;doi=10.1002/14651858.CD007961.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007961.pub3&amp;doi=10.1002/14651858.CD007961.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007961.pub3&amp;doi=10.1002/14651858.CD007961.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007961.pub3&amp;doi=10.1002/14651858.CD007961.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007961.pub3&amp;doi=10.1002/14651858.CD007961.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007961.pub3&amp;doi=10.1002/14651858.CD007961.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="kKvAiZoF";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD007961\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD007961\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007961\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007961\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","th","ms","ja","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD007961.pub3",title:"Topical microbicides for preventing sexually transmitted infections",firstPublishedDate:"Mar 13, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane STI Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=kKvAiZoF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007961.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007961.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD007961.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD007961.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007961.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD007961.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD007961.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD007961.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD007961.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD007961.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3851 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD007961.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007961.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007961.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007961.pub3/full#CD007961-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007961.pub3/full#CD007961-sec-0084"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007961.pub3/full#CD007961-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007961.pub3/full#CD007961-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007961.pub3/full#CD007961-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007961.pub3/full#CD007961-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007961.pub3/full#CD007961-sec-0042"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007961.pub3/full#CD007961-sec-0078"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007961.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007961.pub3/appendices#CD007961-sec-0089"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007961.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007961.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/table_n/CD007961StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/table_n/CD007961StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007961.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007961.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007961.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007961.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007961.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD007961.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Topical microbicides for preventing sexually transmitted infections</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007961.pub3/information#CD007961-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Jael Obiero</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007961.pub3/information#CD007961-cr-0005">Paul Ogongo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007961.pub3/information#CD007961-cr-0006">Peter G Mwethera</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007961.pub3/information#CD007961-cr-0007">Charles S Wiysonge</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/information/en#CD007961-sec-0099">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 13 March 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD007961.pub3">https://doi.org/10.1002/14651858.CD007961.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD007961-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007961-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007961-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007961-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007961-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD007961-abs-0006">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007961-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD007961-abs-0001" lang="en"> <section id="CD007961-sec-0001"> <h3 class="title" id="CD007961-sec-0001">Background</h3> <p>This is a updated version of our Cochrane Review published in Issue 6, 2012. Sexually‐transmitted infections (STIs) continue to rise worldwide, imposing an enormous morbidity and mortality burden. Effective prevention strategies, including microbicides, are needed to achieve the goals of the World Heath Organization (WHO) global strategy for the prevention and control of these infections. </p> </section> <section id="CD007961-sec-0002"> <h3 class="title" id="CD007961-sec-0002">Objectives</h3> <p>To determine the effectiveness and safety of topical microbicides for preventing acquisition of STIs, including HIV. </p> </section> <section id="CD007961-sec-0003"> <h3 class="title" id="CD007961-sec-0003">Search methods</h3> <p>We undertook a comprehensive search of the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, LILACS, CLIB, Web of Science, <a href="http://ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a>, WHO International Clinical Trials Registry Platform, and reference lists of relevant articles up to August 2020. In addition, we contacted relevant organisations and experts. </p> </section> <section id="CD007961-sec-0004"> <h3 class="title" id="CD007961-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials of vaginal microbicides compared to placebo (except for nonoxynol‐9 because it is covered in related Cochrane Reviews). Eligible participants were sexually‐active non‐pregnant, WSM and MSM, who had no laboratory confirmed STIs. </p> </section> <section id="CD007961-sec-0005"> <h3 class="title" id="CD007961-sec-0005">Data collection and analysis</h3> <p>Two review authors independently screened and selected studies, extracted data, and assessed risks of bias in duplicate, resolving differences by consensus. We conducted a fixed‐effect meta‐analysis, stratified by type of microbicide, and assessed the certainty of the evidence using the GRADE approach. </p> </section> <section id="CD007961-sec-0006"> <h3 class="title" id="CD007961-sec-0006">Main results</h3> <p>We included eight trials from the earlier version of the review and four new trials, i.e. a total of 12 trials with 32,464 participants (all WSM). We did not find any eligible study that enrolled MSM or reported fungal STI as an outcome. We have no study awaiting assessment. </p> <p>All 12 trials were conducted in sub‐Saharan Africa, with one having a study site in the USA, and another having a site in India. Vaginal microbicides tested were BufferGel and PRO 2000 (1 trial, 3101 women), Carraguard (1 trial, 6202 women), cellulose sulphate (2 trials, 3069 women), dapivirine (2 trials, 4588 women), PRO 2000 (1 trial, 9385 women), C31G (SAVVY) (2 trials, 4295 women), and tenofovir (3 trials, 4958 women). All microbicides were compared to placebo and all trials had low risk of bias. </p> <p>Dapivirine probably reduces the risk of acquiring HIV infection: risk ratio (RR) 0.71, (95% confidence interval (CI) 0.57 to 0.89, I<sup>2</sup> = 0%, 2 trials, 4588 women; moderate‐certainty evidence). The other microbicides may result in little to no difference in the risk of acquiring HIV (low‐certainty evidence); including tenofovir (RR 0.83, 95% CI 0.68 to 1.02, cellulose sulphate (RR 1.20, 95% CI 0.74 to 1.95, BufferGel (RR 1.05, 95% CI 0.73 to 1.52), Carraguard (RR 0.89, 95% CI 0.71 to 1.11), PRO 2000 (RR 0.93, 95% CI 0.77 to 1.14), and SAVVY (RR 1.38, 95% CI 0.79 to 2.41). </p> <p>Existing evidence suggests that cellulose sulphate (RR 0.99, 95% CI 0.37 to 2.62, 1 trial, 1425 women), and PRO 2000 (RR 0.95, 95% CI 0.73 to 1.23) may result in little to no difference in the risk of getting herpes simplex virus type 2 infection (low‐certainty evidence). Two studies reported data on tenofovir's effect on this virus. One suggested that tenofovir may reduce the risk (RR 0.55, 95% CI 0.36 to 0.82; 224 participants) while the other did not find evidence of an effect (RR 0.94, 95% CI 0.85 to 1.03; 1003 participants). We have not reported the pooled result because of substantial heterogeneity of effect between the two studies (l<sup>2</sup> = 85%). </p> <p>The evidence also suggests that dapivirine (RR 1.70, 95% CI 0.63 to 4.59), tenofovir (RR 1.27, 95% CI 0.58 to 2.78), cellulose sulphate (RR 0.69, 95% CI 0.26 to 1.81), and (Carraguard (RR 1.07, 95% CI 0.75 to 1.52) may have little or no effect on the risk of acquiring syphilis (low‐certainty evidence). </p> <p>In addition, dapivirine (RR 0.97, 95% CI 0.89 to 1.07), tenofovir (RR 0.90, 95% CI 0.71 to 1.13), cellulose sulphate (RR 0.70, 95% CI 0.49 to 0.99), BufferGel (RR 0.97, 95% CI 0.65 to 1.45), Carraguard (RR 0.96, 95% CI 0.83 to 1.12), and PRO 2000 (RR 1.01, 95% CI 0.84 to 1.22) may result in little to no difference in the risk of acquiring chlamydia infection (low‐certainty evidence). </p> <p>The evidence also suggests that current topical microbicides may not have an effect on the risk of acquiring gonorrhoea, condyloma acuminatum, trichomoniasis, or human papillomavirus infection (low‐certainty evidence). Microbicide use in the 12 trials, compared to placebo, did not lead to any difference in adverse event rates. </p> <p>No study reported on acceptability of the intervention. </p> </section> <section id="CD007961-sec-0007"> <h3 class="title" id="CD007961-sec-0007">Authors' conclusions</h3> <p>Current evidence shows that vaginal dapivirine microbicide probably reduces HIV acquisition in women who have sex with men. Other types of vaginal microbicides have not shown evidence of an effect on acquisition of STIs, including HIV. Further research should continue on the development and testing of new microbicides. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD007961-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007961-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007961-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007961-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007961-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD007961-abs-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD007961-abs-0009">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD007961-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD007961-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD007961-abs-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007961-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD007961-abs-0002" lang="en"> <h3>Vaginal inserts for prevention of sexually transmitted infections</h3> <p><b>Review question</b> </p> <p>In this Cochrane Review we assessed the effects of topical microbicides (chemical substances that can be applied inside the vagina or rectum), compared to placebo (inactive substance), to prevent women who have sex with men and men who have sex with men from getting sexually‐transmitted infections (STIs), including HIV. </p> <p><b>Background</b> </p> <p>This is an updated version of our Cochrane Review published in 2012. Both curable and incurable STIs continue to rise, despite the prevention strategies implemented to date. Women often have the highest rates of STIs and account for a disproportionate number of new infections. STIs are often without symptoms. Despite their greater vulnerability, current options to reduce the spread of STI remain limited for women. There is thus a clear need for new and effective strategies to prevent people from getting STIs, including HIV. </p> <p><b>Trial characteristics</b> </p> <p>Cochrane researchers searched the available literature up to August 2020 and included 12 trials with 32,464 women who have sex with men. The trials included seven types of inserts (six vaginal gels and one vaginal ring) that were compared with placebo, all conducted among women aged over 16 years. All trials were conducted in sub‐Saharan Africa, with one having a study site in India and another having a site in the USA. The Cochrane researchers did not find any studies that were conducted among men who have sex with men. </p> <p><b>Key results</b> </p> <p>Compared with placebo, the rate of HIV infection was lower in the group that took vaginal inserts containing the antiretroviral drug known as dapivirine, but other STIs occurred at similar rates in dapivirine and placebo groups. Tenofovir gel may also reduce the rates of herpes simplex virus infection, but not other STIs. In addition, the cellulose sulphate gel resulted in lower rates of chlamydia infection, compared to placebo. When other microbicide gels were compared with placebo, could be little or no difference in the rates of STI. None of the trials reported fungal STI as outcome. </p> <p>Compared with placebo, the rate of HIV infection was lower in the group that took vaginal inserts containing the antiretroviral drug known as dapivirine, but other STIs occurred at similar rates in dapivirine and placebo groups. Tenofovir gel probably reduces the rates of herpes simplex virus infection, but not other STIs. Cellulose sulphate gel probably results in lower rates of chlamydia infection, compared to placebo. When other microbicide gels were compared with placebo, could be, there is little or no difference in the rates of STI. None of the trials reported fungal STI as outcome. </p> <p><b>Certainty of evidence</b> </p> <p>The certainty of evidence was low for most outcomes reported in this review, due to heterogeneity and small number of studies and participants for certain microbicides. This led to imprecision of the findings (ranging from large clinical benefits to substantial harm). </p> <p><b>How up‐to‐date is this review?</b> </p> <p>The review authors searched for studies that were published up to August 2020.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD007961-sec-0084" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD007961-sec-0084"></div> <h3 class="title" id="CD007961-sec-0085">Implications for practice</h3> <section id="CD007961-sec-0085"> <p>Current evidence shows that vaginal dapivirine microbicide probably reduces HIV acquisition in heterosexual women. Due to the very low quality of the evidence, the effects of tenofovir in the management of HSV and cellulose sulphate in the management of chlamydia infection are uncertain. Our review does not consider the use of any vaginal microbicide for preventing STIs. </p> </section> <h3 class="title" id="CD007961-sec-0086">Implications for research</h3> <section id="CD007961-sec-0086"> <p>Further high‐quality trials are needed to confirm the beneficial effects of microbicides containing dapivirine and tenofovir in vaginal sex. In addition, high‐quality research should continue on the development and testing of new topical microbicides. These trials should aim to explore the challenges experienced in the previous microbicide trials that led to the premature termination of some of the studies. Also, trials should aim to explore strategies for combining agents with different mechanisms of action to achieve synergistic or additive effects, such as maximized activity and broader spectrum of activity against STIs. As the evidence base grows, it would be helpful to conduct a network meta‐analysis to estimate the relative effectiveness and safety of the competing microbicide options. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD007961-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD007961-sec-0008"></div> <div class="table" id="CD007961-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Dapivirine vaginal microbicide for preventing sexually transmitted infections</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Topical microbicides for preventing sexually transmitted infections</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Population:</b> heterosexual women<br/><b>Settings:</b> Local clinics and community based locations in Malawi, South Africa, Uganda, and Zimbabwe (1 study) and South Africa and Uganda (1 study)<br/><b>Intervention:</b> dapivirine vaginal microbicide rings<br/><b>Comparison:</b> identical placebo rings </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty </b>of the evidence<br/>(GRADE) </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Dapivirine</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HIV infection</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>78 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>55 per 1000</b> </p> <p>(44 to 69)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.71</b> </p> <p>(0.57 to 0.89)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4588<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Herpes simplex virus</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Data not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The dapivirine studies did not screen for herpes simplex virus</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gonorrhoea</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>153 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>153 per 1000</b> </p> <p>(133 to 175)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b> <br/>(0.87 to 1.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4588<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>1,2</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trichomoniasis</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>144 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>153 per 1000</b> </p> <p>(133 to 177)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.06</b> </p> <p>(0.92 to 1.23)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4588<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Chlamydia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>293 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>285 per 1000</b> </p> <p>(261 to 314)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.97</b> </p> <p>(0.89 to 1.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4588</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>moderate</b><sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Syphilis</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>8 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>13 per 1000</b> </p> <p>(5 to 35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.70</b> </p> <p>(0.63 to 4.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1956</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>low<sup>3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>110 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>123 per 1000</b> </p> <p>(103 to 145)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.12</b> </p> <p>(0.94 to 1.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4588<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceptability</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>No study reported this outcome in a form that could be put in a forest plot</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Minor adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>No study reported this outcome in a form that could be put in a forest plot</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the risk in the placebo group is the median risk across control groups of the included studies. The corresponding risk for dapivirine (and its 95% confidence interval) is based on the median risk in the dapivirine group and the risk ratio of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by one level for imprecision, due to lack of optimal information size.<br/><sup>2</sup> Downgraded by one level for inconsistency: I<sup>2</sup> = 62% (gonorrhoea), I<sup>2</sup> = 87% (serious adverse events)<br/><sup>3</sup> Downgraded by two levels for substantial imprecision. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007961-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Tenofovir vaginal microbicide for preventing sexually transmitted infections</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Topical microbicides for preventing sexually transmitted infections</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Population:</b> Heterosexual women<br/><b>Settings:</b> Community clinics in South Africa (2 studies), Uganda and Zimbabwe (1 study)<br/><b>Intervention:</b> Tenofovir vaginal microbicide gels<br/><b>Comparison:</b> Identical placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty </b>of the evidence<br/>(GRADE) </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Tenofovir</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HIV infection</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>78 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>64 per 1000</b> </p> <p>(53 to 79)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.83</b> </p> <p>(0.68 to 1.02)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4958<br/>(3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Herpes simplex virus</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>426 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>384 per 1000</b> </p> <p>(350 to 422)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.90</b> </p> <p>(0.82 to 0.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2439<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>low</b><sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Gonorrhoea</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>48 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>24 per 1000</b> </p> <p>(14 to 39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.66</b> </p> <p>(0.40 to 1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2010<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>low<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trichomoniasis</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>51 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>62 per 1000</b> </p> <p>(43 to 64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.21</b> </p> <p>(0.84, 1.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2010<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Chlamydia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>129 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>116 per 1000</b> </p> <p>(22 to 145)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.90</b> </p> <p>(0.71 to 1.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2010<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Syphilis</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>11 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>14 per 1000</b> </p> <p><b>(6 to 30)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.27</b> </p> <p>(0.58 to 2.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2010<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>63 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>63 per 1000</b> </p> <p>(51 to 78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.00</b> </p> <p>(0.81 to 1.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4958<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝</p> <p><b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceptability</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>No study reported this outcome in a form that could be put in a forest plot</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Minor adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>No study reported this outcome in a form that could be put in a forest plot</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the risk in the placebo group is the median risk across control groups of the included studies. The corresponding risk for tenofovir (and its 95% confidence interval) is based on the median risk in the tenofovir group and the risk ratio of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by two levels for substantial imprecision, due to lack of optimal information size.<br/><sup>2</sup> Downgraded by two levels for substantial inconsistency: I<sup>2</sup> = 85%. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007961-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Cellulose sulphate vaginal microbicide for preventing sexually transmitted infections</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Topical microbicide for preventing sexually transmitted infections</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> Heterosexual women </p> <p><b>Settings:</b> Community clinics Nigeria (1 study), South Africa, Uganda, Benin and India (1 study) </p> <p><b>Intervention:</b> Cellulose sulphate vaginal gel </p> <p><b>Comparison:</b> Identical placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty </b>of the evidence<br/>(GRADE) </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Cellulose sulphate</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>HIV Infection</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>19 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>23 per 1000</b> </p> <p>(14 to 37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.2</b> </p> <p>(0.74 to 1.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3069<br/>(2 studies </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>low<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Herpes simplex</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>11 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>11 per 1000</b><br/>(4 to 30) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.99</b> </p> <p>(0.37 to 2.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1425<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>low<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Gonorrhoea</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>66 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>59 per 1000</b><br/>(44 to 77) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.89</b> <br/>(0.67 to 1.17) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3069<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/><b>very low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trichomoniasis</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>55 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>53 per 1000</b><br/>(34 to 82) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.96</b> <br/>(0.62 to 1.49) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1425<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Chlamydia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>48 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>34 per 1000</b><br/>(24 to 48) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.70</b> <br/>(0.49 to 0.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3069<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>low<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Syphilis</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>14 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>10 per 1000</b><br/>(4 to 26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.69</b> <br/>(0.26 to 1.81) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1425<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>low<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>33 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>42 per 1000</b> </p> <p>(29 to 60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.25</b> </p> <p>(0.87 to 1.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3069<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceptability</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>No study reported this outcome in a form that could be put in a forest plot</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Minor adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>No study reported this outcome in a form that could be put in a forest plot</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the risk in the placebo group is the median risk across control groups of the included studies. The corresponding risk for cellulose sulphate (and its 95% confidence interval) is based on the median risk in the cellulose sulphate group and the risk ratio of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by two levels for substantial imprecision, due to lack of optimal information size<br/><sup>2</sup> Downgraded by one level for inconsistency: I<sup>2</sup> = 50% </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD007961-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD007961-sec-0009"></div> <p>This is an updated version of the original Cochrane review published in Issue 6, 2012 (<a href="./references#CD007961-bbs2-0085" title="ObieroJ , MwetheraPG , WiysongeCS . Topical microbicides for prevention of sexually transmitted infections. Cochrane Database of Systematic Reviews2012, Issue 6. Art. No: CD007961. [DOI: 10.1002/14651858.CD007961.pub2]">Obiero 2012a</a>) </p> <section id="CD007961-sec-0010"> <h3 class="title" id="CD007961-sec-0010">Description of the condition</h3> <p>Sexually‐transmitted infections (STIs) refer to a variety of clinical syndromes and infections caused by pathogens that can be acquired and transmitted through sexual activity (<a href="./references#CD007961-bbs2-0033" title="CDC 2015. Sexually transmitted diseases treatment guidelines, 2015. www.cdc.gov/mmwr/preview/mmwrhtml/rr6403a1.htm.">CDC 2015</a>). STIs are common global causes of illness, long‐term disability, and death with serious medical and psychological consequences for millions of people (<a href="./references#CD007961-bbs2-0056" title="NewmanL , RowleyJ , Vander HoornS , WijesooriyaNS , UnemoM , LowN , et al. Global estimates of the prevalence and Incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. PloS One2015;10(12):e0143304.">Newman 2015</a>). They have far‐reaching health, social, and economic consequences in countries and communities where socio‐economic conditions are poor (<a href="./references#CD007961-bbs2-0069" title="TsaiCA , HungJK , WeiserDS . Is food insecurity associated with HIV risk? cross-sectional evidence from sexually active women in Brazil. PLoS Medicine.2012;9(4):e1001203.">Tsai 2012</a>; <a href="./references#CD007961-bbs2-0071" title="VogenthalerSN , KushelBM , CraigH , Frongillo JrAE , Riley DE BangsbergRD , et al. Food insecurity and risky sexual behaviours among homeless and marginally housed HIV-Infected individuals in San Francisco. AIDS Behaviour2013;17(5):1688-93.">Vogenthaler 2013</a>).There are over 30 bacterial, viral, and parasitic pathogens that can be transmitted sexually. According to 2008 World Health Organization (WHO) estimates, 499 million new curable cases of the four most common curable infections, chlamydia, gonorrhoea, syphilis and trichomoniasis, occur annually throughout the world (<a href="./references#CD007961-bbs2-0077" title="World Health Organization. Global incidence and prevalence of selected sexually transmitted infections–2008. www.who.int/reproductivehealth/publications/rtis/stisestimates/en/ (accessed 02 June 2018).">WHO 2012</a>). In addition, over 500 million people are estimated to have a viral STI such as herpes simplex virus type 2 (HSV‐2) or human papillomavirus (HPV) at any point in time (<a href="./references#CD007961-bbs2-0041" title="GottliebSL , LowN , NewmanLM , BolanG , KambM , BrouteN . Toward global prevention of sexually transmitted infections (STIs): The need for STI vaccines. Vaccine2014;34:1527–35.">Gotlieb 2014</a>). In the developed world, viral infections have become increasingly common and important, whereas bacterial STIs are more common in low‐ and middle‐income countries, but even this is changing with the increasing recognition of viral infections (<a href="./references#CD007961-bbs2-0029" title="AdlerM , Cowan, F, FrenchP , MitchellL , RichensJ . ABC of Sexually Transmitted Infections, Fifth Edition. BMJ Publishig Group, 2004.">Adler 2004</a>). </p> <p>The three most common presenting symptoms of an STI are urethral discharge, genital ulceration and vaginal discharge with or without vulval irritation (<a href="./references#CD007961-bbs2-0066" title="SonkarSC , WasnikK , KumarA , SharmaV , MittalP , MishraPK , et al. Evaluating the utility of syndromic case management for three sexually transmitted infections in women visiting hospitals in Delhi, India. Scientific Reports2017;7(1):1465.">Sonkar 2017</a>), Assymptomatic STIs (<i>C. trachomatis</i> , <i>N. gonorrhoea</i> and syphilis are more frequent in women than in men and in women the risk of complications and sequels are higher and also there is the risk of maternal to child transmission (<a href="./references#CD007961-bbs2-0059" title="OakeshottP , KerryS , AghaizuA , AthertonH , HayS , Taylor-RobinsonD , et al. Randomised controlled trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: the POPI (prevention of pelvic infection) trial. BMJ2010;340:c1642.">Oakeshott 2010</a>; <a href="./references#CD007961-bbs2-0073" title="WasserheitJN . The significance and scope of reproductive tract infections among third world women. International Journal of Gynecology and Obstetrics1989;Suppl 3:145-68.">Wasserheit 1989</a>: <a href="./references#CD007961-bbs2-0076" title="World Health Organization. Global strategy for the prevention and control of sexually transmitted infections: 2006–2015: Breaking the chain of transmission. apps.who.int/iris/bitstream/handle/10665/69361/WHO_RHR_06.10_eng.pdf;jsessionid=76C8F0A1DD8BEEDE7B3B675018C3E3C1?sequence=1 2007 (accessed 02 June 2018).">WHO 2007</a>:<a href="./references#CD007961-bbs2-0080" title="World Health Organization. Treatment of Trepanoma pallidum. apps.who.int/iris/bitstream/10665/249572/1/9789241549806-eng.pdf (accessed 08 June 2018).">WHO 2016</a>; <a href="./references#CD007961-bbs2-0072" title="WalkerGJA , WalkerDG . Congenital syphilis: A continuing but neglected problem. Seminars in Fetal &amp; Neonatal Medicine2007;12:198-206.">Walker 2007</a>). STIs also frequently result in stigma due to their sexual nature of transmission, stereotyping and vulnerability, and have been associated with gender‐based violence (<a href="./references#CD007961-bbs2-0030" title="AminA , Garcia MorenoC . Addressing gender-based violence to reduce risk of STI and HIV. Sexually Transmitted Infections.2013;89:A8.">Amin 2013</a>). Often, screening and treatment are not given priority within public health services, nor do STIs receive the political, socio‐economic and cultural attention they warrant (<a href="./references#CD007961-bbs2-0060" title="OrtayliN , RingheimK , CollinsL , SladdenT . Sexually transmitted infections: progress and challenges since the 1994 International Conference on Population and Development (ICPD). Contraception2014;90:(6 Suppl):S22-31.">Ortayli 2014</a>). Clinical symptoms of STIs can be non‐specific, and where possible the diagnosis needs to be confirmed by laboratory testing (<a href="./references#CD007961-bbs2-0039" title="Gaitán-DuarteHG , Rodríguez-HernándezAE , Arévalo-RodríguezI , Angel-MüllerE , López-RamosHE , Estrada-Mesa, JS, et al. Clinical practice guideline for syndromic management of patients with sexually transmitted infections and other genital tract infections. Revista Colombia Obstetrics and Gynecology2013;64:126-77.">Gaitán‐Duarte 2013</a>). Current STI control is hampered by several behavioural, biological and implementation challenges including a large proportion of asymptomatic infections, lack of feasible diagnostic tests, antimicrobial resistance, repeat infections and barriers to intervention access, availability and scale‐up (<a href="./references#CD007961-bbs2-0060" title="OrtayliN , RingheimK , CollinsL , SladdenT . Sexually transmitted infections: progress and challenges since the 1994 International Conference on Population and Development (ICPD). Contraception2014;90:(6 Suppl):S22-31.">Ortayli 2014</a>). In low and middle income countries, laboratory testing is not always available and women and men reporting symptoms suggestive of an STI are often treated according to algorithms without confirmatory tests (<a href="./references#CD007961-bbs2-0068" title="Trollope-KumarK , GuyattG . Syndromic approach for treatment of STIs: time for a change. Lancet2006;367(9520):1380-1.">Trollope‐Kumar 2006</a>). This approach is effective for certain infections such as male urethritis and genital ulcers, but with vaginal discharge the risk of misdiagnosis is high (<a href="./references#CD007961-bbs2-0065" title="SonkarSC , WasnikK , KumarA , MittalP , SalujaD . Comparative analysis of syndromic and PCR-based diagnostic assay reveals misdiagnosis/ overtreatment for trichomoniasis based on subjective judgment in symptomatic patients. Infectious Diseases of Porvety2016;5:42.">Sonkar 2016</a>). Syndromic management of STI can therefore lead to over‐treatment and adverse social consequences such as stigma and intimate partner violence (<a href="./references#CD007961-bbs2-0074" title="WhiteRG , MoodleyP , McGrathN , HosegoodV , ZabaBK , HerbstK , et al. Low effectiveness of syndromic treatment services for curable sexually transmitted infections in rural South Africa. Sexually Transmitted Infections2008;84(7):528-34.">White 2008</a>). In addition, it misses asymptomatic infections, which are by far the greatest burden of disease (<a href="./references#CD007961-bbs2-0078" title="World Health Organization. Sexually transmitted infections (STIs). apps.who.int/iris/bitstream/handle/10665/82207/WHO_RHR_13.02_eng.pdf?sequence=1 (accessed 02 June 2018).">WHO 2013a</a>). </p> <p>The rising trend and complications of the infections suggest limited impact of prevention approaches to date (<a href="./references#CD007961-bbs2-0070" title="UNAIDS. Global report: UNAIDS report on the global AIDS epidemic 2010. UNAIDS/10.11E/JC1958E. www.unaids.org/globalreport/documents/20101123_GlobalReport_Foreword_em.pdf (accessed 02 June 2018).">UNAIDS 2010</a>; <a href="./references#CD007961-bbs2-0079" title="World Health Organization. The importance of a renewed commitment to STI prevention and control in achieving global sexual and reproductive health. apps.who.int/iris/handle/10665/75838?mode=full (accessed 02 June 2018).">WHO 2013b</a>). Both male and female condoms have been considered one of the most effective biological mechanisms for reducing the transmission of STIs (<a href="./references#CD007961-bbs2-0052" title="MatsonPA , AdlerNE , MillsteinSG , TschannJM , EllenJM . Developmental changes in condom use among urban adolescent females: influence of partner context. Journal of Adolescent Health2011;48(4):386–90.">Matson 2011</a>). However, the positive impact of their use may be affected by inconsistent and incorrect use. In addition, several factors are known to be associated with low uptake of this method, including perception of reduced pleasure (<a href="./references#CD007961-bbs2-0062" title="SarkarNN . Barriers to condom use. European Journal of Contraception and Reprodive Health Care2008;13(2):114-22.">Sarkar 2008</a>), discomfort (<a href="./references#CD007961-bbs2-0034" title="CrosbyR , YarberWL , SandersSA , GrahamCA . Condom discomfort and associated problems with their use among university students. Journal of American College Health2005;54(3):143-7.">Crosby 2005</a>), partner trust (<a href="./references#CD007961-bbs2-0027" title="AbdullahAS , FieldingR , HedleyAJ , EbrahimSH , LukYK . Reasons for not using condoms among the HongKong Chinese population: implications for HIV and STD prevention. Sexually Transmitted Infections2002;78(3):180-4.">Abdullah 2002</a>), religious beliefs (<a href="./references#CD007961-bbs2-0067" title="ThomsenS , StalkerM , Toroitich-RutoC . Fifty ways to leave your rubber: how men in Mombasa rationalise unsafe sex. Sexually Transmitted Infections2004;80(6):430-4.">Thomsen 2004</a>), availability and accessibility (<a href="./references#CD007961-bbs2-0050" title="KumarGA , DandonaR , GutierrezJP , McPhersonS , BertozziSM , DandonaL . Access to condoms for female sex workers in Andhra Pradesh. National Medical Journal of India2006;19(6):306-12.">Kumar 2006</a>), existing inequalities in gender‐based norms and values (<a href="./references#CD007961-bbs2-0053" title="MayaudP , McComickD . The changing face of HIV and AIDS. British Medical Bulletin2001;58:129-53.">Mayaud 2001</a>), cost (<a href="./references#CD007961-bbs2-0038" title="EssienE , MeshackA , PetersR , OgungbadeG , OsemeneN . Strategies to prevent HIV transmission among heterosexual African-American men. BMC Public Health2005;5:3.">Essien 2005</a>), women's lack of empowerment (<a href="./references#CD007961-bbs2-0062" title="SarkarNN . Barriers to condom use. European Journal of Contraception and Reprodive Health Care2008;13(2):114-22.">Sarkar 2008</a>), and negative community attitudes towards homosexuality combined with legal restrictions among MSM (<a href="./references#CD007961-bbs2-0028" title="AdimoraAA , AuerbachJD . Structural interventions for HIV prevention in the United States. Journal of AcquiredImmune Deficiency Syndromes2010;55(S132–5):1525–4135.">Adimora 2010</a>). </p> </section> <section id="CD007961-sec-0011"> <h3 class="title" id="CD007961-sec-0011">Description of the intervention</h3> <p>Microbicides are compounds that can be applied inside the vagina or rectum to protect against STIs including HIV (<a href="./references#CD007961-bbs2-0064" title="SmritiN , MarfatiaYS , PrasadTL . Microbicides and HIV: A Review and an update. Indian Journal of Sexually Transmitted Diseases2012;33(2):81-90.">Smriti 2012</a>; <a href="./references#CD007961-bbs2-0075" title="World Health Organization. Microbicides. www.who.int/hiv/topics/microbicides/microbicides/en/ (accessed 02 June 2018).">WHO 2000</a>). They can be formulated as gels, creams, films, rings, sponges or suppositories (<a href="./references#CD007961-bbs2-0051" title="LopezLM , GreyTW , ChenM , DenisonJ , StuartG . Behavioral interventions for improving contraceptive use among women living with HIV. Cochrane Database of Systematic Reviews2016, Issue 8. Art. No: CD010243. [DOI: 10.1002/14651858.CD010243.pub3]">Lopez 2016</a>; <a href="./references#CD007961-bbs2-0063" title="SinghO , GargT , RathG , GoyalAK . Microbicides for the treatment of sexually transmitted HIV Infections. Journal of Pharmceutics2014;2014:1-18.">Singh 2014</a>). Microbicides would greatly empower women and men who have sex with men (MSM) to protect themselves, as they are a potential preventive option that they can easily control and do not require the co‐operation, consent or even knowledge of the partner. Microbicides may or may not have spermicidal activity (contraceptive effect). An ideal microbicide would be safe and effective against a range of STI‐causing organisms, available in both spermicidal and non‐spermicidal formulations, effective over relatively long periods, acceptable to potential users, bio‐diffusible, bio‐adhesive, can be effective immediately, are stable at high temperatures and economically affordable in middle‐ and low‐income countries (<a href="./references#CD007961-bbs2-0044" title="HanL , LvF , XuP , ZhangG , JuniperNS , WuZ . Microbicide acceptability among female sex workers in Beijing, China:results from a pilot study.. Journal of Womens Health (Larchmt)2009;18(9):1377-84.">Han 2009</a>). Microbicides that have been developed include vaginal gels and rings. The microbicides are applied intravaginally or rectally before or before and after each sexual episode (<a href="./references#CD007961-bbs2-0001" title="Abdool KarimQ , Abdool KarimSS , FrohlichJA , GroblerAC , BaxterC , MansoorEL , et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science2010;329(5996):1168-74. Abdool KarimSS , Abdool KarimQ , KharsanyAB , BaxterC , GroblerAC , WernerL . Tenofovir gel for the prevention of herpes simplex virus type 2 infection. New England Journal of Medicine 20152015;373(6):530-9. KarimQA , KharsanyAB , FrohlichJA , BaxterC , YendeN , MansoorLE , et al. Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials2011;12:67. KellerDM . AIDS 2010, XVIII International AIDS Conference: Tenofovir vaginal gel first microbicide to prevent HIV, HSV infections. Medscape Medical News July 2010. ">Abdool Karim 2010</a>; <a href="./references#CD007961-bbs2-0005" title="FeldblumPJ , AdeigaA , BakareR , WevillS , LendvayA , ObadakiF , et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomised controlled trial in Nigeria. PLoS One2008;3(1):e1474. ">Feldblum 2008</a>), The rings are slow‐release devices that are effective for a longer period of time (<a href="./references#CD007961-bbs2-0003" title="BaetenJM , Palanee-PhillipsT , BrownER , SchwartzK , Soto-TorresLE , GovenderV , et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. New England Journal of Medicine2016;375(22):2121-32. MTN 2016. Dapivirine vaginal ring helped protect women against HIV in ASPIRE Phase lll trial. Media release. ">Baeten 2016</a>). </p> </section> <section id="CD007961-sec-0012"> <h3 class="title" id="CD007961-sec-0012">How the intervention might work</h3> <p>The principal target of microbicides is to reduce male‐to‐female and male‐to‐male STI transmission, although they could also potentially prevent female‐to‐male transmission. Topical microbicides are grouped based on their mode and site of action (<a href="./references#CD007961-bbs2-0035" title="CutlerB , JustmanJ . Vaginal microbicides and the prevention of HIV transmission. Lancet Infectious Diseases2008;8(11):685-97.">Cutler 2008</a>); They include: </p> <p><b>Surfactants:</b> These are detergent‐like products that disrupt cell membranes or change membrane structure, which make it more porous and liable to disruption. These products are non‐specific and impact on all cells (host, commensal.and pathogen). Hence these products have a wide spectrum of activity against several microbes, spermatozoa and cell membranes, e.g. SAVVY and nonoxynol‐9 (<a href="./references#CD007961-bbs2-0010" title="PetersonL , NandaK , OpokuBK , AmpofoWK , Owusu-AmoakoM , BoakyeAY , et al. SAVVY (C31G) gel for prevention of HIV infection in women: a phase 3, double-blind, randomised, placebo-controlled trial in Ghana. PLoS One2007;2(12):e1312. ">Peterson 2007</a>; <a href="./references#CD007961-bbs2-0081" title="WilkinsonD , RamjeeG , TholandiM , RutherfordG . Nonoxynol-9 for preventing vaginal acquisition of sexually transmitted infections by women from men. Cochrane Database of Systematic Reviews2002, Issue 1. Art. No: CD003939. [DOI: 10.1002/14651858.CD003939]">Wilkinson 2002a</a>; <a href="./references#CD007961-bbs2-0082" title="WilkinsonD , RamjeeG , TholandiM , RutherfordG . Nonoxynol-9 for preventing vaginal acquisition of HIV infection by women from men. Cochrane Database of Systematic Reviews2002, Issue 3. Art. No: CD003936. [DOI: 10.1002/14651858.CD003936]">Wilkinson 2002b</a>). </p> <p><b>Vaginal defence enhancers:</b> These are acid‐buffering agents that assist the natural immune defences of the vagina to deactivate the pathogen. They augment vaginal mucosal defence by increasing microbicidal activity of genital secretions. Lactic acid bacteria, notably lactobacilli, occur naturally in the vagina and release a variety of antimicrobial compounds such as lactic acid, hydrogen peroxide, bacteriocins and bio‐surfactants. A disruption of the natural balance of the vaginal ecosystem raises the risk of STI infection. The vagina is usually maintained at a low pH of about 4 to 5, which is achieved through secretion of lactic acid bacteria. These microbicides maintain the colonisation or re‐colonisation of the vagina with lactobacilli when these commensal organisms have been adversely affected, for example by use of antibiotics or reproductive tract infections. They also assist the vagina to maintain low pH in the presence of alkaline semen, the effect of which on the vaginal pH results in the loss of barrier to pathogens, e. g. Buffergel (<a href="./references#CD007961-bbs2-0002" title="Abdool KarimSS , RichardsonBA , RamjeeG , HoffmanIF , ChirenjeZM , TahaT , et al. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS2011;25(7):957-66. GuffeyMB , RichardsonB , HusnikM , MakananiB , ChilongoziD , YuE , et al. HPTN 035 Phase II/IIb Randomized safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in women. Sexually Transmitted Infections2014;90(5):1-15. ">Abdool Karim 2011</a>; <a href="./references#CD007961-bbs2-0048" title="KellerMJ , CarpenterCA , LoY , EinsteinMH , LiuC , FredricksDN , et al. Phase I randomized safety study of twice daily dosing of acid form vaginal gel: candidate antimicrobial contraceptive. PLOS One2012;7:10:e46901.">Keller 2012</a>). </p> <p><b>Entry inhibitors:</b> This class of microbicide agents blocks the attachment of the pathogen to the host cell, fusion with the host‐cell membrane or entry into the host cells. They are polymers that act against viruses, predominantly by interfering with attachment to host cells. The envelope of HIV, particularly the gp41 component, which enables fusion with the cell membrane, is a critical target for a potentially successful microbicide. Polymers act by blocking viral entry into susceptible cells by blocking CD4 attachment or receptor attachment, or both, e.g. Carragurard and Pro2000 (<a href="./references#CD007961-bbs2-0002" title="Abdool KarimSS , RichardsonBA , RamjeeG , HoffmanIF , ChirenjeZM , TahaT , et al. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS2011;25(7):957-66. GuffeyMB , RichardsonB , HusnikM , MakananiB , ChilongoziD , YuE , et al. HPTN 035 Phase II/IIb Randomized safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in women. Sexually Transmitted Infections2014;90(5):1-15. ">Abdool Karim 2011</a>; <a href="./references#CD007961-bbs2-0011" title="MaraisD , GawareckiD , AllanB , AhmedK , AltiniL , CassimN , et al. The effectiveness of Carraguard, a vaginal microbicide, in protecting women against high-risk human papillomavirus infection. Antiviral Therapy2011;16(8):1219-26. Skoler-KarpoffS , RamjeeG , AhmedK , AltiniL , PlagianosMG , FriedlandB , et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9654):1977-87. ">Skoler‐Karpoff 2008</a>). </p> <p><b>Agents that prevent replication of the pathogen after it has entered the cell:</b> These are antiretroviral drugs developed as microbicides because of their capacity to inhibit the replication process of the pathogen. They act locally in the reproductive tract mucosa at specific steps in the replication cycle of the pathogen and therefore have a narrow spectrum against viruses, notably HIV, e.g. tenofovir (<a href="./references#CD007961-bbs2-0001" title="Abdool KarimQ , Abdool KarimSS , FrohlichJA , GroblerAC , BaxterC , MansoorEL , et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science2010;329(5996):1168-74. Abdool KarimSS , Abdool KarimQ , KharsanyAB , BaxterC , GroblerAC , WernerL . Tenofovir gel for the prevention of herpes simplex virus type 2 infection. New England Journal of Medicine 20152015;373(6):530-9. KarimQA , KharsanyAB , FrohlichJA , BaxterC , YendeN , MansoorLE , et al. Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials2011;12:67. KellerDM . AIDS 2010, XVIII International AIDS Conference: Tenofovir vaginal gel first microbicide to prevent HIV, HSV infections. Medscape Medical News July 2010. ">Abdool Karim 2010</a>; <a href="./references#CD007961-bbs2-0004" title="Delany-MoretlweS , LombardC , BaronD , BekkerLG , NkalaB , Ahmed K et al. Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised,double-blind, placebo-controlled trial. The Lancet Infectious Diseases2018;18(11):1241-50. ReesHS , SineadA , Delany- MoretiwaS , BaronD , PachiaR , et al. In: FACTS 001 Phase III Trial of Pericoital Tenofovir 1% Gel for HIV Prevention in Women.The 22nd Conference on Retroviruses and Opportunistic Infections;2015 Feb 23-26; Seattle Washington. 2015. ">Delany‐Moretlwe 2018</a>) and dapivirine (<a href="./references#CD007961-bbs2-0003" title="BaetenJM , Palanee-PhillipsT , BrownER , SchwartzK , Soto-TorresLE , GovenderV , et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. New England Journal of Medicine2016;375(22):2121-32. MTN 2016. Dapivirine vaginal ring helped protect women against HIV in ASPIRE Phase lll trial. Media release. ">Baeten 2016</a>). </p> </section> <section id="CD007961-sec-0013"> <h3 class="title" id="CD007961-sec-0013">Why it is important to do this review</h3> <p>Despite the greater vulnerability of women and of men who have sex with men, current options to reduce acquisition of STI remain limited for women and men who are receptive partners during anal sex (<a href="./references#CD007961-bbs2-0057" title="NunesR , SarmentoB , Das NevesJ . Formulation and delivery of anti-HIV rectal microbicides: advances and challenges. Journal of Control Release2014;194:278-94.">Nunes 2014</a>). There is a clear need for new and effective prevention strategies that women and MSM can use and control to reduce their risk of sexual acquisition of STIs. In the absence of a definitive cure or preventative vaccine, microbicides could offer an alternative or a complement to condoms as the most feasible method for primary prevention of STIs. </p> <p>A registered vaginal or rectal microbicide is not yet available, despite the fact that over 60 candidate agents have been identified which have in vitro activity against STIs (<a href="./references#CD007961-bbs2-0063" title="SinghO , GargT , RathG , GoyalAK . Microbicides for the treatment of sexually transmitted HIV Infections. Journal of Pharmceutics2014;2014:1-18.">Singh 2014</a>). Some of the microbicides have already undergone large‐scale phase lll trials (<a href="./references#CD007961-bbs2-0085" title="ObieroJ , MwetheraPG , WiysongeCS . Topical microbicides for prevention of sexually transmitted infections. Cochrane Database of Systematic Reviews2012, Issue 6. Art. No: CD007961. [DOI: 10.1002/14651858.CD007961.pub2]">Obiero 2012a</a>). There is thus a need for a comprehensive and up‐to‐date synthesis of this evidence. This Cochrane Review is an update of one published in 2012 (<a href="./references#CD007961-bbs2-0085" title="ObieroJ , MwetheraPG , WiysongeCS . Topical microbicides for prevention of sexually transmitted infections. Cochrane Database of Systematic Reviews2012, Issue 6. Art. No: CD007961. [DOI: 10.1002/14651858.CD007961.pub2]">Obiero 2012a</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD007961-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD007961-sec-0014"></div> <p>To determine the effectiveness and safety of topical microbicides for preventing acquisition of STIs, including HIV. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD007961-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD007961-sec-0015"></div> <section id="CD007961-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD007961-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs), which followed up participants for at least 12 months. We exclude quasi‐randomised trials because these produce effect estimates that indicate more extreme benefits when they are compared with randomised trials (<a href="./references#CD007961-bbs2-0046" title="HigginsJPT , ThomasJ , (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated August 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Higgins 2019</a>). We exclude cross‐over and cluster trials, because of the nature of the condition and intervention (<a href="./references#CD007961-bbs2-0046" title="HigginsJPT , ThomasJ , (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated August 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Higgins 2019</a>). The unit of randomisation was the individual. </p> </section> <section id="CD007961-sec-0018"> <h4 class="title">Types of participants</h4> <p>Eligible participants were sexually active non‐pregnant heterosexual women (i.e. WSM), and men who have sex with men (MSM), aged 16 years and above in any setting, who had no laboratory‐confirmed STIs at baseline. </p> </section> <section id="CD007961-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Eligible interventions were topical microbicides including detergent‐like products (surfactants) , vaginal defence enhancers, entry inhibitors, and agents that prevent replication of the pathogen after it has entered the host cell. We performed meta‐analyses separately for each STI, according to the assessed intervention based on its mechanism of action. We excluded nonoxynol‐9 because it is covered in other Cochrane Reviews (<a href="./references#CD007961-bbs2-0081" title="WilkinsonD , RamjeeG , TholandiM , RutherfordG . Nonoxynol-9 for preventing vaginal acquisition of sexually transmitted infections by women from men. Cochrane Database of Systematic Reviews2002, Issue 1. Art. No: CD003939. [DOI: 10.1002/14651858.CD003939]">Wilkinson 2002a</a>; <a href="./references#CD007961-bbs2-0082" title="WilkinsonD , RamjeeG , TholandiM , RutherfordG . Nonoxynol-9 for preventing vaginal acquisition of HIV infection by women from men. Cochrane Database of Systematic Reviews2002, Issue 3. Art. No: CD003936. [DOI: 10.1002/14651858.CD003936]">Wilkinson 2002b</a>). Eligible comparison interventions Included: placebo, no intervention, condom, diaphragm, vaginal sponge, and cervical cap. However, we did not find studies that compared microbicides with other active interventions. </p> </section> <section id="CD007961-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD007961-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD007961-list-0001"> <li> <p>Laboratory confirmed incidence of STIs (viral, bacterial, fungal, protozoan). We reported the laboratory methods used for measurement of the outcomes included. </p> </li> <li> <p>Serious adverse events, i.e. the proportion of participants who experience any adverse effect requiring hospitalisation or discontinuation of therapy, or both. </p> </li> </ul> </p> </section> <section id="CD007961-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD007961-list-0002"> <li> <p>Acceptability, i.e. proportion of participants that tolerated or allowed the intervention.</p> </li> <li> <p>Minor adverse events, e.g. vaginal discharge, burning sensation, genital pain, rash, ulceration, erythema, vaginitis. </p> </li> </ul> </p> </section> </section> </section> <section id="CD007961-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>We attempted to identify as many relevant randomised trials as possible of "topical microbicide", irrespective of language of publication or publication status (published or unpublished). We used both electronic searching in bibliographic databases and handsearching, as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007961-bbs2-0046" title="HigginsJPT , ThomasJ , (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated August 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Higgins 2019</a>) </p> <section id="CD007961-sec-0024"> <h4 class="title">Electronic searches</h4> <p>With the assistance of the Information Specialist of the Cochrane Sexually Transmitted Infections Group, we implemented a comprehensive search strategy to identify as many relevant trials as possible in electronic databases. We used a combination of controlled vocabulary (MeSH, Emtree, DeCS, including exploded terms) and free‐text terms (considering spelling variants, synonyms, acronyms and truncation) for topical microbicides, with field labels, proximity operators, and boolean operators.  </p> <p>For the initial version of the review published in 2012 (<a href="./references#CD007961-bbs2-0085" title="ObieroJ , MwetheraPG , WiysongeCS . Topical microbicides for prevention of sexually transmitted infections. Cochrane Database of Systematic Reviews2012, Issue 6. Art. No: CD007961. [DOI: 10.1002/14651858.CD007961.pub2]">Obiero 2012a</a>), we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (1980 to 22 July 2011), MEDLINE (1980 to July 2011), Embase (1980 to July 2011), Web of Science (1980 to May 2009), LILACS (1980 to May 2009), NML Gateway (1980 to December 2009), WHO International Clinical Trials Registry Platform (ICTRP: <a href="http://www.who.int/ictrp/search/en/" target="_blank">www.who.int/ictrp/search/en/</a>) (22 July 2011), and <a href="http://clinicalTrials.gov" target="_blank">ClinicalTrials.gov</a> (22 July 2011).  </p> <p>For this review update, we conducted searches between June 2015 and August 2020 (<a href="./appendices#CD007961-sec-0090">Appendix 1</a>; <a href="./appendices#CD007961-sec-0091">Appendix 2</a>; <a href="./appendices#CD007961-sec-0092">Appendix 3</a>; <a href="./appendices#CD007961-sec-0093">Appendix 4</a>: <a href="./appendices#CD007961-sec-0094">Appendix 5</a>; <a href="./appendices#CD007961-sec-0095">Appendix 6</a>) in MEDLINE, Embase, LILACS, Web of Science, ICTRP, <a href="http://ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a> and CENTRAL for trials that were done after 2011. </p> </section> <section id="CD007961-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We conducted searches of conference proceedings and reference lists of relevant journal articles, and contacted organisations involved in microbicide research. </p> <section id="CD007961-sec-0026"> <h5 class="title">Conference proceedings</h5> <p>We searched proceedings of the following conferences from August 2011 to 22 August 2020 for relevant studies: </p> <p> <ul id="CD007961-list-0003"> <li> <p>International Conference on AIDS and STDs in Africa (ICASA)</p> </li> <li> <p>Biennial meeting of the International Society for Sexually Transmitted Diseases Research</p> </li> <li> <p>International Congress of Sexually Transmitted Infections</p> </li> <li> <p>Biannual International Microbicide Conference and Modern Mucosal Vaccines, Adjuvants and Microbicides </p> </li> <li> <p>Annual Conference on Retroviruses and Opportunistic Infections (CROI)</p> </li> </ul> </p> </section> <section id="CD007961-sec-0027"> <h5 class="title">Researchers, organisations and pharmaceutical companies</h5> <p>We contacted organisations involved in microbicide research, including the Alliance for Microbicide Development, International Partnership for Microbicides (IPM), the Joint United Nations Programme on HIV/AIDS (UNAIDS), and WHO. We also contacted microbicide and HIV prevention experts. </p> </section> <section id="CD007961-sec-0028"> <h5 class="title">Reference lists</h5> <p>We checked the reference lists of relevant previous reviews (<a href="./references#CD007961-bbs2-0032" title="Buckheit RW Jr, WatsonKM , MorrowKM , HamAS . Development of topical microbicides to prevent the sexual transmission of HIV. Antiviral Research2010;85(1):142-58.">Buckheit 2010</a>; <a href="./references#CD007961-bbs2-0035" title="CutlerB , JustmanJ . Vaginal microbicides and the prevention of HIV transmission. Lancet Infectious Diseases2008;8(11):685-97.">Cutler 2008</a>; <a href="./references#CD007961-bbs2-0040" title="GargAB , NuttallJ , RomanoJ . The future of HIV microbicides: challenges and opportunities. Antiviral Chemistry &amp; Chemotherapy2009;19(4):143-50.">Garg 2009</a>; <a href="./references#CD007961-bbs2-0049" title="KlassePJ , ShattockR , MooreJP . Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission. Annual Review of Medicine2008;59:455-71.">Klasse 2008</a>; <a href="./references#CD007961-bbs2-0058" title="NuttallJ . Microbicides in the prevention of HIV infection: current status and future directions. Drugs2010;70(10):1231-43.">Nuttall 2010</a>; <a href="./references#CD007961-bbs2-0063" title="SinghO , GargT , RathG , GoyalAK . Microbicides for the treatment of sexually transmitted HIV Infections. Journal of Pharmceutics2014;2014:1-18.">Singh 2014</a>; <a href="./references#CD007961-bbs2-0081" title="WilkinsonD , RamjeeG , TholandiM , RutherfordG . Nonoxynol-9 for preventing vaginal acquisition of sexually transmitted infections by women from men. Cochrane Database of Systematic Reviews2002, Issue 1. Art. No: CD003939. [DOI: 10.1002/14651858.CD003939]">Wilkinson 2002a</a>; <a href="./references#CD007961-bbs2-0082" title="WilkinsonD , RamjeeG , TholandiM , RutherfordG . Nonoxynol-9 for preventing vaginal acquisition of HIV infection by women from men. Cochrane Database of Systematic Reviews2002, Issue 3. Art. No: CD003936. [DOI: 10.1002/14651858.CD003936]">Wilkinson 2002b</a>) and full‐text articles reviewed for inclusion in this review. </p> </section> </section> </section> <section id="CD007961-sec-0029"> <h3 class="title" id="CD007961-sec-0029">Data collection and analysis</h3> <section id="CD007961-sec-0030"> <h4 class="title">Selection of studies</h4> <p>For the original review (<a href="./references#CD007961-bbs2-0085" title="ObieroJ , MwetheraPG , WiysongeCS . Topical microbicides for prevention of sexually transmitted infections. Cochrane Database of Systematic Reviews2012, Issue 6. Art. No: CD007961. [DOI: 10.1002/14651858.CD007961.pub2]">Obiero 2012a</a>), Jael Obiero (JO) and Charles Shey Wiysonge (CSW) independently screened all citations and abstracts identified by the search strategy for potentially eligible studies. For this review update, JO and Paul Ogongo (PO) independently performed screening and study selection. The two review authors independently assessed the full‐text articles of potentially relevant studies using the prespecified trial inclusion criteria. We resolved any disagreements by discussion and consensus. When a disagreement could not be resolved, a third review author (Peter Gichuhi Mwethera (PGM) for the original review and CSW for this update) arbitrated. We excluded potentially eligible studies that did not meet our inclusion criteria and documented the reasons for exclusion in the table of <a href="./references#CD007961-sec-0106" title="">Characteristics of excluded studies</a>. </p> </section> <section id="CD007961-sec-0031"> <h4 class="title">Data extraction and management</h4> <p>For the current update, JO and PO independently extracted data from included trials using a data extraction form. Extracted information included trial methods, participant characteristics, interventions, and outcomes. For all trials, we extracted the number of participants randomised, the number of participants with each outcome, and the number analysed. The authors resolved differences by discussion and consensus, with arbitration by PGM and CSW. </p> </section> <section id="CD007961-sec-0032"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Three review authors (JO, PO, and CSW) independently assessed the risks of bias in each included trial addressing seven specific domains: generation of allocation sequence, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective outcome reporting and 'other issues'. For each included trial, the three review authors independently described what the trial authors reported that they did for each domain and then made a decision relating to the risk of bias for that domain by assigning a judgement of 'low risk' of bias, 'high risk' of bias, or 'unclear risk' of bias. The review authors compared the results of their independent assessments of risks of bias and resolved any discrepancies by discussion and consensus (<a href="./references#CD007961-bbs2-0047" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Higgins 2020</a>). We assessed risk of bias using the Cochrane 'Risk of bias' tool. We provided justification for risk of bias (high, low, unclear) in the 'Risk of bias' table by direct reference to the relevant report. </p> </section> <section id="CD007961-sec-0033"> <h4 class="title">Measures of treatment effect</h4> <p>Our outcomes were all dichotomous in nature, so we presented the trial results as risk ratios (RRs) with 95% confidence intervals (CIs). The RR is used as a relative effect measure that works well with a low or high rate of events, and is easy to interpret and use in clinical practice. We performed meta‐analyses separately for each STI, stratified by type of microbicide,compared to their respective placebos. This was because the microbicides in the trial belonged to different classes and their mechanisms of action differ. </p> </section> <section id="CD007961-sec-0034"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the participant who received the preventive treatment.</p> </section> <section id="CD007961-sec-0035"> <h4 class="title">Dealing with missing data</h4> <p>We identified the levels of attrition in the included trials and performed analyses for all outcomes as far as possible on an intention‐to‐treat basis, i.e. we analysed all participants in the group to which they were allocated, regardless of whether or not they received the allocated intervention. The denominator for each outcome in each trial was the number randomised. </p> </section> <section id="CD007961-sec-0036"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed statistical heterogeneity in each meta‐analysis using the Tau<sup>2</sup>, I<sup>2</sup> statistic, and Chi<sup>2</sup> test (<a href="./references#CD007961-bbs2-0046" title="HigginsJPT , ThomasJ , (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated August 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Higgins 2019</a>). We regarded heterogeneity as substantial if the I<sup>2</sup> statistic value was greater than 40% and if either the Tau<sup>2</sup> value was greater than zero or there was a P value less than 0.10 in the Chi<sup>2</sup> test. </p> <p>We considered whether the clinical and methodological characteristics of the included studies were sufficiently similar for meta‐analysis to provide a clinically meaningful summary. We assessed statistical heterogeneity using the I<sup>2</sup> statistic as follows: not relevant (l<sup>2</sup> value below 40%), important (l<sup>2</sup> value 40% to 75%), or substantial (l<sup>2</sup> value above 75%) (Sutton 2008; <a href="./references#CD007961-bbs2-0047" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Higgins 2020</a>). We also assessed statistical heterogeneity in each meta‐analysis using the t<sup>2</sup> and Chi<sup>2</sup> statistics. </p> <p>If we detected substantial heterogeneity, we explored possible explanations for it in subgroup analyses (see <a href="#CD007961-sec-0039">Subgroup analysis and investigation of heterogeneity</a>). We took statistical heterogeneity into account if is not relevant we used fixed effects model, if heterogeneity is important we used a random‐effects analysis, and if heterogeneity is substantial and there is not explanation we did not pool data </p> </section> <section id="CD007961-sec-0037"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to explore publication bias through assessment of funnel plot asymmetry and formal tests. For dichotomous outcomes we planned to use the test proposed by <a href="./references#CD007961-bbs2-0045" title="HarbordRM , EggerM , SterneJA . A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Statistics in Medicine2006;25.(20):3443-57.">Harbord 2006</a>. However, as we included fewer than 10 trials in the meta‐analyses we did not perform these analyses. </p> </section> <section id="CD007961-sec-0038"> <h4 class="title">Data synthesis</h4> <p>We performed statistical analyses using Review Manager 5 (RevMan: <a href="./references#CD007961-bbs2-0061" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>). For this version of the review, we used a fixed‐effect meta‐analysis, i.e. the trials examined the same intervention, and we judged the trials’ populations and methods to be sufficiently similar. We would have used a random‐effects model if there were clinical heterogeneity sufficient to expect that the underlying treatment effects differed between trials or if we detected substantial heterogeneity (I<sup>2</sup> = 40% or greater) to produce an overall summary if we considered an average treatment effect across trials to be clinically meaningful. In such circumstances, we would have treated the random‐effects summary as the average range of possible treatment effects and discussed the clinical implications of treatment effects differing between trials. </p> </section> <section id="CD007961-sec-0039"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to explore possible causes of any significant statistical heterogeneity of effects by using subgroup analyses, with subgroups defined by the sex of study participants (WSM or MSM), sexual route of transmission (vaginal or anal), population (high versus low risk), intervention type, and type of comparison group (placebo, condom, diaphragm, vaginal sponge, or cervical cap). </p> </section> <section id="CD007961-sec-0040"> <h4 class="title">Sensitivity analysis</h4> <p>We conducted sensitivity analyses to investigate the effect of type of meta‐analysis (fixed‐effect versus random‐effects) on the robustness of the results. </p> </section> <section id="CD007961-sec-0041"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We graded our confidence in the evidence and summarised the findings in a 'Summary of findings' table using the approach recommended by the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Working Group (<a href="./references#CD007961-bbs2-0083" title="McMaster UniversityGRADEpro GDT [GRADEpro GDT]. GRADE Working Group, Version 2015. Canada: McMaster University, 2015. gradepro.org..">GRADEpro GDT 2015</a>). We compared the effectiveness of topical microbicides (surfactants<b>,</b> vaginal defence enhancers, entry inhibitors and agents that prevent replication of the pathogen after it has entered the cell) with placebo, no intervention, condom, diaphragm, vaginal sponge, and cervical cap for prevention of STI for each of the following important outcomes: laboratory confirmed incidence of STIs (viral, bacterial, fungal, protozoan), severe adverse events, acceptability and minor adverse events. We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and risk of bias) to assess the certainty of the evidence as it relates the outcomes (<a href="./references#CD007961-bbs2-0031" title="BalshemB , HelfandM , SchünemannHJ , OxmanAD , KunzR , BrozeJ , et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology2011;64(4):401-6.">Balshem 2011</a>; <a href="./references#CD007961-bbs2-0042" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. introduction - GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383-94.">Guyatt 2011</a>; <a href="./references#CD007961-bbs2-0043" title="GuyattG , OxmanAD , SultanS , et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. J Clin Epidemiol2013;66(2):151-157.">Guyatt 2013</a>) . We used methods and recommendations described in Section 8.5 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007961-bbs2-0047" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Higgins 2020</a>). </p> <p>We plan to extract study data, format our comparisons in data tables and prepare a summary of findings table before writing the results and conclusions of our review. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD007961-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD007961-sec-0042"></div> <section id="CD007961-sec-0043"> <h3 class="title">Description of studies</h3> <section id="CD007961-sec-0044"> <h4 class="title">Results of the search</h4> <p>For the previous version of the review, we conducted searches up to July 2011 and included eight randomised trials (<a href="./references#CD007961-bbs2-0085" title="ObieroJ , MwetheraPG , WiysongeCS . Topical microbicides for prevention of sexually transmitted infections. Cochrane Database of Systematic Reviews2012, Issue 6. Art. No: CD007961. [DOI: 10.1002/14651858.CD007961.pub2]">Obiero 2012a</a>). For the current update, we conducted searches between June 2015 and August 2020 for trials conducted after 2011 and identified 1980 records (1834 without duplicates). From these records, we identified 16 potentially eligible studies (<a href="#CD007961-fig-0001">Figure 1</a>). We included four of the studies, which met our inclusion criteria (<a href="./references#CD007961-bbs2-0003" title="BaetenJM , Palanee-PhillipsT , BrownER , SchwartzK , Soto-TorresLE , GovenderV , et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. New England Journal of Medicine2016;375(22):2121-32. MTN 2016. Dapivirine vaginal ring helped protect women against HIV in ASPIRE Phase lll trial. Media release. ">Baeten 2016</a>; <a href="./references#CD007961-bbs2-0007" title="MarrazzoJM , RamjeeG , RichardsonBA , GomezK , MgodiN , NairG , et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. New England Journal of Medicine2015;372(6):509-17. ">Marrazzo 2015</a>; <a href="./references#CD007961-bbs2-0009" title="NelA , Van NiekerkN , KapigaS , BekkerLG , GamaC , GillK . Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. New England Journal of Medicine2016;375(22):2133-45. ">Nel 2016</a>; <a href="./references#CD007961-bbs2-0004" title="Delany-MoretlweS , LombardC , BaronD , BekkerLG , NkalaB , Ahmed K et al. Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised,double-blind, placebo-controlled trial. The Lancet Infectious Diseases2018;18(11):1241-50. ReesHS , SineadA , Delany- MoretiwaS , BaronD , PachiaR , et al. In: FACTS 001 Phase III Trial of Pericoital Tenofovir 1% Gel for HIV Prevention in Women.The 22nd Conference on Retroviruses and Opportunistic Infections;2015 Feb 23-26; Seattle Washington. 2015. ">Delany‐Moretlwe 2018</a>). Six of the 12 trials were stopped early due to safety concerns (<a href="./references#CD007961-bbs2-0005" title="FeldblumPJ , AdeigaA , BakareR , WevillS , LendvayA , ObadakiF , et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomised controlled trial in Nigeria. PLoS One2008;3(1):e1474. ">Feldblum 2008</a>: <a href="./references#CD007961-bbs2-0006" title="HalpernV , OgunsolaF , ObungeO , WangCH , OnyejepuN , OduyeboO , et al. Effectiveness of cellulose sulphate vaginal gel for the prevention of HIV infection: results of a phase III trial in Nigeria. PLoS One2008;3(11):e3784. ">Halpern 2008</a>; <a href="./references#CD007961-bbs2-0007" title="MarrazzoJM , RamjeeG , RichardsonBA , GomezK , MgodiN , NairG , et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. New England Journal of Medicine2015;372(6):509-17. ">Marrazzo 2015</a>; <a href="./references#CD007961-bbs2-0008" title="McCormackS , RamjeeG , KamaliA , ReesH , CrookAM , GafosM , et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet2010;376(9749):1329-37. ">McCormack 2010</a>; <a href="./references#CD007961-bbs2-0010" title="PetersonL , NandaK , OpokuBK , AmpofoWK , Owusu-AmoakoM , BoakyeAY , et al. SAVVY (C31G) gel for prevention of HIV infection in women: a phase 3, double-blind, randomised, placebo-controlled trial in Ghana. PLoS One2007;2(12):e1312. ">Peterson 2007</a>; <a href="./references#CD007961-bbs2-0012" title="Van DammeL , GovindenR , MirembeFM , GuédouF , SolomonS , BeckerML , et al. Lack of effectiveness of cellulose sulphate gel for the prevention of vaginal HIV transmission. New England Journal of Medicine2008;359(5):463-73. ">Van Damme 2008</a>). We conducted sensitivity analyses and found that risk of bias (high versus moderate/low risk of bias) had no impact on the robustness of the findings. </p> <div class="figure" id="CD007961-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA diagram showing the search and selection of studies" data-id="CD007961-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/image_n/nCD007961-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA diagram showing the search and selection of studies</p> </div> </div> </div> <p>Combining data from the previous version of the review and the recent searches, gives 14 excluded and 12 included studies (<a href="#CD007961-fig-0001">Figure 1</a>; <a href="#CD007961-tbl-0004">Table 1</a>). In this update, we do not have any studies awaiting assessment. </p> <div class="table" id="CD007961-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary table with the description of included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Outcome</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD007961-bbs2-0001" title="Abdool KarimQ , Abdool KarimSS , FrohlichJA , GroblerAC , BaxterC , MansoorEL , et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science2010;329(5996):1168-74. Abdool KarimSS , Abdool KarimQ , KharsanyAB , BaxterC , GroblerAC , WernerL . Tenofovir gel for the prevention of herpes simplex virus type 2 infection. New England Journal of Medicine 20152015;373(6):530-9. KarimQA , KharsanyAB , FrohlichJA , BaxterC , YendeN , MansoorLE , et al. Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials2011;12:67. KellerDM . AIDS 2010, XVIII International AIDS Conference: Tenofovir vaginal gel first microbicide to prevent HIV, HSV infections. Medscape Medical News July 2010. "><b>Abdool Karim 2010</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>889 women</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tenofovir gel</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo gel</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV, HSV‐2, HPV, Adverse events</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD007961-bbs2-0002" title="Abdool KarimSS , RichardsonBA , RamjeeG , HoffmanIF , ChirenjeZM , TahaT , et al. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS2011;25(7):957-66. GuffeyMB , RichardsonB , HusnikM , MakananiB , ChilongoziD , YuE , et al. HPTN 035 Phase II/IIb Randomized safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in women. Sexually Transmitted Infections2014;90(5):1-15. "><b>Abdool Karim 2011</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3101 women</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Buffergel</p> <p>0.5% PRO 2000 gel</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo gel</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV, Chlamydia, Gonorrhoea, Trichomoniasis, HSV‐2</p> <p>Adverse events</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD007961-bbs2-0003" title="BaetenJM , Palanee-PhillipsT , BrownER , SchwartzK , Soto-TorresLE , GovenderV , et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. New England Journal of Medicine2016;375(22):2121-32. MTN 2016. Dapivirine vaginal ring helped protect women against HIV in ASPIRE Phase lll trial. Media release. "><b>Baeten 2016</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2629 women</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dapivirine ring</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo ring</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐1, Gonorrhoea, Trichomoniasis, Chlamydia, Adverse events</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD007961-bbs2-0005" title="FeldblumPJ , AdeigaA , BakareR , WevillS , LendvayA , ObadakiF , et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomised controlled trial in Nigeria. PLoS One2008;3(1):e1474. "><b>Feldblum 2008</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2153 women</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAVVY gel</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo gel</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV, Adverse events</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD007961-bbs2-0006" title="HalpernV , OgunsolaF , ObungeO , WangCH , OnyejepuN , OduyeboO , et al. Effectiveness of cellulose sulphate vaginal gel for the prevention of HIV infection: results of a phase III trial in Nigeria. PLoS One2008;3(11):e3784. "><b>Halpern 2008</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1644 women</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cellulose sulphate gel</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo gel</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV, Gonorrhoea, Chlamydia, Adverse events</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD007961-bbs2-0007" title="MarrazzoJM , RamjeeG , RichardsonBA , GomezK , MgodiN , NairG , et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. New England Journal of Medicine2015;372(6):509-17. "><b>Marrazzo 2015</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2010 women</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tenofovir gel</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo gel</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV, HSV, Gonorrhoea, Chlamydia, Syphilis, Trichomoniasis, Adverse events</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD007961-bbs2-0009" title="NelA , Van NiekerkN , KapigaS , BekkerLG , GamaC , GillK . Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. New England Journal of Medicine2016;375(22):2133-45. "><b>Nel 2016</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1959 women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dapivirine ring</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo ring</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HIV, Gonorrhoea, Chlamydia, Syphilis, Trichomoniasis, Adverse events</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD007961-bbs2-0008" title="McCormackS , RamjeeG , KamaliA , ReesH , CrookAM , GafosM , et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet2010;376(9749):1329-37. "><b>McCormack 2010</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9385 women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2% PRO 2000 gel</p> <p>0.5% PRO 2000 gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HIV, HSV, Gonorrhoea, Chlamydia</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD007961-bbs2-0010" title="PetersonL , NandaK , OpokuBK , AmpofoWK , Owusu-AmoakoM , BoakyeAY , et al. SAVVY (C31G) gel for prevention of HIV infection in women: a phase 3, double-blind, randomised, placebo-controlled trial in Ghana. PLoS One2007;2(12):e1312. "><b>Peterson 2007</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2142 women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SAVVY gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HIV, Adverse events</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD007961-bbs2-0004" title="Delany-MoretlweS , LombardC , BaronD , BekkerLG , NkalaB , Ahmed K et al. Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised,double-blind, placebo-controlled trial. The Lancet Infectious Diseases2018;18(11):1241-50. ReesHS , SineadA , Delany- MoretiwaS , BaronD , PachiaR , et al. In: FACTS 001 Phase III Trial of Pericoital Tenofovir 1% Gel for HIV Prevention in Women.The 22nd Conference on Retroviruses and Opportunistic Infections;2015 Feb 23-26; Seattle Washington. 2015. "><b>Delany‐Moretlwe 2018</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2059 women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tenofovir gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HIV, HSV, Adverse events</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD007961-bbs2-0011" title="MaraisD , GawareckiD , AllanB , AhmedK , AltiniL , CassimN , et al. The effectiveness of Carraguard, a vaginal microbicide, in protecting women against high-risk human papillomavirus infection. Antiviral Therapy2011;16(8):1219-26. Skoler-KarpoffS , RamjeeG , AhmedK , AltiniL , PlagianosMG , FriedlandB , et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9654):1977-87. "><b>Skoler‐Karpoff 2008</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6202 women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Carraguard gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HIV, Gonorrhoea, Chlamydia, Syphilis, Trichomoniasis, Adverse events</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD007961-bbs2-0012" title="Van DammeL , GovindenR , MirembeFM , GuédouF , SolomonS , BeckerML , et al. Lack of effectiveness of cellulose sulphate gel for the prevention of vaginal HIV transmission. New England Journal of Medicine2008;359(5):463-73. "><b>Van Damme 2008</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1428 women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cellulose sulphate gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HIV, HSV, Gonorrhoea, Chlamydia, Syphilis, Condyloma, Trichomoniasis</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD007961-sec-0045"> <h4 class="title">Included studies</h4> <p>See: <a href="./references#CD007961-sec-0105" title="">Characteristics of included studies</a>. </p> <section id="CD007961-sec-0046"> <h5 class="title">Study design</h5> <p>All 12 included trials were parallel RCT. Seven trials were multicentre (<a href="./references#CD007961-bbs2-0002" title="Abdool KarimSS , RichardsonBA , RamjeeG , HoffmanIF , ChirenjeZM , TahaT , et al. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS2011;25(7):957-66. GuffeyMB , RichardsonB , HusnikM , MakananiB , ChilongoziD , YuE , et al. HPTN 035 Phase II/IIb Randomized safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in women. Sexually Transmitted Infections2014;90(5):1-15. ">Abdool Karim 2011</a>; <a href="./references#CD007961-bbs2-0003" title="BaetenJM , Palanee-PhillipsT , BrownER , SchwartzK , Soto-TorresLE , GovenderV , et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. New England Journal of Medicine2016;375(22):2121-32. MTN 2016. Dapivirine vaginal ring helped protect women against HIV in ASPIRE Phase lll trial. Media release. ">Baeten 2016</a>; <a href="./references#CD007961-bbs2-0004" title="Delany-MoretlweS , LombardC , BaronD , BekkerLG , NkalaB , Ahmed K et al. Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised,double-blind, placebo-controlled trial. The Lancet Infectious Diseases2018;18(11):1241-50. ReesHS , SineadA , Delany- MoretiwaS , BaronD , PachiaR , et al. In: FACTS 001 Phase III Trial of Pericoital Tenofovir 1% Gel for HIV Prevention in Women.The 22nd Conference on Retroviruses and Opportunistic Infections;2015 Feb 23-26; Seattle Washington. 2015. ">Delany‐Moretlwe 2018</a>; <a href="./references#CD007961-bbs2-0007" title="MarrazzoJM , RamjeeG , RichardsonBA , GomezK , MgodiN , NairG , et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. New England Journal of Medicine2015;372(6):509-17. ">Marrazzo 2015</a>; <a href="./references#CD007961-bbs2-0008" title="McCormackS , RamjeeG , KamaliA , ReesH , CrookAM , GafosM , et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet2010;376(9749):1329-37. ">McCormack 2010</a>; <a href="./references#CD007961-bbs2-0009" title="NelA , Van NiekerkN , KapigaS , BekkerLG , GamaC , GillK . Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. New England Journal of Medicine2016;375(22):2133-45. ">Nel 2016</a>; <a href="./references#CD007961-bbs2-0012" title="Van DammeL , GovindenR , MirembeFM , GuédouF , SolomonS , BeckerML , et al. Lack of effectiveness of cellulose sulphate gel for the prevention of vaginal HIV transmission. New England Journal of Medicine2008;359(5):463-73. ">Van Damme 2008</a>), with two having study sites outside Africa: one in the USA (<a href="./references#CD007961-bbs2-0002" title="Abdool KarimSS , RichardsonBA , RamjeeG , HoffmanIF , ChirenjeZM , TahaT , et al. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS2011;25(7):957-66. GuffeyMB , RichardsonB , HusnikM , MakananiB , ChilongoziD , YuE , et al. HPTN 035 Phase II/IIb Randomized safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in women. Sexually Transmitted Infections2014;90(5):1-15. ">Abdool Karim 2011</a>) and one in India (<a href="./references#CD007961-bbs2-0012" title="Van DammeL , GovindenR , MirembeFM , GuédouF , SolomonS , BeckerML , et al. Lack of effectiveness of cellulose sulphate gel for the prevention of vaginal HIV transmission. New England Journal of Medicine2008;359(5):463-73. ">Van Damme 2008</a>). The rest of the trials were conducted solely in Africa (<a href="./references#CD007961-bbs2-0001" title="Abdool KarimQ , Abdool KarimSS , FrohlichJA , GroblerAC , BaxterC , MansoorEL , et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science2010;329(5996):1168-74. Abdool KarimSS , Abdool KarimQ , KharsanyAB , BaxterC , GroblerAC , WernerL . Tenofovir gel for the prevention of herpes simplex virus type 2 infection. New England Journal of Medicine 20152015;373(6):530-9. KarimQA , KharsanyAB , FrohlichJA , BaxterC , YendeN , MansoorLE , et al. Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials2011;12:67. KellerDM . AIDS 2010, XVIII International AIDS Conference: Tenofovir vaginal gel first microbicide to prevent HIV, HSV infections. Medscape Medical News July 2010. ">Abdool Karim 2010</a>; <a href="./references#CD007961-bbs2-0004" title="Delany-MoretlweS , LombardC , BaronD , BekkerLG , NkalaB , Ahmed K et al. Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised,double-blind, placebo-controlled trial. The Lancet Infectious Diseases2018;18(11):1241-50. ReesHS , SineadA , Delany- MoretiwaS , BaronD , PachiaR , et al. In: FACTS 001 Phase III Trial of Pericoital Tenofovir 1% Gel for HIV Prevention in Women.The 22nd Conference on Retroviruses and Opportunistic Infections;2015 Feb 23-26; Seattle Washington. 2015. ">Delany‐Moretlwe 2018</a>; <a href="./references#CD007961-bbs2-0005" title="FeldblumPJ , AdeigaA , BakareR , WevillS , LendvayA , ObadakiF , et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomised controlled trial in Nigeria. PLoS One2008;3(1):e1474. ">Feldblum 2008</a>; <a href="./references#CD007961-bbs2-0006" title="HalpernV , OgunsolaF , ObungeO , WangCH , OnyejepuN , OduyeboO , et al. Effectiveness of cellulose sulphate vaginal gel for the prevention of HIV infection: results of a phase III trial in Nigeria. PLoS One2008;3(11):e3784. ">Halpern 2008</a>; <a href="./references#CD007961-bbs2-0010" title="PetersonL , NandaK , OpokuBK , AmpofoWK , Owusu-AmoakoM , BoakyeAY , et al. SAVVY (C31G) gel for prevention of HIV infection in women: a phase 3, double-blind, randomised, placebo-controlled trial in Ghana. PLoS One2007;2(12):e1312. ">Peterson 2007</a>; <a href="./references#CD007961-bbs2-0011" title="MaraisD , GawareckiD , AllanB , AhmedK , AltiniL , CassimN , et al. The effectiveness of Carraguard, a vaginal microbicide, in protecting women against high-risk human papillomavirus infection. Antiviral Therapy2011;16(8):1219-26. Skoler-KarpoffS , RamjeeG , AhmedK , AltiniL , PlagianosMG , FriedlandB , et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9654):1977-87. ">Skoler‐Karpoff 2008</a>). The trials lasted for at least two years, except for the trials that were stopped early for data‐dependent processes (<a href="./references#CD007961-bbs2-0005" title="FeldblumPJ , AdeigaA , BakareR , WevillS , LendvayA , ObadakiF , et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomised controlled trial in Nigeria. PLoS One2008;3(1):e1474. ">Feldblum 2008</a>; <a href="./references#CD007961-bbs2-0006" title="HalpernV , OgunsolaF , ObungeO , WangCH , OnyejepuN , OduyeboO , et al. Effectiveness of cellulose sulphate vaginal gel for the prevention of HIV infection: results of a phase III trial in Nigeria. PLoS One2008;3(11):e3784. ">Halpern 2008</a>; <a href="./references#CD007961-bbs2-0007" title="MarrazzoJM , RamjeeG , RichardsonBA , GomezK , MgodiN , NairG , et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. New England Journal of Medicine2015;372(6):509-17. ">Marrazzo 2015</a>; <a href="./references#CD007961-bbs2-0008" title="McCormackS , RamjeeG , KamaliA , ReesH , CrookAM , GafosM , et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet2010;376(9749):1329-37. ">McCormack 2010</a>: <a href="./references#CD007961-bbs2-0010" title="PetersonL , NandaK , OpokuBK , AmpofoWK , Owusu-AmoakoM , BoakyeAY , et al. SAVVY (C31G) gel for prevention of HIV infection in women: a phase 3, double-blind, randomised, placebo-controlled trial in Ghana. PLoS One2007;2(12):e1312. ">Peterson 2007</a>; <a href="./references#CD007961-bbs2-0012" title="Van DammeL , GovindenR , MirembeFM , GuédouF , SolomonS , BeckerML , et al. Lack of effectiveness of cellulose sulphate gel for the prevention of vaginal HIV transmission. New England Journal of Medicine2008;359(5):463-73. ">Van Damme 2008</a>). </p> </section> <section id="CD007961-sec-0047"> <h5 class="title">Population</h5> <p>The age of trial participants ranged from 16 to 72 years. These were non‐pregnant women who did not have any reproductive tract complications. The total number of participants in these trials was 32,464. The number of participants in each trial ranged from 889 (<a href="./references#CD007961-bbs2-0001" title="Abdool KarimQ , Abdool KarimSS , FrohlichJA , GroblerAC , BaxterC , MansoorEL , et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science2010;329(5996):1168-74. Abdool KarimSS , Abdool KarimQ , KharsanyAB , BaxterC , GroblerAC , WernerL . Tenofovir gel for the prevention of herpes simplex virus type 2 infection. New England Journal of Medicine 20152015;373(6):530-9. KarimQA , KharsanyAB , FrohlichJA , BaxterC , YendeN , MansoorLE , et al. Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials2011;12:67. KellerDM . AIDS 2010, XVIII International AIDS Conference: Tenofovir vaginal gel first microbicide to prevent HIV, HSV infections. Medscape Medical News July 2010. ">Abdool Karim 2010</a>) to 9385 women (<a href="./references#CD007961-bbs2-0008" title="McCormackS , RamjeeG , KamaliA , ReesH , CrookAM , GafosM , et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet2010;376(9749):1329-37. ">McCormack 2010</a>). </p> <p>We did not find any eligible trial that enrolled MSM.</p> </section> <section id="CD007961-sec-0048"> <h5 class="title">Intervention</h5> <p>Two trials (<a href="./references#CD007961-bbs2-0003" title="BaetenJM , Palanee-PhillipsT , BrownER , SchwartzK , Soto-TorresLE , GovenderV , et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. New England Journal of Medicine2016;375(22):2121-32. MTN 2016. Dapivirine vaginal ring helped protect women against HIV in ASPIRE Phase lll trial. Media release. ">Baeten 2016</a>; <a href="./references#CD007961-bbs2-0009" title="NelA , Van NiekerkN , KapigaS , BekkerLG , GamaC , GillK . Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. New England Journal of Medicine2016;375(22):2133-45. ">Nel 2016</a>) used davipirine using vaginal rings and the remaining trials used vaginal gels. In the trials that used vaginal rings, women randomised to the intervention arm used silicone elastomer vaginal matrix rings containing 25 mg of dapivirine. The women were instructed to wear the ring for the entire month and then replace it with a new ring at the monthly follow‐up visit. </p> <p>In two trials that used 1% tenofovir (<a href="./references#CD007961-bbs2-0001" title="Abdool KarimQ , Abdool KarimSS , FrohlichJA , GroblerAC , BaxterC , MansoorEL , et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science2010;329(5996):1168-74. Abdool KarimSS , Abdool KarimQ , KharsanyAB , BaxterC , GroblerAC , WernerL . Tenofovir gel for the prevention of herpes simplex virus type 2 infection. New England Journal of Medicine 20152015;373(6):530-9. KarimQA , KharsanyAB , FrohlichJA , BaxterC , YendeN , MansoorLE , et al. Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials2011;12:67. KellerDM . AIDS 2010, XVIII International AIDS Conference: Tenofovir vaginal gel first microbicide to prevent HIV, HSV infections. Medscape Medical News July 2010. ">Abdool Karim 2010</a>; <a href="./references#CD007961-bbs2-0004" title="Delany-MoretlweS , LombardC , BaronD , BekkerLG , NkalaB , Ahmed K et al. Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised,double-blind, placebo-controlled trial. The Lancet Infectious Diseases2018;18(11):1241-50. ReesHS , SineadA , Delany- MoretiwaS , BaronD , PachiaR , et al. In: FACTS 001 Phase III Trial of Pericoital Tenofovir 1% Gel for HIV Prevention in Women.The 22nd Conference on Retroviruses and Opportunistic Infections;2015 Feb 23-26; Seattle Washington. 2015. ">Delany‐Moretlwe 2018</a>), the women were instructed to insert one gel intravaginally in the 12 hours before vaginal sex and a second gel as soon as possible after the intercourse, with no more than two doses in a 24‐hour period. In the third tenofovir study (<a href="./references#CD007961-bbs2-0007" title="MarrazzoJM , RamjeeG , RichardsonBA , GomezK , MgodiN , NairG , et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. New England Journal of Medicine2015;372(6):509-17. ">Marrazzo 2015</a>), the gel was inserted up to one hour before each episode of vaginal intercourse. The gels were provided in prefilled applicators for single use. </p> <p>For the other five types of vaginal microbicide gels that were used (cellulose sulphate (<a href="./references#CD007961-bbs2-0006" title="HalpernV , OgunsolaF , ObungeO , WangCH , OnyejepuN , OduyeboO , et al. Effectiveness of cellulose sulphate vaginal gel for the prevention of HIV infection: results of a phase III trial in Nigeria. PLoS One2008;3(11):e3784. ">Halpern 2008</a>; <a href="./references#CD007961-bbs2-0012" title="Van DammeL , GovindenR , MirembeFM , GuédouF , SolomonS , BeckerML , et al. Lack of effectiveness of cellulose sulphate gel for the prevention of vaginal HIV transmission. New England Journal of Medicine2008;359(5):463-73. ">Van Damme 2008</a>), SAVVY (<a href="./references#CD007961-bbs2-0005" title="FeldblumPJ , AdeigaA , BakareR , WevillS , LendvayA , ObadakiF , et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomised controlled trial in Nigeria. PLoS One2008;3(1):e1474. ">Feldblum 2008</a>; <a href="./references#CD007961-bbs2-0010" title="PetersonL , NandaK , OpokuBK , AmpofoWK , Owusu-AmoakoM , BoakyeAY , et al. SAVVY (C31G) gel for prevention of HIV infection in women: a phase 3, double-blind, randomised, placebo-controlled trial in Ghana. PLoS One2007;2(12):e1312. ">Peterson 2007</a>), PRO 2000 (<a href="./references#CD007961-bbs2-0002" title="Abdool KarimSS , RichardsonBA , RamjeeG , HoffmanIF , ChirenjeZM , TahaT , et al. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS2011;25(7):957-66. GuffeyMB , RichardsonB , HusnikM , MakananiB , ChilongoziD , YuE , et al. HPTN 035 Phase II/IIb Randomized safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in women. Sexually Transmitted Infections2014;90(5):1-15. ">Abdool Karim 2011</a>; <a href="./references#CD007961-bbs2-0008" title="McCormackS , RamjeeG , KamaliA , ReesH , CrookAM , GafosM , et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet2010;376(9749):1329-37. ">McCormack 2010</a>), BufferGel (<a href="./references#CD007961-bbs2-0002" title="Abdool KarimSS , RichardsonBA , RamjeeG , HoffmanIF , ChirenjeZM , TahaT , et al. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS2011;25(7):957-66. GuffeyMB , RichardsonB , HusnikM , MakananiB , ChilongoziD , YuE , et al. HPTN 035 Phase II/IIb Randomized safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in women. Sexually Transmitted Infections2014;90(5):1-15. ">Abdool Karim 2011</a>), Carraguard (<a href="./references#CD007961-bbs2-0011" title="MaraisD , GawareckiD , AllanB , AhmedK , AltiniL , CassimN , et al. The effectiveness of Carraguard, a vaginal microbicide, in protecting women against high-risk human papillomavirus infection. Antiviral Therapy2011;16(8):1219-26. Skoler-KarpoffS , RamjeeG , AhmedK , AltiniL , PlagianosMG , FriedlandB , et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9654):1977-87. ">Skoler‐Karpoff 2008</a>)), women were instructed to insert the contents of the applicator of their assigned gel into the vagina within the hour preceding each act of vaginal intercourse. All the gels were provided in prefilled applicators for single use. Follow‐up visits were on a monthly basis, and during the visits gels were re‐supplied to the women. </p> </section> <section id="CD007961-sec-0049"> <h5 class="title">Comparators</h5> <p>All included trials used identical placebo. The two vaginal ring trials used identical placebo rings. The latter were flexible platinum‐catalysed‐cured silicone matrix rings, which contained no active drug. The microbicide gel studies used identical placebo gels. All the gels were similar to their respective microbicides in terms of appearance, packaging, and administration. All included studies provided condoms to both intervention and comparison arms. We did not find studies that had used condom, diaphragm, vaginal sponge, and cervical cap or not intervention. </p> </section> <section id="CD007961-sec-0050"> <h5 class="title">Outcomes</h5> <p>All trials reported HIV incidence as the primary outcome. Except for four trials (<a href="./references#CD007961-bbs2-0004" title="Delany-MoretlweS , LombardC , BaronD , BekkerLG , NkalaB , Ahmed K et al. Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised,double-blind, placebo-controlled trial. The Lancet Infectious Diseases2018;18(11):1241-50. ReesHS , SineadA , Delany- MoretiwaS , BaronD , PachiaR , et al. In: FACTS 001 Phase III Trial of Pericoital Tenofovir 1% Gel for HIV Prevention in Women.The 22nd Conference on Retroviruses and Opportunistic Infections;2015 Feb 23-26; Seattle Washington. 2015. ">Delany‐Moretlwe 2018</a>; <a href="./references#CD007961-bbs2-0005" title="FeldblumPJ , AdeigaA , BakareR , WevillS , LendvayA , ObadakiF , et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomised controlled trial in Nigeria. PLoS One2008;3(1):e1474. ">Feldblum 2008</a>; <a href="./references#CD007961-bbs2-0010" title="PetersonL , NandaK , OpokuBK , AmpofoWK , Owusu-AmoakoM , BoakyeAY , et al. SAVVY (C31G) gel for prevention of HIV infection in women: a phase 3, double-blind, randomised, placebo-controlled trial in Ghana. PLoS One2007;2(12):e1312. ">Peterson 2007</a>: <a href="./references#CD007961-bbs2-0012" title="Van DammeL , GovindenR , MirembeFM , GuédouF , SolomonS , BeckerML , et al. Lack of effectiveness of cellulose sulphate gel for the prevention of vaginal HIV transmission. New England Journal of Medicine2008;359(5):463-73. ">Van Damme 2008</a>), all studies reported other STIs as outcomes. However, they differed in the types of STIs reported. Other outcomes reported by individual trials included safety (<a href="./references#CD007961-bbs2-0001" title="Abdool KarimQ , Abdool KarimSS , FrohlichJA , GroblerAC , BaxterC , MansoorEL , et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science2010;329(5996):1168-74. Abdool KarimSS , Abdool KarimQ , KharsanyAB , BaxterC , GroblerAC , WernerL . Tenofovir gel for the prevention of herpes simplex virus type 2 infection. New England Journal of Medicine 20152015;373(6):530-9. KarimQA , KharsanyAB , FrohlichJA , BaxterC , YendeN , MansoorLE , et al. Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials2011;12:67. KellerDM . AIDS 2010, XVIII International AIDS Conference: Tenofovir vaginal gel first microbicide to prevent HIV, HSV infections. Medscape Medical News July 2010. ">Abdool Karim 2010</a>; <a href="./references#CD007961-bbs2-0002" title="Abdool KarimSS , RichardsonBA , RamjeeG , HoffmanIF , ChirenjeZM , TahaT , et al. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS2011;25(7):957-66. GuffeyMB , RichardsonB , HusnikM , MakananiB , ChilongoziD , YuE , et al. HPTN 035 Phase II/IIb Randomized safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in women. Sexually Transmitted Infections2014;90(5):1-15. ">Abdool Karim 2011</a><a href="./references#CD007961-bbs2-0003" title="BaetenJM , Palanee-PhillipsT , BrownER , SchwartzK , Soto-TorresLE , GovenderV , et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. New England Journal of Medicine2016;375(22):2121-32. MTN 2016. Dapivirine vaginal ring helped protect women against HIV in ASPIRE Phase lll trial. Media release. ">Baeten 2016</a>: <a href="./references#CD007961-bbs2-0004" title="Delany-MoretlweS , LombardC , BaronD , BekkerLG , NkalaB , Ahmed K et al. Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised,double-blind, placebo-controlled trial. The Lancet Infectious Diseases2018;18(11):1241-50. ReesHS , SineadA , Delany- MoretiwaS , BaronD , PachiaR , et al. In: FACTS 001 Phase III Trial of Pericoital Tenofovir 1% Gel for HIV Prevention in Women.The 22nd Conference on Retroviruses and Opportunistic Infections;2015 Feb 23-26; Seattle Washington. 2015. ">Delany‐Moretlwe 2018</a>; <a href="./references#CD007961-bbs2-0007" title="MarrazzoJM , RamjeeG , RichardsonBA , GomezK , MgodiN , NairG , et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. New England Journal of Medicine2015;372(6):509-17. ">Marrazzo 2015</a>; ; <a href="./references#CD007961-bbs2-0011" title="MaraisD , GawareckiD , AllanB , AhmedK , AltiniL , CassimN , et al. The effectiveness of Carraguard, a vaginal microbicide, in protecting women against high-risk human papillomavirus infection. Antiviral Therapy2011;16(8):1219-26. Skoler-KarpoffS , RamjeeG , AhmedK , AltiniL , PlagianosMG , FriedlandB , et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9654):1977-87. ">Skoler‐Karpoff 2008</a>), adherence (<a href="./references#CD007961-bbs2-0003" title="BaetenJM , Palanee-PhillipsT , BrownER , SchwartzK , Soto-TorresLE , GovenderV , et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. New England Journal of Medicine2016;375(22):2121-32. MTN 2016. Dapivirine vaginal ring helped protect women against HIV in ASPIRE Phase lll trial. Media release. ">Baeten 2016</a>; <a href="./references#CD007961-bbs2-0004" title="Delany-MoretlweS , LombardC , BaronD , BekkerLG , NkalaB , Ahmed K et al. Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised,double-blind, placebo-controlled trial. The Lancet Infectious Diseases2018;18(11):1241-50. ReesHS , SineadA , Delany- MoretiwaS , BaronD , PachiaR , et al. In: FACTS 001 Phase III Trial of Pericoital Tenofovir 1% Gel for HIV Prevention in Women.The 22nd Conference on Retroviruses and Opportunistic Infections;2015 Feb 23-26; Seattle Washington. 2015. ">Delany‐Moretlwe 2018</a>; <a href="./references#CD007961-bbs2-0007" title="MarrazzoJM , RamjeeG , RichardsonBA , GomezK , MgodiN , NairG , et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. New England Journal of Medicine2015;372(6):509-17. ">Marrazzo 2015</a>; <a href="./references#CD007961-bbs2-0009" title="NelA , Van NiekerkN , KapigaS , BekkerLG , GamaC , GillK . Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. New England Journal of Medicine2016;375(22):2133-45. ">Nel 2016</a>), Other outcomes that were reported are: drug concentration (<a href="./references#CD007961-bbs2-0003" title="BaetenJM , Palanee-PhillipsT , BrownER , SchwartzK , Soto-TorresLE , GovenderV , et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. New England Journal of Medicine2016;375(22):2121-32. MTN 2016. Dapivirine vaginal ring helped protect women against HIV in ASPIRE Phase lll trial. Media release. ">Baeten 2016</a>; <a href="./references#CD007961-bbs2-0007" title="MarrazzoJM , RamjeeG , RichardsonBA , GomezK , MgodiN , NairG , et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. New England Journal of Medicine2015;372(6):509-17. ">Marrazzo 2015</a>; <a href="./references#CD007961-bbs2-0009" title="NelA , Van NiekerkN , KapigaS , BekkerLG , GamaC , GillK . Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. New England Journal of Medicine2016;375(22):2133-45. ">Nel 2016</a>), drug resistance (<a href="./references#CD007961-bbs2-0007" title="MarrazzoJM , RamjeeG , RichardsonBA , GomezK , MgodiN , NairG , et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. New England Journal of Medicine2015;372(6):509-17. ">Marrazzo 2015</a>; <a href="./references#CD007961-bbs2-0009" title="NelA , Van NiekerkN , KapigaS , BekkerLG , GamaC , GillK . Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. New England Journal of Medicine2016;375(22):2133-45. ">Nel 2016</a>), rates of pregnancy (<a href="./references#CD007961-bbs2-0009" title="NelA , Van NiekerkN , KapigaS , BekkerLG , GamaC , GillK . Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. New England Journal of Medicine2016;375(22):2133-45. ">Nel 2016</a>), pharmacokinetics and delayed seroconversion (<a href="./references#CD007961-bbs2-0004" title="Delany-MoretlweS , LombardC , BaronD , BekkerLG , NkalaB , Ahmed K et al. Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised,double-blind, placebo-controlled trial. The Lancet Infectious Diseases2018;18(11):1241-50. ReesHS , SineadA , Delany- MoretiwaS , BaronD , PachiaR , et al. In: FACTS 001 Phase III Trial of Pericoital Tenofovir 1% Gel for HIV Prevention in Women.The 22nd Conference on Retroviruses and Opportunistic Infections;2015 Feb 23-26; Seattle Washington. 2015. ">Delany‐Moretlwe 2018</a>; <a href="./references#CD007961-bbs2-0007" title="MarrazzoJM , RamjeeG , RichardsonBA , GomezK , MgodiN , NairG , et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. New England Journal of Medicine2015;372(6):509-17. ">Marrazzo 2015</a>). </p> </section> <section id="CD007961-sec-0051"> <h5 class="title">Length of follow up</h5> <p>In all trials, monthly follow‐up visits were scheduled for at least 12 months. During follow‐up visits, the participants were provided with comprehensive HIV prevention services (HIV pre‐ and post‐test counselling, HIV risk reduction counselling, condoms, and STI treatment) and reproductive health services, and assigned gels or rings as required. </p> </section> </section> <section id="CD007961-sec-0052"> <h4 class="title">Excluded studies</h4> <p>See: <a href="./references#CD007961-sec-0106" title="">Characteristics of excluded studies</a>. </p> <p>We excluded 10 new studies for this update, making a total of 14 excluded studies. The most common reason for exclusion was that microbicide used in the study was nonoxynol‐9 which is not included this Cochrane review (12 studies), (<a href="./references#CD007961-bbs2-0013" title="ArtzL , MacalusoM , Meinzen-DerrJ , KelaghanJ , AustinH , FleenorM , et al. A randomised trial of clinician-delivered interventions promoting barrier contraception for sexually transmitted disease prevention. Sexually Transmitted Diseases2005;32:672-9. ">Artz 2005</a>; <a href="./references#CD007961-bbs2-0014" title="BarboneF , AustinH , LouvWC , AlexanderWJ . A follow-up study of methods of contraception, sexual activity, and rates of trichomoniasis, candidiasis, and bacterial vaginosis. American Journal of Obstetrics and Gynaecology1990;163(2):510-4. ">Barbone 1990</a>; <a href="./references#CD007961-bbs2-0015" title="CutlerJC , SinghB , CarpenterU , NickensO , ScarolaA , SussmanN , et al. Vaginal contraceptives as prophylaxis against gonorrhoeaand other sexually transmissible diseases. Advances in Planned Parenthood1977;12:45-56. ">Cutler 1997</a>; <a href="./references#CD007961-bbs2-0016" title="Ettiègne-TraoréV , GhysPD , Van DammeL , N'KrumahM , MaïgaA , TiémeléA , et al. Acceptability and feasibility of a clinical trial to assess the efficacy of a microbicide-containing vaginal gel to prevent HIV infection among female sex workers in Abidjan, Cote d'Ivoire. AIDS1997;11(13):1660-2. ">Ettiègne‐Traoré 1997</a>; <a href="./references#CD007961-bbs2-0017" title="KreissJ , NgugiE , HolmesKK , Ndinya-AcholaJ , WaiyakiP , RobertsPL , et al. Efficacy of nonoxynol-9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA1992;268(4):477-82. ">Kreiss 1992</a>; <a href="./references#CD007961-bbs2-0018" title="LouvWC , AustinH , AlexanderWJ , StagnoS , CheeksJ . A clinical trial of nonoxynol-9 for preventing gonococcal and chlamydial infection. Journal of Infectious Diseases1988;158(3):518-23. ">Louv 1998</a>; <a href="./references#CD007961-bbs2-0019" title="NiruthisardS , RoddyRE , ChutivongseS . Use of nonoxynol-9 and reduction in rate of gonococcal and chlamydial cervical infections. Lancet1992;339(8806):1371-5. ">Niruthisard 1992</a>; <a href="./references#CD007961-bbs2-0021" title="RoddyRE , ZekengL , RyanKA , TamouféU , WeirSS , WongEL . A controlled trial of nonoxynol-9 film to reduce male to female transmission of sexually transmitted diseases. New England Journal of Medicine1998;339(8):504–10. ">Roddy 1988</a>; <a href="./references#CD007961-bbs2-0020" title="RendonAL , CovarrubiasJ , McCarneyKE , Marion-LandaisG , Luna del VillarJ . A controlled comparative study of phenyl mercuric acetate, nonoxynol-9 and placebo vaginal suppositories as prophylactic agents against gonorrhoea. Current Therapeutic Research1980;27:780-3. ">Rendon 1980</a>; <a href="./references#CD007961-bbs2-0022" title="RosenbergMJ , FeldblumPJ , RojanapithayakornW , SawasdivornW . The contraceptive sponge's protection against Chlamydia trachomatis and Neisseria gonorrhoeae. Sexually Transmitted Diseases1987;14(3):147-52. ">Rosenberg 1987a</a>; <a href="./references#CD007961-bbs2-0023" title="RosenbergMJ , RojanapithayakornW , FeldblumPJ , HigginsJE . Effect of the contraceptive sponge on chlamydial infection, gonorrhoea, and candidiasis - a comparative clinical trial. JAMA1987;257(17):780–3. ">Rosenberg 1987b</a>; <a href="./references#CD007961-bbs2-0024" title="SacksSL , VarnerTL , DaviesKS , RekartML , StiverHG , DeLongER , et al. Randomised, double-blind,placebo-controlled, patient initiated study of topical high and low-dose interferon-alpha with nonoxynol-9 in the treatment of recurrent genital herpes. Journal of Infectious Diseases1990;161:692–8. ">Sacks 1990</a>). See <a href="./references#CD007961-bbs2-0081" title="WilkinsonD , RamjeeG , TholandiM , RutherfordG . Nonoxynol-9 for preventing vaginal acquisition of sexually transmitted infections by women from men. Cochrane Database of Systematic Reviews2002, Issue 1. Art. No: CD003939. [DOI: 10.1002/14651858.CD003939]">Wilkinson 2002a</a> and <a href="./references#CD007961-bbs2-0082" title="WilkinsonD , RamjeeG , TholandiM , RutherfordG . Nonoxynol-9 for preventing vaginal acquisition of HIV infection by women from men. Cochrane Database of Systematic Reviews2002, Issue 3. Art. No: CD003936. [DOI: 10.1002/14651858.CD003936]">Wilkinson 2002b</a>. One study used an in‐vitro or animal study (<a href="./references#CD007961-bbs2-0026" title="ZaneveldLJ , AndersonRA , DiaoXH , WallerDP , ChanyC , FeathergillK , et al. Use of mandelic acid condensation polymer (SAMMA), a new antimicrobial contraceptive agent, for vaginal prophylaxis. Fertility and Sterility2002;78(5):1107-15. ">Zaneveld 2002</a>) and one other study included HIV‐positive participants (<a href="./references#CD007961-bbs2-0025" title="Van der StratenA , NapieralaS , ChengH , MauckC , DepineresT , DhlakamaP , et al. A randomised controlled safety trial of the diaphragm and cellulose sulphate microbicide gel in sexually active women in Zimbabwe. Contraception2007;76:389-99. ">Van der Straten 2007</a>) (see <a href="./references#CD007961-sec-0106" title="">Characteristics of excluded studies</a> table). </p> </section> </section> <section id="CD007961-sec-0053"> <h3 class="title">Risk of bias in included studies</h3> <p>  See below the risk of bias in included studies by domain.</p> <section id="CD007961-sec-0054"> <h4 class="title">Allocation</h4> <p><b>Random sequence generation</b> </p> <p>All trials adequately reported the random process of sequence generation, for example, random number table or computer random number generator, making selection bias unlikely. </p> <p><b>Allocation concealment</b> </p> <p>For allocation concealment central randomisation was used in eight trials (<a href="./references#CD007961-bbs2-0001" title="Abdool KarimQ , Abdool KarimSS , FrohlichJA , GroblerAC , BaxterC , MansoorEL , et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science2010;329(5996):1168-74. Abdool KarimSS , Abdool KarimQ , KharsanyAB , BaxterC , GroblerAC , WernerL . Tenofovir gel for the prevention of herpes simplex virus type 2 infection. New England Journal of Medicine 20152015;373(6):530-9. KarimQA , KharsanyAB , FrohlichJA , BaxterC , YendeN , MansoorLE , et al. Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials2011;12:67. KellerDM . AIDS 2010, XVIII International AIDS Conference: Tenofovir vaginal gel first microbicide to prevent HIV, HSV infections. Medscape Medical News July 2010. ">Abdool Karim 2010</a>; <a href="./references#CD007961-bbs2-0002" title="Abdool KarimSS , RichardsonBA , RamjeeG , HoffmanIF , ChirenjeZM , TahaT , et al. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS2011;25(7):957-66. GuffeyMB , RichardsonB , HusnikM , MakananiB , ChilongoziD , YuE , et al. HPTN 035 Phase II/IIb Randomized safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in women. Sexually Transmitted Infections2014;90(5):1-15. ">Abdool Karim 2011</a>; <a href="./references#CD007961-bbs2-0003" title="BaetenJM , Palanee-PhillipsT , BrownER , SchwartzK , Soto-TorresLE , GovenderV , et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. New England Journal of Medicine2016;375(22):2121-32. MTN 2016. Dapivirine vaginal ring helped protect women against HIV in ASPIRE Phase lll trial. Media release. ">Baeten 2016</a>; <a href="./references#CD007961-bbs2-0004" title="Delany-MoretlweS , LombardC , BaronD , BekkerLG , NkalaB , Ahmed K et al. Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised,double-blind, placebo-controlled trial. The Lancet Infectious Diseases2018;18(11):1241-50. ReesHS , SineadA , Delany- MoretiwaS , BaronD , PachiaR , et al. In: FACTS 001 Phase III Trial of Pericoital Tenofovir 1% Gel for HIV Prevention in Women.The 22nd Conference on Retroviruses and Opportunistic Infections;2015 Feb 23-26; Seattle Washington. 2015. ">Delany‐Moretlwe 2018</a>; <a href="./references#CD007961-bbs2-0007" title="MarrazzoJM , RamjeeG , RichardsonBA , GomezK , MgodiN , NairG , et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. New England Journal of Medicine2015;372(6):509-17. ">Marrazzo 2015</a>; <a href="./references#CD007961-bbs2-0008" title="McCormackS , RamjeeG , KamaliA , ReesH , CrookAM , GafosM , et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet2010;376(9749):1329-37. ">McCormack 2010</a>; <a href="./references#CD007961-bbs2-0009" title="NelA , Van NiekerkN , KapigaS , BekkerLG , GamaC , GillK . Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. New England Journal of Medicine2016;375(22):2133-45. ">Nel 2016</a>; <a href="./references#CD007961-bbs2-0011" title="MaraisD , GawareckiD , AllanB , AhmedK , AltiniL , CassimN , et al. The effectiveness of Carraguard, a vaginal microbicide, in protecting women against high-risk human papillomavirus infection. Antiviral Therapy2011;16(8):1219-26. Skoler-KarpoffS , RamjeeG , AhmedK , AltiniL , PlagianosMG , FriedlandB , et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9654):1977-87. ">Skoler‐Karpoff 2008</a>) and sequentially‐numbered, sealed opaque envelopes in four (<a href="./references#CD007961-bbs2-0005" title="FeldblumPJ , AdeigaA , BakareR , WevillS , LendvayA , ObadakiF , et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomised controlled trial in Nigeria. PLoS One2008;3(1):e1474. ">Feldblum 2008</a>; <a href="./references#CD007961-bbs2-0006" title="HalpernV , OgunsolaF , ObungeO , WangCH , OnyejepuN , OduyeboO , et al. Effectiveness of cellulose sulphate vaginal gel for the prevention of HIV infection: results of a phase III trial in Nigeria. PLoS One2008;3(11):e3784. ">Halpern 2008</a>; <a href="./references#CD007961-bbs2-0010" title="PetersonL , NandaK , OpokuBK , AmpofoWK , Owusu-AmoakoM , BoakyeAY , et al. SAVVY (C31G) gel for prevention of HIV infection in women: a phase 3, double-blind, randomised, placebo-controlled trial in Ghana. PLoS One2007;2(12):e1312. ">Peterson 2007</a>; <a href="./references#CD007961-bbs2-0012" title="Van DammeL , GovindenR , MirembeFM , GuédouF , SolomonS , BeckerML , et al. Lack of effectiveness of cellulose sulphate gel for the prevention of vaginal HIV transmission. New England Journal of Medicine2008;359(5):463-73. ">Van Damme 2008</a>). We judged the risk of bias to be low in all trials. </p> </section> <section id="CD007961-sec-0055"> <h4 class="title">Blinding</h4> <p>Participants, trial personnel, and outcome assessors were blind to treatment allocation in all trials. In these trials, the intervention and placebo were identical in appearance and packaging. We therefore judged the risk of performance bias (blinding of participants and study personnel) and detection bias (blinding of outcome assessors) to be low in all trials. </p> </section> <section id="CD007961-sec-0056"> <h4 class="title">Incomplete outcome data</h4> <p>All the included trials addressed completeness of outcome data adequately by providing information on participant dropout which was equally distributed between the intervention groups and also reported intention to treat data. The level of missing data in 10 trials (<a href="./references#CD007961-bbs2-0001" title="Abdool KarimQ , Abdool KarimSS , FrohlichJA , GroblerAC , BaxterC , MansoorEL , et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science2010;329(5996):1168-74. Abdool KarimSS , Abdool KarimQ , KharsanyAB , BaxterC , GroblerAC , WernerL . Tenofovir gel for the prevention of herpes simplex virus type 2 infection. New England Journal of Medicine 20152015;373(6):530-9. KarimQA , KharsanyAB , FrohlichJA , BaxterC , YendeN , MansoorLE , et al. Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials2011;12:67. KellerDM . AIDS 2010, XVIII International AIDS Conference: Tenofovir vaginal gel first microbicide to prevent HIV, HSV infections. Medscape Medical News July 2010. ">Abdool Karim 2010</a>; <a href="./references#CD007961-bbs2-0002" title="Abdool KarimSS , RichardsonBA , RamjeeG , HoffmanIF , ChirenjeZM , TahaT , et al. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS2011;25(7):957-66. GuffeyMB , RichardsonB , HusnikM , MakananiB , ChilongoziD , YuE , et al. HPTN 035 Phase II/IIb Randomized safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in women. Sexually Transmitted Infections2014;90(5):1-15. ">Abdool Karim 2011</a>; <a href="./references#CD007961-bbs2-0003" title="BaetenJM , Palanee-PhillipsT , BrownER , SchwartzK , Soto-TorresLE , GovenderV , et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. New England Journal of Medicine2016;375(22):2121-32. MTN 2016. Dapivirine vaginal ring helped protect women against HIV in ASPIRE Phase lll trial. Media release. ">Baeten 2016</a>; <a href="./references#CD007961-bbs2-0004" title="Delany-MoretlweS , LombardC , BaronD , BekkerLG , NkalaB , Ahmed K et al. Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised,double-blind, placebo-controlled trial. The Lancet Infectious Diseases2018;18(11):1241-50. ReesHS , SineadA , Delany- MoretiwaS , BaronD , PachiaR , et al. In: FACTS 001 Phase III Trial of Pericoital Tenofovir 1% Gel for HIV Prevention in Women.The 22nd Conference on Retroviruses and Opportunistic Infections;2015 Feb 23-26; Seattle Washington. 2015. ">Delany‐Moretlwe 2018</a>; <a href="./references#CD007961-bbs2-0007" title="MarrazzoJM , RamjeeG , RichardsonBA , GomezK , MgodiN , NairG , et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. New England Journal of Medicine2015;372(6):509-17. ">Marrazzo 2015</a>; <a href="./references#CD007961-bbs2-0008" title="McCormackS , RamjeeG , KamaliA , ReesH , CrookAM , GafosM , et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet2010;376(9749):1329-37. ">McCormack 2010</a>; <a href="./references#CD007961-bbs2-0009" title="NelA , Van NiekerkN , KapigaS , BekkerLG , GamaC , GillK . Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. New England Journal of Medicine2016;375(22):2133-45. ">Nel 2016</a>; <a href="./references#CD007961-bbs2-0010" title="PetersonL , NandaK , OpokuBK , AmpofoWK , Owusu-AmoakoM , BoakyeAY , et al. SAVVY (C31G) gel for prevention of HIV infection in women: a phase 3, double-blind, randomised, placebo-controlled trial in Ghana. PLoS One2007;2(12):e1312. ">Peterson 2007</a>; <a href="./references#CD007961-bbs2-0011" title="MaraisD , GawareckiD , AllanB , AhmedK , AltiniL , CassimN , et al. The effectiveness of Carraguard, a vaginal microbicide, in protecting women against high-risk human papillomavirus infection. Antiviral Therapy2011;16(8):1219-26. Skoler-KarpoffS , RamjeeG , AhmedK , AltiniL , PlagianosMG , FriedlandB , et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9654):1977-87. ">Skoler‐Karpoff 2008</a>; <a href="./references#CD007961-bbs2-0012" title="Van DammeL , GovindenR , MirembeFM , GuédouF , SolomonS , BeckerML , et al. Lack of effectiveness of cellulose sulphate gel for the prevention of vaginal HIV transmission. New England Journal of Medicine2008;359(5):463-73. ">Van Damme 2008</a>) was less than 20% and the attrition probably was not related to the outcomes, making attrition bias unlikely. We thus considered these trials to be at low risk of attrition bias. In two trials (<a href="./references#CD007961-bbs2-0006" title="HalpernV , OgunsolaF , ObungeO , WangCH , OnyejepuN , OduyeboO , et al. Effectiveness of cellulose sulphate vaginal gel for the prevention of HIV infection: results of a phase III trial in Nigeria. PLoS One2008;3(11):e3784. ">Halpern 2008</a>; <a href="./references#CD007961-bbs2-0005" title="FeldblumPJ , AdeigaA , BakareR , WevillS , LendvayA , ObadakiF , et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomised controlled trial in Nigeria. PLoS One2008;3(1):e1474. ">Feldblum 2008</a>) loss to follow‐up was more than 20%, so we judged the risk of attrition bias as high in these two trials. </p> </section> <section id="CD007961-sec-0057"> <h4 class="title">Selective reporting</h4> <p>Eleven trials reported outcomes as stated in the respective trial protocols, and we judged these to have low risk of reporting bias. However, one trial (<a href="./references#CD007961-bbs2-0004" title="Delany-MoretlweS , LombardC , BaronD , BekkerLG , NkalaB , Ahmed K et al. Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised,double-blind, placebo-controlled trial. The Lancet Infectious Diseases2018;18(11):1241-50. ReesHS , SineadA , Delany- MoretiwaS , BaronD , PachiaR , et al. In: FACTS 001 Phase III Trial of Pericoital Tenofovir 1% Gel for HIV Prevention in Women.The 22nd Conference on Retroviruses and Opportunistic Infections;2015 Feb 23-26; Seattle Washington. 2015. ">Delany‐Moretlwe 2018</a>) described the primary outcomes but stated that the other outcomes will be reported elsewhere, so we judged the risk of bias of selective reporting as unclear in this trial. </p> </section> <section id="CD007961-sec-0058"> <h4 class="title">Other potential sources of bias</h4> <p>One trial has a potential source of bias as it was funded by a pharmaceutical company (<a href="./references#CD007961-bbs2-0008" title="McCormackS , RamjeeG , KamaliA , ReesH , CrookAM , GafosM , et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet2010;376(9749):1329-37. ">McCormack 2010</a>), but we do not think that necessarily introduced bias. The remaining 11 trials appeared to be free from other sources of bias. </p> <section id="CD007961-sec-0059"> <h5 class="title">Summary of risk of bias</h5> <p>Our judgements about the risk of bias in each included trial are summarised in <a href="#CD007961-fig-0002">Figure 2</a> and <a href="#CD007961-fig-0003">Figure 3</a>. Overall, we judged nine trials to be at low risk of bias, one trial to be at moderate risk of bias (<a href="./references#CD007961-bbs2-0004" title="Delany-MoretlweS , LombardC , BaronD , BekkerLG , NkalaB , Ahmed K et al. Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised,double-blind, placebo-controlled trial. The Lancet Infectious Diseases2018;18(11):1241-50. ReesHS , SineadA , Delany- MoretiwaS , BaronD , PachiaR , et al. In: FACTS 001 Phase III Trial of Pericoital Tenofovir 1% Gel for HIV Prevention in Women.The 22nd Conference on Retroviruses and Opportunistic Infections;2015 Feb 23-26; Seattle Washington. 2015. ">Delany‐Moretlwe 2018</a>), and two to be at high risk of bias (<a href="./references#CD007961-bbs2-0006" title="HalpernV , OgunsolaF , ObungeO , WangCH , OnyejepuN , OduyeboO , et al. Effectiveness of cellulose sulphate vaginal gel for the prevention of HIV infection: results of a phase III trial in Nigeria. PLoS One2008;3(11):e3784. ">Halpern 2008</a>; <a href="./references#CD007961-bbs2-0005" title="FeldblumPJ , AdeigaA , BakareR , WevillS , LendvayA , ObadakiF , et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomised controlled trial in Nigeria. PLoS One2008;3(1):e1474. ">Feldblum 2008</a>). </p> <div class="figure" id="CD007961-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD007961-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/image_n/nCD007961-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD007961-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD007961-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/image_n/nCD007961-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <p>We could not formally evaluate the risk of publication bias, because there were too few included trials in each comparison. </p> </section> </section> </section> <section id="CD007961-sec-0060"> <h3 class="title" id="CD007961-sec-0060">Effects of interventions</h3> <p>See: <a href="./full#CD007961-tbl-0001"><b>Summary of findings 1</b> Dapivirine vaginal microbicide for preventing sexually transmitted infections</a>; <a href="./full#CD007961-tbl-0002"><b>Summary of findings 2</b> Tenofovir vaginal microbicide for preventing sexually transmitted infections</a>; <a href="./full#CD007961-tbl-0003"><b>Summary of findings 3</b> Cellulose sulphate vaginal microbicide for preventing sexually transmitted infections</a> </p> <section id="CD007961-sec-0061"> <h4 class="title"><i>Overall quality of the body of evidence: Summary of findings tab</i>le </h4> <p>See: <a href="./full#CD007961-tbl-0001">summary of findings Table 1</a> Dapirine vaginal microbicide compared to placebo for preventing sexually transmitted infections; <a href="./full#CD007961-tbl-0002">summary of findings Table 2</a> Tenofovir vaginal microbicide for preventing sexually transmitted infections; <a href="./full#CD007961-tbl-0003">summary of findings Table 3</a> Cellulose sulphate vaginal microbicide for preventing sexually transmitted infections. </p> <section id="CD007961-sec-0062"> <h5 class="title">1. Primary outcomes</h5> <p><b>1.1. Laboratory confirmed incidence of viral sexually transmitted infections</b> </p> <section id="CD007961-sec-0063"> <h6 class="title">1.1.1. HIV infection</h6> <p>Dapivirine vaginal ring (<a href="./references#CD007961-bbs2-0003" title="BaetenJM , Palanee-PhillipsT , BrownER , SchwartzK , Soto-TorresLE , GovenderV , et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. New England Journal of Medicine2016;375(22):2121-32. MTN 2016. Dapivirine vaginal ring helped protect women against HIV in ASPIRE Phase lll trial. Media release. ">Baeten 2016</a>; <a href="./references#CD007961-bbs2-0009" title="NelA , Van NiekerkN , KapigaS , BekkerLG , GamaC , GillK . Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. New England Journal of Medicine2016;375(22):2133-45. ">Nel 2016</a>) probably decreases the risk of acquisition of HIV infection when compared to placebo (RR 0.71, 95% CI 0.57 to 0.89; I<sup>2</sup> = 0%; 2 trials, 4588 women; moderate‐certainty evidence; <a href="./references#CD007961-fig-0004" title="">Analysis 1.1</a>). Our only concern with the data is that only two studies have so far assessed this microbicide (<a href="./full#CD007961-tbl-0001">summary of findings Table 1</a>). </p> <p>Tenofovir vaginal gel (<a href="./references#CD007961-bbs2-0001" title="Abdool KarimQ , Abdool KarimSS , FrohlichJA , GroblerAC , BaxterC , MansoorEL , et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science2010;329(5996):1168-74. Abdool KarimSS , Abdool KarimQ , KharsanyAB , BaxterC , GroblerAC , WernerL . Tenofovir gel for the prevention of herpes simplex virus type 2 infection. New England Journal of Medicine 20152015;373(6):530-9. KarimQA , KharsanyAB , FrohlichJA , BaxterC , YendeN , MansoorLE , et al. Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials2011;12:67. KellerDM . AIDS 2010, XVIII International AIDS Conference: Tenofovir vaginal gel first microbicide to prevent HIV, HSV infections. Medscape Medical News July 2010. ">Abdool Karim 2010</a>; <a href="./references#CD007961-bbs2-0004" title="Delany-MoretlweS , LombardC , BaronD , BekkerLG , NkalaB , Ahmed K et al. Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised,double-blind, placebo-controlled trial. The Lancet Infectious Diseases2018;18(11):1241-50. ReesHS , SineadA , Delany- MoretiwaS , BaronD , PachiaR , et al. In: FACTS 001 Phase III Trial of Pericoital Tenofovir 1% Gel for HIV Prevention in Women.The 22nd Conference on Retroviruses and Opportunistic Infections;2015 Feb 23-26; Seattle Washington. 2015. ">Delany‐Moretlwe 2018</a>; <a href="./references#CD007961-bbs2-0007" title="MarrazzoJM , RamjeeG , RichardsonBA , GomezK , MgodiN , NairG , et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. New England Journal of Medicine2015;372(6):509-17. ">Marrazzo 2015</a>; ) may not lead to any difference in the risk of HIV acquisition, compared to placebo (RR 0.83, 95% CI 0.68 to 1.02, I<sup>2</sup> = 31%; 3 trials, 4958 women; low‐certainty evidence; <a href="./references#CD007961-fig-0004" title="">Analysis 1.1</a>). Our main concern with this evidence is imprecision, as the effect of tenofovir on HIV acquisition ranged from a large clinical benefit to a small increase in harm (<a href="./full#CD007961-tbl-0002">summary of findings Table 2</a>). </p> <p>None of the other microbicides tested showed evidence of an effect on the risk of acquiring HIV acquisition (<a href="./references#CD007961-fig-0004" title="">Analysis 1.1</a>): </p> <p> <ul id="CD007961-list-0004"> <li> <p>BufferGel (<a href="./references#CD007961-bbs2-0002" title="Abdool KarimSS , RichardsonBA , RamjeeG , HoffmanIF , ChirenjeZM , TahaT , et al. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS2011;25(7):957-66. GuffeyMB , RichardsonB , HusnikM , MakananiB , ChilongoziD , YuE , et al. HPTN 035 Phase II/IIb Randomized safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in women. Sexually Transmitted Infections2014;90(5):1-15. ">Abdool Karim 2011</a>): RR 1.05, 95% CI 0.73 to 1.52; 1 trial, 1546 women; </p> </li> <li> <p>Carraguard (<a href="./references#CD007961-bbs2-0011" title="MaraisD , GawareckiD , AllanB , AhmedK , AltiniL , CassimN , et al. The effectiveness of Carraguard, a vaginal microbicide, in protecting women against high-risk human papillomavirus infection. Antiviral Therapy2011;16(8):1219-26. Skoler-KarpoffS , RamjeeG , AhmedK , AltiniL , PlagianosMG , FriedlandB , et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9654):1977-87. ">Skoler‐Karpoff 2008</a>): RR 0.89, 95% CI 0.71 to 1.11; 1 trial, 6202 women; </p> </li> <li> <p>Cellulose sulphate (<a href="./references#CD007961-bbs2-0006" title="HalpernV , OgunsolaF , ObungeO , WangCH , OnyejepuN , OduyeboO , et al. Effectiveness of cellulose sulphate vaginal gel for the prevention of HIV infection: results of a phase III trial in Nigeria. PLoS One2008;3(11):e3784. ">Halpern 2008</a>; <a href="./references#CD007961-bbs2-0012" title="Van DammeL , GovindenR , MirembeFM , GuédouF , SolomonS , BeckerML , et al. Lack of effectiveness of cellulose sulphate gel for the prevention of vaginal HIV transmission. New England Journal of Medicine2008;359(5):463-73. ">Van Damme 2008</a>): RR 1.20, 95% CI 0.74 to 1.95; I<sup>2</sup> = 43%; 2 trials 3069 women; </p> </li> <li> <p>PRO 2000 (<a href="./references#CD007961-bbs2-0002" title="Abdool KarimSS , RichardsonBA , RamjeeG , HoffmanIF , ChirenjeZM , TahaT , et al. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS2011;25(7):957-66. GuffeyMB , RichardsonB , HusnikM , MakananiB , ChilongoziD , YuE , et al. HPTN 035 Phase II/IIb Randomized safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in women. Sexually Transmitted Infections2014;90(5):1-15. ">Abdool Karim 2011</a>; <a href="./references#CD007961-bbs2-0008" title="McCormackS , RamjeeG , KamaliA , ReesH , CrookAM , GafosM , et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet2010;376(9749):1329-37. ">McCormack 2010</a>): RR 0.93, 95% CI 0.77 to 1.14; I<sup>2</sup> = 55%; 2 trials, 8191 women; </p> </li> <li> <p>SAVVY (<a href="./references#CD007961-bbs2-0005" title="FeldblumPJ , AdeigaA , BakareR , WevillS , LendvayA , ObadakiF , et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomised controlled trial in Nigeria. PLoS One2008;3(1):e1474. ">Feldblum 2008</a>; <a href="./references#CD007961-bbs2-0010" title="PetersonL , NandaK , OpokuBK , AmpofoWK , Owusu-AmoakoM , BoakyeAY , et al. SAVVY (C31G) gel for prevention of HIV infection in women: a phase 3, double-blind, randomised, placebo-controlled trial in Ghana. PLoS One2007;2(12):e1312. ">Peterson 2007</a>): RR 1.38, 95% CI 0.79 to 2.41; I<sup>2</sup> = 22%; 2 trials, 4295 women. </p> </li> </ul> </p> </section> <section id="CD007961-sec-0064"> <h6 class="title">1.1.2. Herpes simplex virus infection</h6> <p>Four studies reported herpes simplex virus (HSV) incidence (<a href="./references#CD007961-bbs2-0001" title="Abdool KarimQ , Abdool KarimSS , FrohlichJA , GroblerAC , BaxterC , MansoorEL , et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science2010;329(5996):1168-74. Abdool KarimSS , Abdool KarimQ , KharsanyAB , BaxterC , GroblerAC , WernerL . Tenofovir gel for the prevention of herpes simplex virus type 2 infection. New England Journal of Medicine 20152015;373(6):530-9. KarimQA , KharsanyAB , FrohlichJA , BaxterC , YendeN , MansoorLE , et al. Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials2011;12:67. KellerDM . AIDS 2010, XVIII International AIDS Conference: Tenofovir vaginal gel first microbicide to prevent HIV, HSV infections. Medscape Medical News July 2010. ">Abdool Karim 2010</a>; <a href="./references#CD007961-bbs2-0007" title="MarrazzoJM , RamjeeG , RichardsonBA , GomezK , MgodiN , NairG , et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. New England Journal of Medicine2015;372(6):509-17. ">Marrazzo 2015</a>; <a href="./references#CD007961-bbs2-0008" title="McCormackS , RamjeeG , KamaliA , ReesH , CrookAM , GafosM , et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet2010;376(9749):1329-37. ">McCormack 2010</a>; <a href="./references#CD007961-bbs2-0012" title="Van DammeL , GovindenR , MirembeFM , GuédouF , SolomonS , BeckerML , et al. Lack of effectiveness of cellulose sulphate gel for the prevention of vaginal HIV transmission. New England Journal of Medicine2008;359(5):463-73. ">Van Damme 2008</a>). It is uncertain whether cellulose sulphate improved the incidence of HSV compared to placebo (RR 0.99, 95% CI 0.37 to 2.62; 1 trial, 1425 participants; very low‐certainty evidence; <a href="./references#CD007961-fig-0005" title="">Analysis 1.2</a>) or for 0.5% PRO 2000 (RR 0.95, 95% CI 0.73 to 1.23; 1 trial, 6651 participants; very low‐certainty evidence; <a href="./references#CD007961-fig-0005" title="">Analysis 1.2</a>). Two studies reported data on the effect of tenofovir. One study with 224 participants suggests that tenofovir may reduce the risk of getting HSV (RR 0.55, 95% CI 0.36 to 0.82; <a href="./references#CD007961-bbs2-0001" title="Abdool KarimQ , Abdool KarimSS , FrohlichJA , GroblerAC , BaxterC , MansoorEL , et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science2010;329(5996):1168-74. Abdool KarimSS , Abdool KarimQ , KharsanyAB , BaxterC , GroblerAC , WernerL . Tenofovir gel for the prevention of herpes simplex virus type 2 infection. New England Journal of Medicine 20152015;373(6):530-9. KarimQA , KharsanyAB , FrohlichJA , BaxterC , YendeN , MansoorLE , et al. Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials2011;12:67. KellerDM . AIDS 2010, XVIII International AIDS Conference: Tenofovir vaginal gel first microbicide to prevent HIV, HSV infections. Medscape Medical News July 2010. ">Abdool Karim 2010</a>) but the other study found that it probably makes little or no difference in preventing this infection (RR 0.94, 95% CI 0.85 to 1.03; 1003 participants; <a href="./references#CD007961-bbs2-0007" title="MarrazzoJM , RamjeeG , RichardsonBA , GomezK , MgodiN , NairG , et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. New England Journal of Medicine2015;372(6):509-17. ">Marrazzo 2015</a>). We have not reported the pooled result because of substantial heterogeneity of effect (l<sup>2</sup> = 85%; <a href="./references#CD007961-fig-0005" title="">Analysis 1.2</a>). Our concerns with the evidence were considerable unexplained heterogeneity for tenofovir (<a href="./full#CD007961-tbl-0002">summary of findings Table 2</a>) and imprecision for the other microbicides (<a href="./full#CD007961-tbl-0003">summary of findings Table 3</a>). The two dapivirine studies (<a href="./references#CD007961-bbs2-0003" title="BaetenJM , Palanee-PhillipsT , BrownER , SchwartzK , Soto-TorresLE , GovenderV , et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. New England Journal of Medicine2016;375(22):2121-32. MTN 2016. Dapivirine vaginal ring helped protect women against HIV in ASPIRE Phase lll trial. Media release. ">Baeten 2016</a>; <a href="./references#CD007961-bbs2-0009" title="NelA , Van NiekerkN , KapigaS , BekkerLG , GamaC , GillK . Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. New England Journal of Medicine2016;375(22):2133-45. ">Nel 2016</a> did not screen for HSV (<a href="./full#CD007961-tbl-0001">summary of findings Table 1</a>). </p> </section> <section id="CD007961-sec-0065"> <h6 class="title">1.1.3 Condyloma acuminatum</h6> <p>We are uncertain whether the effect of cellulose sulphate on the risk of acquisition of condylomata acuminatum is different from that of placebo (RR 3.46, 95% CI 0.72 to 16.58; 1 trial (<a href="./references#CD007961-bbs2-0012" title="Van DammeL , GovindenR , MirembeFM , GuédouF , SolomonS , BeckerML , et al. Lack of effectiveness of cellulose sulphate gel for the prevention of vaginal HIV transmission. New England Journal of Medicine2008;359(5):463-73. ">Van Damme 2008</a>), 1425 women; very low‐certainty evidence; <a href="./references#CD007961-fig-0006" title="">Analysis 1.3</a>). Our main concern was substantial imprecision of the effect estimate. </p> </section> <section id="CD007961-sec-0066"> <h6 class="title">1. 1.4 High‐risk Human papillomavirus</h6> <p>The risk of acquiring HPV was reported by a sub‐study of the Carraguard trial (<a href="./references#CD007961-bbs2-0011" title="MaraisD , GawareckiD , AllanB , AhmedK , AltiniL , CassimN , et al. The effectiveness of Carraguard, a vaginal microbicide, in protecting women against high-risk human papillomavirus infection. Antiviral Therapy2011;16(8):1219-26. Skoler-KarpoffS , RamjeeG , AhmedK , AltiniL , PlagianosMG , FriedlandB , et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9654):1977-87. ">Skoler‐Karpoff 2008</a>) involving 1718 women. At the end of the study the incidence of high‐risk HPV infection was 23.5% in women on Carraguard and 23.0% in the placebo arm (RR 1.02, 95% CI 0.86 to 1.21; very low‐certainty evidence; <a href="./references#CD007961-fig-0007" title="">Analysis 1.4</a>). Our main concerns were imprecision and study limitations. </p> <p><b>1.2. Laboratory confirmed incidence of bacterial sexually transmitted infections</b> </p> </section> <section id="CD007961-sec-0067"> <h6 class="title">1.2.1 Gonorrhoea infection</h6> <p>Seven trials reported gonorrhoea incidence, finding no evidence of a difference in effects between the microbicide and placebo groups (<a href="./references#CD007961-fig-0008" title="">Analysis 1.5</a>): Carraguard (RR 1.06, 95% CI 0.88 to 1.27; 1 trial, 6202 women; low‐certainty evidence); cellulose sulphate (RR 0.89, 95% CI 0.67 to 1.17; l<sup>2</sup> = 50%; 2 trials, 3069 women; low‐certainty evidence); PRO 2000 (RR 1.15, 95% CI 0.87 to 1.52; I<sup>2</sup> = 45%; 2 trials, 8191 women; low‐certainty evidence); BufferGel (RR 0.99, 95% CI 0.51 to 1.93; 1 trial, 1546 women; low‐certainty evidence); tenofovir (RR 0.66, 95% CI 0.40 to 1.10; 1 trial, 2010 women; low‐certainty evidence); dapivirine (RR 1.00, 95% CI 0.87 to 1.15; 2 trials, 4586 women; low‐certainty evidence). Our main concern was very serious imprecision of effects, as most of the findings range from large beneficial effects to large harmful effects (<a href="./full#CD007961-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD007961-tbl-0002">summary of findings Table 2</a>: <a href="./full#CD007961-tbl-0003">summary of findings Table 3</a>). </p> </section> <section id="CD007961-sec-0068"> <h6 class="title">1.2.2. Chlamydia trachomatis</h6> <p>Eight trials reported Chlamydia trachomatis incidence, finding no evidence of a difference in effects between microbicide and placebo groups, except for cellulose sulphate. The results suggest that cellulose sulphate may reduce the risk of acquiring chlamydia infection (RR 0.70, 95% CI 0.49 to 0.99; I<sup>2</sup> = 0%; 2 trials, 3069 women; low‐certainty evidence; <a href="./references#CD007961-fig-0009" title="">Analysis 1.6</a>). There was no evidence of an effect for other microbicides: BufferGel (RR 0.97, 95% CI 0.65 to 1.45; 1 trial, 1546 women; low‐certainty evidence; <a href="./references#CD007961-fig-0009" title="">Analysis 1.6</a>); Carraguard (RR 0.96, 95% CI 0.83 to 1.12; 1 trial, 6202 women; low‐certainty evidence; <a href="./references#CD007961-fig-0009" title="">Analysis 1.6</a>); dapivirine (RR 0.97, 95% CI 0.89 to 1.07; I<sup>2</sup> = 0%; 2 trials, 4586 women; moderate‐certainty evidence; <a href="./references#CD007961-fig-0009" title="">Analysis 1.6</a>); PRO 2000 (RR 1.01, 95% CI 0.84 to 1.22; I<sup>2</sup> = 0%; 2 trials, 8191 women; low‐certainty evidence; <a href="./references#CD007961-fig-0009" title="">Analysis 1.6</a>), and tenofovir (RR 0.90, 95% CI 0.71 to 1.13; 1 trial, 2010 women; low‐certainty evidence; <a href="./references#CD007961-fig-0009" title="">Analysis 1.6</a>). Our main concern was substantial imprecision in the effect estimates (<a href="./full#CD007961-tbl-0001">summary of findings Table 1</a>,<a href="./full#CD007961-tbl-0002">summary of findings Table 2</a>, and <a href="./full#CD007961-tbl-0003">summary of findings Table 3</a> </p> </section> <section id="CD007961-sec-0069"> <h6 class="title">1.2.3. Syphilis</h6> <p>From data reported by four trials (<a href="./references#CD007961-bbs2-0007" title="MarrazzoJM , RamjeeG , RichardsonBA , GomezK , MgodiN , NairG , et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. New England Journal of Medicine2015;372(6):509-17. ">Marrazzo 2015</a>; <a href="./references#CD007961-bbs2-0009" title="NelA , Van NiekerkN , KapigaS , BekkerLG , GamaC , GillK . Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. New England Journal of Medicine2016;375(22):2133-45. ">Nel 2016</a>; <a href="./references#CD007961-bbs2-0011" title="MaraisD , GawareckiD , AllanB , AhmedK , AltiniL , CassimN , et al. The effectiveness of Carraguard, a vaginal microbicide, in protecting women against high-risk human papillomavirus infection. Antiviral Therapy2011;16(8):1219-26. Skoler-KarpoffS , RamjeeG , AhmedK , AltiniL , PlagianosMG , FriedlandB , et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9654):1977-87. ">Skoler‐Karpoff 2008</a>; <a href="./references#CD007961-bbs2-0012" title="Van DammeL , GovindenR , MirembeFM , GuédouF , SolomonS , BeckerML , et al. Lack of effectiveness of cellulose sulphate gel for the prevention of vaginal HIV transmission. New England Journal of Medicine2008;359(5):463-73. ">Van Damme 2008</a>), the effects of the following microbicides on the risk of syphilis acquisition may not be different from those of placebo: Carraguard (RR 1.07, 95% CI 0.75 to 1.52; 1 trial, 6202 women; low‐certainty evidence; <a href="./references#CD007961-fig-0010" title="">Analysis 1.7</a>.1); cellulose sulphate (RR 0.69, 95% CI 0.26 to 1.81; 1 trial, 1425 women; low‐certainty evidence; <a href="./references#CD007961-fig-0010" title="">Analysis 1.7</a>); dapivirine (RR 1.70, 95% CI 0.63 to 4.59: 1 trial, 1956 women; low‐certainty evidence; <a href="./references#CD007961-fig-0010" title="">Analysis 1.7</a>); and tenofovir (RR 1.27, 95% CI 0.58 to 2.78; 1 trial, 2010 women; low‐certainty evidence; <a href="./references#CD007961-fig-0010" title="">Analysis 1.7</a>). We downgraded the evidence for each microbicide to low because of substantial imprecision with the effect estimates (<a href="./full#CD007961-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD007961-tbl-0002">summary of findings Table 2</a>: <a href="./full#CD007961-tbl-0003">summary of findings Table 3</a>). </p> <p><b>1.3. Laboratory confirmed incidence of protozoan sexually transmitted infections</b> </p> </section> <section id="CD007961-sec-0070"> <h6 class="title">1.3.1. Trichomoniasis</h6> <p>Six trials reported the effect of microbicides on the risk of acquiring trichomoniasis (<a href="./references#CD007961-bbs2-0002" title="Abdool KarimSS , RichardsonBA , RamjeeG , HoffmanIF , ChirenjeZM , TahaT , et al. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS2011;25(7):957-66. GuffeyMB , RichardsonB , HusnikM , MakananiB , ChilongoziD , YuE , et al. HPTN 035 Phase II/IIb Randomized safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in women. Sexually Transmitted Infections2014;90(5):1-15. ">Abdool Karim 2011</a>; <a href="./references#CD007961-bbs2-0003" title="BaetenJM , Palanee-PhillipsT , BrownER , SchwartzK , Soto-TorresLE , GovenderV , et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. New England Journal of Medicine2016;375(22):2121-32. MTN 2016. Dapivirine vaginal ring helped protect women against HIV in ASPIRE Phase lll trial. Media release. ">Baeten 2016</a>; <a href="./references#CD007961-bbs2-0007" title="MarrazzoJM , RamjeeG , RichardsonBA , GomezK , MgodiN , NairG , et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. New England Journal of Medicine2015;372(6):509-17. ">Marrazzo 2015</a>; <a href="./references#CD007961-bbs2-0009" title="NelA , Van NiekerkN , KapigaS , BekkerLG , GamaC , GillK . Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. New England Journal of Medicine2016;375(22):2133-45. ">Nel 2016</a>; <a href="./references#CD007961-bbs2-0011" title="MaraisD , GawareckiD , AllanB , AhmedK , AltiniL , CassimN , et al. The effectiveness of Carraguard, a vaginal microbicide, in protecting women against high-risk human papillomavirus infection. Antiviral Therapy2011;16(8):1219-26. Skoler-KarpoffS , RamjeeG , AhmedK , AltiniL , PlagianosMG , FriedlandB , et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9654):1977-87. ">Skoler‐Karpoff 2008</a>; <a href="./references#CD007961-bbs2-0012" title="Van DammeL , GovindenR , MirembeFM , GuédouF , SolomonS , BeckerML , et al. Lack of effectiveness of cellulose sulphate gel for the prevention of vaginal HIV transmission. New England Journal of Medicine2008;359(5):463-73. ">Van Damme 2008</a>). Dapirivine may not lead to any difference in the risk of trichomoniasis acquisition, compared to placebo (RR 1.06, 95% CI 0.92 to 1.23; I<sup>2</sup> = 0%: 2 trials, 4588 participants; low‐certainty evidence; <a href="./references#CD007961-fig-0011" title="">Analysis 1.8</a>). The effect of BufferGel (RR 0.96, 95% CI 0.80 to 1.15; 1 trial, 1546 women; low‐certainty evidence; <a href="./references#CD007961-fig-0011" title="">Analysis 1.8</a>); Carraguard (RR 0.85, 95% CI 0.72 to 1.01; 1 trial, 6202 women; low‐certainty evidence; <a href="./references#CD007961-fig-0011" title="">Analysis 1.8</a>); cellulose sulphate (RR 0.96, 95% CI 0.62 to 1.49; 1 trial, 1425 women; low‐certainty evidence; <a href="./references#CD007961-fig-0011" title="">Analysis 1.8</a>); PRO 2000 (RR 1.18, 95% CI 0.99 to 1.39; 1 trial, 1546 women; low‐certainty evidence; <a href="./references#CD007961-fig-0011" title="">Analysis 1.8</a>); and tenofovir (RR 1.21, 95% CI 0.84 to 1.74; 2010 women; low‐certainty evidence; <a href="./references#CD007961-fig-0011" title="">Analysis 1.8</a>) may not be different from that of placebo. We rated the evidence for each of these microbicides as low because of substantial imprecision in the effect estimates (<a href="./full#CD007961-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD007961-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD007961-tbl-0003">summary of findings Table 3</a>). </p> </section> <section id="CD007961-sec-0071"> <h6 class="title">1.4. Serious adverse events</h6> <p>All included microbicide trials reported serious adverse events which included death and hospitalisation. There was no clear evidence of a difference between microbicides used and placebo in the rate of serious adverse events (dapivirine vaginal ring, RR 1.12, 95% CI 0.94 to 1.32; I<sup>2</sup> = 87%; 2 trials, 4588 women; tenofovir vaginal gel, RR 1.00, 95% CI 0.81 to1.24; I<sup>2</sup> = 45%; 3 trials, 4958 women; BufferGel vaginal gel, RR 1.29, 95% CI 0.81 to 2.06;1 trial, 1546 women; Carraguard vaginal gel, RR 0.92, 95% CI 0.67to 1.27; 1 trial, 6202 women: cellulose sulphate vaginal gel, RR 1.25, 95% CI 0.87 to 1.79: I<sup>2</sup> = 0; 2 trials, 3069 women: PRO 2000 vaginal gel, RR 1.18, 95% CI 0.96 to 1.46; I<sup>2</sup> = 0; 2 trials, 8191 women; and SAVVY vaginal gel, RR 1.18, 95% CI 0.96 to 1.46; I<sup>2</sup> = 67%; 2 trials, 4295 women, low‐certainty evidence (<a href="./references#CD007961-fig-0012" title="">Analysis 1.9</a>) </p> </section> </section> <section id="CD007961-sec-0072"> <h5 class="title">2. Secondary outcomes</h5> <section id="CD007961-sec-0073"> <h6 class="title">2.1. Acceptability</h6> <p>One study reported vaginal microbicide gel acceptability to be high, with 99% of women stating at study exit that they would use a microbicide gel if it were found to be effective (<a href="./references#CD007961-bbs2-0002" title="Abdool KarimSS , RichardsonBA , RamjeeG , HoffmanIF , ChirenjeZM , TahaT , et al. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS2011;25(7):957-66. GuffeyMB , RichardsonB , HusnikM , MakananiB , ChilongoziD , YuE , et al. HPTN 035 Phase II/IIb Randomized safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in women. Sexually Transmitted Infections2014;90(5):1-15. ">Abdool Karim 2011</a>). </p> </section> <section id="CD007961-sec-0074"> <h6 class="title">2.2. Minor adverse events</h6> <p>All trials reported minor adverse events with substantial variation in the number and type of events.Those reported by both dapivirine trials (<a href="./references#CD007961-bbs2-0003" title="BaetenJM , Palanee-PhillipsT , BrownER , SchwartzK , Soto-TorresLE , GovenderV , et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. New England Journal of Medicine2016;375(22):2121-32. MTN 2016. Dapivirine vaginal ring helped protect women against HIV in ASPIRE Phase lll trial. Media release. ">Baeten 2016</a>; <a href="./references#CD007961-bbs2-0009" title="NelA , Van NiekerkN , KapigaS , BekkerLG , GamaC , GillK . Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. New England Journal of Medicine2016;375(22):2133-45. ">Nel 2016</a>) included urogenital symptoms (vulvovaginal candidiasis, menorrhagia, menometrorrhagia, bacterial vaginosis, cervical dysplasia,procedural, metrorrhagia, urinary tract infection, pelvic and procedural pain) upper respiratory tract infections and malaria, Additional common events reported by individual dapivirine trials were vaginal discharge gastroenteritis, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) increase, abdominal loss of weight, genitourinary chlamydia infection, vaginal pruritis, genitourinary tract gonococcal infection, haemoglobin decrease, neutrophil count increase (<a href="./references#CD007961-bbs2-0003" title="BaetenJM , Palanee-PhillipsT , BrownER , SchwartzK , Soto-TorresLE , GovenderV , et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. New England Journal of Medicine2016;375(22):2121-32. MTN 2016. Dapivirine vaginal ring helped protect women against HIV in ASPIRE Phase lll trial. Media release. ">Baeten 2016</a>) vulvovaginitis, viral rhinitis, nasopharyngitis, dysmenorrhoea, diarrhoea, myalgia, arthralgia.and headache (<a href="./references#CD007961-bbs2-0009" title="NelA , Van NiekerkN , KapigaS , BekkerLG , GamaC , GillK . Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. New England Journal of Medicine2016;375(22):2133-45. ">Nel 2016</a>). </p> <p>Events reported by all the three tenofovir trials (<a href="./references#CD007961-bbs2-0001" title="Abdool KarimQ , Abdool KarimSS , FrohlichJA , GroblerAC , BaxterC , MansoorEL , et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science2010;329(5996):1168-74. Abdool KarimSS , Abdool KarimQ , KharsanyAB , BaxterC , GroblerAC , WernerL . Tenofovir gel for the prevention of herpes simplex virus type 2 infection. New England Journal of Medicine 20152015;373(6):530-9. KarimQA , KharsanyAB , FrohlichJA , BaxterC , YendeN , MansoorLE , et al. Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials2011;12:67. KellerDM . AIDS 2010, XVIII International AIDS Conference: Tenofovir vaginal gel first microbicide to prevent HIV, HSV infections. Medscape Medical News July 2010. ">Abdool Karim 2010</a>; <a href="./references#CD007961-bbs2-0004" title="Delany-MoretlweS , LombardC , BaronD , BekkerLG , NkalaB , Ahmed K et al. Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised,double-blind, placebo-controlled trial. The Lancet Infectious Diseases2018;18(11):1241-50. ReesHS , SineadA , Delany- MoretiwaS , BaronD , PachiaR , et al. In: FACTS 001 Phase III Trial of Pericoital Tenofovir 1% Gel for HIV Prevention in Women.The 22nd Conference on Retroviruses and Opportunistic Infections;2015 Feb 23-26; Seattle Washington. 2015. ">Delany‐Moretlwe 2018</a>; <a href="./references#CD007961-bbs2-0007" title="MarrazzoJM , RamjeeG , RichardsonBA , GomezK , MgodiN , NairG , et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. New England Journal of Medicine2015;372(6):509-17. ">Marrazzo 2015</a>) included vaginal discharge, vaginal candidiasis, vulvovaginitis, headache, urinary tract infections, disrupted epithelium e.g. genital ulceration, elevated AST) and ALT, gastrointestinal disorders (nausea, diarrhoea, abdominal pain, vomiting), anaemia and hypophosphataemia. Additional common events reported by at least two tenofovir trials were upper respiratory tract infections (<a href="./references#CD007961-bbs2-0001" title="Abdool KarimQ , Abdool KarimSS , FrohlichJA , GroblerAC , BaxterC , MansoorEL , et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science2010;329(5996):1168-74. Abdool KarimSS , Abdool KarimQ , KharsanyAB , BaxterC , GroblerAC , WernerL . Tenofovir gel for the prevention of herpes simplex virus type 2 infection. New England Journal of Medicine 20152015;373(6):530-9. KarimQA , KharsanyAB , FrohlichJA , BaxterC , YendeN , MansoorLE , et al. Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials2011;12:67. KellerDM . AIDS 2010, XVIII International AIDS Conference: Tenofovir vaginal gel first microbicide to prevent HIV, HSV infections. Medscape Medical News July 2010. ">Abdool Karim 2010</a>; <a href="./references#CD007961-bbs2-0004" title="Delany-MoretlweS , LombardC , BaronD , BekkerLG , NkalaB , Ahmed K et al. Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised,double-blind, placebo-controlled trial. The Lancet Infectious Diseases2018;18(11):1241-50. ReesHS , SineadA , Delany- MoretiwaS , BaronD , PachiaR , et al. In: FACTS 001 Phase III Trial of Pericoital Tenofovir 1% Gel for HIV Prevention in Women.The 22nd Conference on Retroviruses and Opportunistic Infections;2015 Feb 23-26; Seattle Washington. 2015. ">Delany‐Moretlwe 2018</a>), neutropenia, and decreased bone density (<a href="./references#CD007961-bbs2-0001" title="Abdool KarimQ , Abdool KarimSS , FrohlichJA , GroblerAC , BaxterC , MansoorEL , et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science2010;329(5996):1168-74. Abdool KarimSS , Abdool KarimQ , KharsanyAB , BaxterC , GroblerAC , WernerL . Tenofovir gel for the prevention of herpes simplex virus type 2 infection. New England Journal of Medicine 20152015;373(6):530-9. KarimQA , KharsanyAB , FrohlichJA , BaxterC , YendeN , MansoorLE , et al. Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials2011;12:67. KellerDM . AIDS 2010, XVIII International AIDS Conference: Tenofovir vaginal gel first microbicide to prevent HIV, HSV infections. Medscape Medical News July 2010. ">Abdool Karim 2010</a>; <a href="./references#CD007961-bbs2-0007" title="MarrazzoJM , RamjeeG , RichardsonBA , GomezK , MgodiN , NairG , et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. New England Journal of Medicine2015;372(6):509-17. ">Marrazzo 2015</a>). The other common events reported by individual trials included influenza, erythema, menorrhagia, raised creatinine, low potassium,raised sodium, fractures (<a href="./references#CD007961-bbs2-0001" title="Abdool KarimQ , Abdool KarimSS , FrohlichJA , GroblerAC , BaxterC , MansoorEL , et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science2010;329(5996):1168-74. Abdool KarimSS , Abdool KarimQ , KharsanyAB , BaxterC , GroblerAC , WernerL . Tenofovir gel for the prevention of herpes simplex virus type 2 infection. New England Journal of Medicine 20152015;373(6):530-9. KarimQA , KharsanyAB , FrohlichJA , BaxterC , YendeN , MansoorLE , et al. Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials2011;12:67. KellerDM . AIDS 2010, XVIII International AIDS Conference: Tenofovir vaginal gel first microbicide to prevent HIV, HSV infections. Medscape Medical News July 2010. ">Abdool Karim 2010</a>), amenorrhoea,intermenstrual bleeding, vulvovaginal itching, reduced creatinine clearance (<a href="./references#CD007961-bbs2-0004" title="Delany-MoretlweS , LombardC , BaronD , BekkerLG , NkalaB , Ahmed K et al. Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised,double-blind, placebo-controlled trial. The Lancet Infectious Diseases2018;18(11):1241-50. ReesHS , SineadA , Delany- MoretiwaS , BaronD , PachiaR , et al. In: FACTS 001 Phase III Trial of Pericoital Tenofovir 1% Gel for HIV Prevention in Women.The 22nd Conference on Retroviruses and Opportunistic Infections;2015 Feb 23-26; Seattle Washington. 2015. ">Delany‐Moretlwe 2018</a>), genitourinary chlamydia infection, bacterial vaginitis, pelvic inflammatory disease, cervicitis<b>,</b> abnormal loss of weight, dizziness, migraine, haemorrhage in pregnancy, post abortion haemorrhage, proteinuria, dysuria, glycosuria, haematuria, pollakiuria cervical dysplasia, pelvic pain, menometrorrhagia, dysmenorrhoea, pelvic pain, and metrorrhagia (<a href="./references#CD007961-bbs2-0007" title="MarrazzoJM , RamjeeG , RichardsonBA , GomezK , MgodiN , NairG , et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. New England Journal of Medicine2015;372(6):509-17. ">Marrazzo 2015</a>). </p> <p>For BufferGel trial (<a href="./references#CD007961-bbs2-0002" title="Abdool KarimSS , RichardsonBA , RamjeeG , HoffmanIF , ChirenjeZM , TahaT , et al. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS2011;25(7):957-66. GuffeyMB , RichardsonB , HusnikM , MakananiB , ChilongoziD , YuE , et al. HPTN 035 Phase II/IIb Randomized safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in women. Sexually Transmitted Infections2014;90(5):1-15. ">Abdool Karim 2011</a>), events reported were vaginal discharge, vulvovaginal pruritis, metrorrhagia, cervical or  uterine haemorrhage, menorrhagia, genital irritation events, abnormal genital bleeding, urinary tract infections, genital pain, intermenstrual bleeding, pregnancy events and coagulation abnormalities. </p> <p>For Carraguard trial (<a href="./references#CD007961-bbs2-0011" title="MaraisD , GawareckiD , AllanB , AhmedK , AltiniL , CassimN , et al. The effectiveness of Carraguard, a vaginal microbicide, in protecting women against high-risk human papillomavirus infection. Antiviral Therapy2011;16(8):1219-26. Skoler-KarpoffS , RamjeeG , AhmedK , AltiniL , PlagianosMG , FriedlandB , et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9654):1977-87. ">Skoler‐Karpoff 2008</a>), the following events were reported; vaginal discharge, dysmenorrhoea, genital pruritis, lower abdominal pain, injury, poisoning, and procedural complications, findings with disrupted epithelium, abnormal Papanicolaou smear and pregnancy outcomes (termination, live and still birth). </p> <p>Events reported by both cellulose sulphate trials (<a href="./references#CD007961-bbs2-0006" title="HalpernV , OgunsolaF , ObungeO , WangCH , OnyejepuN , OduyeboO , et al. Effectiveness of cellulose sulphate vaginal gel for the prevention of HIV infection: results of a phase III trial in Nigeria. PLoS One2008;3(11):e3784. ">Halpern 2008</a>; <a href="./references#CD007961-bbs2-0012" title="Van DammeL , GovindenR , MirembeFM , GuédouF , SolomonS , BeckerML , et al. Lack of effectiveness of cellulose sulphate gel for the prevention of vaginal HIV transmission. New England Journal of Medicine2008;359(5):463-73. ">Van Damme 2008</a>) were bacterial vaginitis,  genital pruritis, genital candidiasis, and vaginal discharge. Additional common events reported by individual trials included, malaria, abdominal pain, headache, pyrexia, respiratory tract infection, menstrual disorder (<a href="./references#CD007961-bbs2-0006" title="HalpernV , OgunsolaF , ObungeO , WangCH , OnyejepuN , OduyeboO , et al. Effectiveness of cellulose sulphate vaginal gel for the prevention of HIV infection: results of a phase III trial in Nigeria. PLoS One2008;3(11):e3784. ">Halpern 2008</a>); cervicitis, pelvic inflammatory disease, urinary tract infection, metrorrhagia pelvic pain genital ulceration and menorrhagia (<a href="./references#CD007961-bbs2-0012" title="Van DammeL , GovindenR , MirembeFM , GuédouF , SolomonS , BeckerML , et al. Lack of effectiveness of cellulose sulphate gel for the prevention of vaginal HIV transmission. New England Journal of Medicine2008;359(5):463-73. ">Van Damme 2008</a>). </p> <p>Both PRO 2000 trials (<a href="./references#CD007961-bbs2-0002" title="Abdool KarimSS , RichardsonBA , RamjeeG , HoffmanIF , ChirenjeZM , TahaT , et al. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS2011;25(7):957-66. GuffeyMB , RichardsonB , HusnikM , MakananiB , ChilongoziD , YuE , et al. HPTN 035 Phase II/IIb Randomized safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in women. Sexually Transmitted Infections2014;90(5):1-15. ">Abdool Karim 2011</a>; <a href="./references#CD007961-bbs2-0008" title="McCormackS , RamjeeG , KamaliA , ReesH , CrookAM , GafosM , et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet2010;376(9749):1329-37. ">McCormack 2010</a>) reported abnormal genital bleeding. However, additional events reported by individual trials included vaginal discharge, vulvovaginal pruritis, metrorrhagia, cervix haemorrhage uterine, menorrhagia, genital irritation events, urinary tract infections, genital pain, intermenstrual bleeding, pregnancy events and coagulation abnormalities (<a href="./references#CD007961-bbs2-0002" title="Abdool KarimSS , RichardsonBA , RamjeeG , HoffmanIF , ChirenjeZM , TahaT , et al. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS2011;25(7):957-66. GuffeyMB , RichardsonB , HusnikM , MakananiB , ChilongoziD , YuE , et al. HPTN 035 Phase II/IIb Randomized safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in women. Sexually Transmitted Infections2014;90(5):1-15. ">Abdool Karim 2011</a>); ulcers, oedema and erythema (<a href="./references#CD007961-bbs2-0008" title="McCormackS , RamjeeG , KamaliA , ReesH , CrookAM , GafosM , et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet2010;376(9749):1329-37. ">McCormack 2010</a>). </p> <p>Both SAVVY trials (<a href="./references#CD007961-bbs2-0005" title="FeldblumPJ , AdeigaA , BakareR , WevillS , LendvayA , ObadakiF , et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomised controlled trial in Nigeria. PLoS One2008;3(1):e1474. ">Feldblum 2008</a>; <a href="./references#CD007961-bbs2-0010" title="PetersonL , NandaK , OpokuBK , AmpofoWK , Owusu-AmoakoM , BoakyeAY , et al. SAVVY (C31G) gel for prevention of HIV infection in women: a phase 3, double-blind, randomised, placebo-controlled trial in Ghana. PLoS One2007;2(12):e1312. ">Peterson 2007</a>) reported vaginal discharge, vaginal candidiasis, bacterial vaginitis, trichomonas vulvovaginitis, genital pruritis, irregular menstruation, gastrointestinal disorders, pregnancy, puerperium and perinatal conditions, renal and urinary disorders. Additional events reported by one study (<a href="./references#CD007961-bbs2-0005" title="FeldblumPJ , AdeigaA , BakareR , WevillS , LendvayA , ObadakiF , et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomised controlled trial in Nigeria. PLoS One2008;3(1):e1474. ">Feldblum 2008</a>) included dysmenorrhoea and pelvic inflammatory disease. </p> </section> </section> <section id="CD007961-sec-0075"> <h5 class="title">Other analyses</h5> <section id="CD007961-sec-0076"> <h6 class="title">Subgroup analyses</h6> <p>There were insufficient studies to do planned subgroup analyses other than by the type of microbicide. </p> </section> <section id="CD007961-sec-0077"> <h6 class="title">Sensitivity analyses</h6> <p>The method of meta‐analysis did not have an impact on the results.</p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD007961-sec-0078" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD007961-sec-0078"></div> <section id="CD007961-sec-0079"> <h3 class="title" id="CD007961-sec-0079">Summary of main results</h3> <p>We include in this updated review 12 randomised trials of seven different vaginal microbicides (BufferGel, Carraguard, cellulose sulphate, dapivirine, PRO 2000, SAVVY, and tenofovir), involving 32,849 sexually active women who have sex with men, conducted in 11 countries. All trials compared the use of microbicide versus placebo. No currently‐available trials have assessed the effect of topical microbicides during anal sex. There was moderate‐certainty evidence that dapivirine was superior to placebo in reducing the risk of HIV acquisition. There was clear evidence of an effect between any of the other microbicides and placebo in the risk of HIV acquisition. Two trials compared tenofovir to placebo, and provide low‐certainty evidence that tenofovir may slightly reduce the risk of acquiring herpes simplex virus type 2 infection. Two other trials provide low‐certainty evidence that cellulose sulphate may decrease the risk of acquisition of chlamydia infection. Our confidence in the evidence between any of the other microbicides and placebo in the risk of acquisition of STIs is very low, providing an indication of the unlikely effect. </p> </section> <section id="CD007961-sec-0080"> <h3 class="title" id="CD007961-sec-0080">Overall completeness and applicability of evidence</h3> <p>We conducted comprehensive searches to identify both published and unpublished RCs. In addition to two trial registers, we searched eight databases with no language restrictions, reducing the risk of publication bias (<a href="./references#CD007961-bbs2-0036" title="EggerM , Zellweger-ZahnerT , SchneiderM , JunkerC , LengelerC , AntesG . Language bias in randomised controlled trials published in English and German. Lancet1997;350:326-9.">Egger 1997a</a>, <a href="./references#CD007961-bbs2-0037" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta-analysis detected by a simple, graphical test. BMJ1997;315:629-34.">Egger 1997b</a>, <a href="./references#CD007961-bbs2-0054" title="MoherD , FortinP , JadaAR , JuniP , KlassenT , Le LorierJ , et al. Completeness of reporting of trials published in languages other than English: implications for conduct and reporting of systematic reviews. Lancet1996;347:363-6.">Moher 1996</a>). We identified 12 trials published between 2007 and 2018 that examined effectiveness of four classes of microbicides with different mechanisms of action; surfactants (SAVVY), vaginal defence enhancers (Buffergel), entry inhibitors (carraguard, PRO 2000, cellulose suphate) and antiretroviral based microbidices (tenofovir and dapivirine). Being in gel form, the microbicides were packaged in single‐use microlax‐type applicators, filled to be dispensed vaginally before every act of vaginal intercourse. </p> <p>Baseline factors appeared well balanced for all trials thus unlikely to cause any differences in outcome between the treatment groups. All trials used a defined range of age limits for inclusion criteria of the participants, thus providing a clear picture of the full range of ages. Ten trials reported including participants aged 18 years and over. One trial stated a lower age limit of 18 years old in their inclusion, but reported to have included participants of a lower age limit of 15 years old (<a href="./references#CD007961-bbs2-0008" title="McCormackS , RamjeeG , KamaliA , ReesH , CrookAM , GafosM , et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet2010;376(9749):1329-37. ">McCormack 2010</a>). One other trial included in the review had a lower age limit of 16 years old in their age criteria (Skoler‐Karpoff 2008). All trials except two (<a href="./references#CD007961-bbs2-0008" title="McCormackS , RamjeeG , KamaliA , ReesH , CrookAM , GafosM , et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet2010;376(9749):1329-37. ">McCormack 2010</a>; <a href="./references#CD007961-bbs2-0011" title="MaraisD , GawareckiD , AllanB , AhmedK , AltiniL , CassimN , et al. The effectiveness of Carraguard, a vaginal microbicide, in protecting women against high-risk human papillomavirus infection. Antiviral Therapy2011;16(8):1219-26. Skoler-KarpoffS , RamjeeG , AhmedK , AltiniL , PlagianosMG , FriedlandB , et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9654):1977-87. ">Skoler‐Karpoff 2008</a>) presented the median age for the participants. This ranged between 23 and 26 years in 10 trials. One trial presented a higher median age (28 years one treatment group and 29 years in the other (<a href="./references#CD007961-bbs2-0012" title="Van DammeL , GovindenR , MirembeFM , GuédouF , SolomonS , BeckerML , et al. Lack of effectiveness of cellulose sulphate gel for the prevention of vaginal HIV transmission. New England Journal of Medicine2008;359(5):463-73. ">Van Damme 2008</a>). </p> <p>This review has several limitations in relation to the applicability of this evidence. HIV infection was the primary outcome in all the studies, but despite including 12 trials we could not pool the data due to the microbicides' different mechanisms of action, limiting data to perform meta‐analyses. Except for one trial that that had a study site in the USA (<a href="./references#CD007961-bbs2-0002" title="Abdool KarimSS , RichardsonBA , RamjeeG , HoffmanIF , ChirenjeZM , TahaT , et al. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS2011;25(7):957-66. GuffeyMB , RichardsonB , HusnikM , MakananiB , ChilongoziD , YuE , et al. HPTN 035 Phase II/IIb Randomized safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in women. Sexually Transmitted Infections2014;90(5):1-15. ">Abdool Karim 2011</a>) the others were conducted in low and middle‐income countries, mainly in Africa, and the duration of follow up varied between trials. Because of the relatively low incidence of HIV infection among women in high‐income countries, effectiveness studies for this intervention may be limited predominantly in low‐income country sites, </p> <p>Six of the 12 trials were stopped early due to safety concerns (<a href="./references#CD007961-bbs2-0005" title="FeldblumPJ , AdeigaA , BakareR , WevillS , LendvayA , ObadakiF , et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomised controlled trial in Nigeria. PLoS One2008;3(1):e1474. ">Feldblum 2008</a>: <a href="./references#CD007961-bbs2-0006" title="HalpernV , OgunsolaF , ObungeO , WangCH , OnyejepuN , OduyeboO , et al. Effectiveness of cellulose sulphate vaginal gel for the prevention of HIV infection: results of a phase III trial in Nigeria. PLoS One2008;3(11):e3784. ">Halpern 2008</a>; <a href="./references#CD007961-bbs2-0007" title="MarrazzoJM , RamjeeG , RichardsonBA , GomezK , MgodiN , NairG , et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. New England Journal of Medicine2015;372(6):509-17. ">Marrazzo 2015</a>; <a href="./references#CD007961-bbs2-0008" title="McCormackS , RamjeeG , KamaliA , ReesH , CrookAM , GafosM , et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet2010;376(9749):1329-37. ">McCormack 2010</a>; <a href="./references#CD007961-bbs2-0010" title="PetersonL , NandaK , OpokuBK , AmpofoWK , Owusu-AmoakoM , BoakyeAY , et al. SAVVY (C31G) gel for prevention of HIV infection in women: a phase 3, double-blind, randomised, placebo-controlled trial in Ghana. PLoS One2007;2(12):e1312. ">Peterson 2007</a>; <a href="./references#CD007961-bbs2-0012" title="Van DammeL , GovindenR , MirembeFM , GuédouF , SolomonS , BeckerML , et al. Lack of effectiveness of cellulose sulphate gel for the prevention of vaginal HIV transmission. New England Journal of Medicine2008;359(5):463-73. ">Van Damme 2008</a>), indicating that surrogates for clinical safety of microbicides still need to be better defined. </p> <p>The studies included in this review did not report all STIs. Only five trials assessed the effect of vaginal microbicides on other viral STIs <a href="./references#CD007961-bbs2-0001" title="Abdool KarimQ , Abdool KarimSS , FrohlichJA , GroblerAC , BaxterC , MansoorEL , et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science2010;329(5996):1168-74. Abdool KarimSS , Abdool KarimQ , KharsanyAB , BaxterC , GroblerAC , WernerL . Tenofovir gel for the prevention of herpes simplex virus type 2 infection. New England Journal of Medicine 20152015;373(6):530-9. KarimQA , KharsanyAB , FrohlichJA , BaxterC , YendeN , MansoorLE , et al. Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials2011;12:67. KellerDM . AIDS 2010, XVIII International AIDS Conference: Tenofovir vaginal gel first microbicide to prevent HIV, HSV infections. Medscape Medical News July 2010. ">Abdool Karim 2010</a>; <a href="./references#CD007961-bbs2-0007" title="MarrazzoJM , RamjeeG , RichardsonBA , GomezK , MgodiN , NairG , et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. New England Journal of Medicine2015;372(6):509-17. ">Marrazzo 2015</a>; <a href="./references#CD007961-bbs2-0008" title="McCormackS , RamjeeG , KamaliA , ReesH , CrookAM , GafosM , et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet2010;376(9749):1329-37. ">McCormack 2010</a>; <a href="./references#CD007961-bbs2-0011" title="MaraisD , GawareckiD , AllanB , AhmedK , AltiniL , CassimN , et al. The effectiveness of Carraguard, a vaginal microbicide, in protecting women against high-risk human papillomavirus infection. Antiviral Therapy2011;16(8):1219-26. Skoler-KarpoffS , RamjeeG , AhmedK , AltiniL , PlagianosMG , FriedlandB , et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9654):1977-87. ">Skoler‐Karpoff 2008</a>; <a href="./references#CD007961-bbs2-0012" title="Van DammeL , GovindenR , MirembeFM , GuédouF , SolomonS , BeckerML , et al. Lack of effectiveness of cellulose sulphate gel for the prevention of vaginal HIV transmission. New England Journal of Medicine2008;359(5):463-73. ">Van Damme 2008</a>). Eight trials assessed vaginal microbicide effects on gonorrhoea (<a href="./references#CD007961-bbs2-0002" title="Abdool KarimSS , RichardsonBA , RamjeeG , HoffmanIF , ChirenjeZM , TahaT , et al. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS2011;25(7):957-66. GuffeyMB , RichardsonB , HusnikM , MakananiB , ChilongoziD , YuE , et al. HPTN 035 Phase II/IIb Randomized safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in women. Sexually Transmitted Infections2014;90(5):1-15. ">Abdool Karim 2011</a>; <a href="./references#CD007961-bbs2-0003" title="BaetenJM , Palanee-PhillipsT , BrownER , SchwartzK , Soto-TorresLE , GovenderV , et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. New England Journal of Medicine2016;375(22):2121-32. MTN 2016. Dapivirine vaginal ring helped protect women against HIV in ASPIRE Phase lll trial. Media release. ">Baeten 2016</a>; <a href="./references#CD007961-bbs2-0006" title="HalpernV , OgunsolaF , ObungeO , WangCH , OnyejepuN , OduyeboO , et al. Effectiveness of cellulose sulphate vaginal gel for the prevention of HIV infection: results of a phase III trial in Nigeria. PLoS One2008;3(11):e3784. ">Halpern 2008</a>; <a href="./references#CD007961-bbs2-0007" title="MarrazzoJM , RamjeeG , RichardsonBA , GomezK , MgodiN , NairG , et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. New England Journal of Medicine2015;372(6):509-17. ">Marrazzo 2015</a>; <a href="./references#CD007961-bbs2-0008" title="McCormackS , RamjeeG , KamaliA , ReesH , CrookAM , GafosM , et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet2010;376(9749):1329-37. ">McCormack 2010</a>; <a href="./references#CD007961-bbs2-0009" title="NelA , Van NiekerkN , KapigaS , BekkerLG , GamaC , GillK . Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. New England Journal of Medicine2016;375(22):2133-45. ">Nel 2016</a>; <a href="./references#CD007961-bbs2-0011" title="MaraisD , GawareckiD , AllanB , AhmedK , AltiniL , CassimN , et al. The effectiveness of Carraguard, a vaginal microbicide, in protecting women against high-risk human papillomavirus infection. Antiviral Therapy2011;16(8):1219-26. Skoler-KarpoffS , RamjeeG , AhmedK , AltiniL , PlagianosMG , FriedlandB , et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9654):1977-87. ">Skoler‐Karpoff 2008</a>; <a href="./references#CD007961-bbs2-0012" title="Van DammeL , GovindenR , MirembeFM , GuédouF , SolomonS , BeckerML , et al. Lack of effectiveness of cellulose sulphate gel for the prevention of vaginal HIV transmission. New England Journal of Medicine2008;359(5):463-73. ">Van Damme 2008</a>), eight on chlamydia (<a href="./references#CD007961-bbs2-0002" title="Abdool KarimSS , RichardsonBA , RamjeeG , HoffmanIF , ChirenjeZM , TahaT , et al. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS2011;25(7):957-66. GuffeyMB , RichardsonB , HusnikM , MakananiB , ChilongoziD , YuE , et al. HPTN 035 Phase II/IIb Randomized safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in women. Sexually Transmitted Infections2014;90(5):1-15. ">Abdool Karim 2011</a>; <a href="./references#CD007961-bbs2-0003" title="BaetenJM , Palanee-PhillipsT , BrownER , SchwartzK , Soto-TorresLE , GovenderV , et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. New England Journal of Medicine2016;375(22):2121-32. MTN 2016. Dapivirine vaginal ring helped protect women against HIV in ASPIRE Phase lll trial. Media release. ">Baeten 2016</a>; <a href="./references#CD007961-bbs2-0006" title="HalpernV , OgunsolaF , ObungeO , WangCH , OnyejepuN , OduyeboO , et al. Effectiveness of cellulose sulphate vaginal gel for the prevention of HIV infection: results of a phase III trial in Nigeria. PLoS One2008;3(11):e3784. ">Halpern 2008</a>; <a href="./references#CD007961-bbs2-0007" title="MarrazzoJM , RamjeeG , RichardsonBA , GomezK , MgodiN , NairG , et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. New England Journal of Medicine2015;372(6):509-17. ">Marrazzo 2015</a>; <a href="./references#CD007961-bbs2-0008" title="McCormackS , RamjeeG , KamaliA , ReesH , CrookAM , GafosM , et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet2010;376(9749):1329-37. ">McCormack 2010</a>; <a href="./references#CD007961-bbs2-0009" title="NelA , Van NiekerkN , KapigaS , BekkerLG , GamaC , GillK . Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. New England Journal of Medicine2016;375(22):2133-45. ">Nel 2016</a>; <a href="./references#CD007961-bbs2-0011" title="MaraisD , GawareckiD , AllanB , AhmedK , AltiniL , CassimN , et al. The effectiveness of Carraguard, a vaginal microbicide, in protecting women against high-risk human papillomavirus infection. Antiviral Therapy2011;16(8):1219-26. Skoler-KarpoffS , RamjeeG , AhmedK , AltiniL , PlagianosMG , FriedlandB , et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9654):1977-87. ">Skoler‐Karpoff 2008</a>; <a href="./references#CD007961-bbs2-0012" title="Van DammeL , GovindenR , MirembeFM , GuédouF , SolomonS , BeckerML , et al. Lack of effectiveness of cellulose sulphate gel for the prevention of vaginal HIV transmission. New England Journal of Medicine2008;359(5):463-73. ">Van Damme 2008</a>), four on syphilis (<a href="./references#CD007961-bbs2-0007" title="MarrazzoJM , RamjeeG , RichardsonBA , GomezK , MgodiN , NairG , et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. New England Journal of Medicine2015;372(6):509-17. ">Marrazzo 2015</a>; <a href="./references#CD007961-bbs2-0009" title="NelA , Van NiekerkN , KapigaS , BekkerLG , GamaC , GillK . Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. New England Journal of Medicine2016;375(22):2133-45. ">Nel 2016</a>; <a href="./references#CD007961-bbs2-0011" title="MaraisD , GawareckiD , AllanB , AhmedK , AltiniL , CassimN , et al. The effectiveness of Carraguard, a vaginal microbicide, in protecting women against high-risk human papillomavirus infection. Antiviral Therapy2011;16(8):1219-26. Skoler-KarpoffS , RamjeeG , AhmedK , AltiniL , PlagianosMG , FriedlandB , et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9654):1977-87. ">Skoler‐Karpoff 2008</a>; <a href="./references#CD007961-bbs2-0012" title="Van DammeL , GovindenR , MirembeFM , GuédouF , SolomonS , BeckerML , et al. Lack of effectiveness of cellulose sulphate gel for the prevention of vaginal HIV transmission. New England Journal of Medicine2008;359(5):463-73. ">Van Damme 2008</a>) and six on trichomoniasis (<a href="./references#CD007961-bbs2-0002" title="Abdool KarimSS , RichardsonBA , RamjeeG , HoffmanIF , ChirenjeZM , TahaT , et al. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS2011;25(7):957-66. GuffeyMB , RichardsonB , HusnikM , MakananiB , ChilongoziD , YuE , et al. HPTN 035 Phase II/IIb Randomized safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in women. Sexually Transmitted Infections2014;90(5):1-15. ">Abdool Karim 2011</a>; <a href="./references#CD007961-bbs2-0003" title="BaetenJM , Palanee-PhillipsT , BrownER , SchwartzK , Soto-TorresLE , GovenderV , et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. New England Journal of Medicine2016;375(22):2121-32. MTN 2016. Dapivirine vaginal ring helped protect women against HIV in ASPIRE Phase lll trial. Media release. ">Baeten 2016</a>; <a href="./references#CD007961-bbs2-0007" title="MarrazzoJM , RamjeeG , RichardsonBA , GomezK , MgodiN , NairG , et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. New England Journal of Medicine2015;372(6):509-17. ">Marrazzo 2015</a>; <a href="./references#CD007961-bbs2-0009" title="NelA , Van NiekerkN , KapigaS , BekkerLG , GamaC , GillK . Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. New England Journal of Medicine2016;375(22):2133-45. ">Nel 2016</a>; <a href="./references#CD007961-bbs2-0011" title="MaraisD , GawareckiD , AllanB , AhmedK , AltiniL , CassimN , et al. The effectiveness of Carraguard, a vaginal microbicide, in protecting women against high-risk human papillomavirus infection. Antiviral Therapy2011;16(8):1219-26. Skoler-KarpoffS , RamjeeG , AhmedK , AltiniL , PlagianosMG , FriedlandB , et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9654):1977-87. ">Skoler‐Karpoff 2008</a>; <a href="./references#CD007961-bbs2-0012" title="Van DammeL , GovindenR , MirembeFM , GuédouF , SolomonS , BeckerML , et al. Lack of effectiveness of cellulose sulphate gel for the prevention of vaginal HIV transmission. New England Journal of Medicine2008;359(5):463-73. ">Van Damme 2008</a>). Like in the case of HIV infections, data were insufficient to perform meta‐analyses for most STI outcomes due microbicide classification based on the mechanisms of action. </p> <p>There was no trial that reported on the effect of microbicides on HIV or STI acquisition among men having sex with men. </p> <p>The most promising intervention for preventing HIV and HSV infection were dapivirine and tenofovir respectively, with both trial sites being limited to Africa. In addition the relatively small sample size and few studies may restrict the broad generalisability of the finding that dapivirine vaginal ring reduces the risk of HIV acquisition (<a href="./references#CD007961-bbs2-0003" title="BaetenJM , Palanee-PhillipsT , BrownER , SchwartzK , Soto-TorresLE , GovenderV , et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. New England Journal of Medicine2016;375(22):2121-32. MTN 2016. Dapivirine vaginal ring helped protect women against HIV in ASPIRE Phase lll trial. Media release. ">Baeten 2016</a>; <a href="./references#CD007961-bbs2-0009" title="NelA , Van NiekerkN , KapigaS , BekkerLG , GamaC , GillK . Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. New England Journal of Medicine2016;375(22):2133-45. ">Nel 2016</a>) and tenofovir reduces the risk of HSV acquisition (<a href="./references#CD007961-bbs2-0001" title="Abdool KarimQ , Abdool KarimSS , FrohlichJA , GroblerAC , BaxterC , MansoorEL , et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science2010;329(5996):1168-74. Abdool KarimSS , Abdool KarimQ , KharsanyAB , BaxterC , GroblerAC , WernerL . Tenofovir gel for the prevention of herpes simplex virus type 2 infection. New England Journal of Medicine 20152015;373(6):530-9. KarimQA , KharsanyAB , FrohlichJA , BaxterC , YendeN , MansoorLE , et al. Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials2011;12:67. KellerDM . AIDS 2010, XVIII International AIDS Conference: Tenofovir vaginal gel first microbicide to prevent HIV, HSV infections. Medscape Medical News July 2010. ">Abdool Karim 2010</a>; <a href="./references#CD007961-bbs2-0007" title="MarrazzoJM , RamjeeG , RichardsonBA , GomezK , MgodiN , NairG , et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. New England Journal of Medicine2015;372(6):509-17. ">Marrazzo 2015</a>; <a href="./references#CD007961-bbs2-0004" title="Delany-MoretlweS , LombardC , BaronD , BekkerLG , NkalaB , Ahmed K et al. Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised,double-blind, placebo-controlled trial. The Lancet Infectious Diseases2018;18(11):1241-50. ReesHS , SineadA , Delany- MoretiwaS , BaronD , PachiaR , et al. In: FACTS 001 Phase III Trial of Pericoital Tenofovir 1% Gel for HIV Prevention in Women.The 22nd Conference on Retroviruses and Opportunistic Infections;2015 Feb 23-26; Seattle Washington. 2015. ">Delany‐Moretlwe 2018</a>) in sexually‐active women. </p> </section> <section id="CD007961-sec-0081"> <h3 class="title" id="CD007961-sec-0081">Quality of the evidence</h3> <p>We considered all 12 included trials to be at low risk of bias. These studies corresponded to the comparison of any microbicide versus placebo. For the comparison of the microbicide dapivirine versus placebo, our confidence in the effect estimate for HIV acquisition was reduced to moderate because only two studies have so far assessed this microbicide. Our confidence in the effect estimate of dapivirine on other STIs as well as the effect estimate of tenofovir and other microbicides on HIV and other STIs was low to very low, due to serious imprecision (i.e. few participants and few outcome events leading to effect estimates with very wide confidence intervals) and inconsistency (unexplained variability in some results) (<a href="./full#CD007961-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD007961-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD007961-tbl-0003">summary of findings Table 3</a>). </p> </section> <section id="CD007961-sec-0082"> <h3 class="title" id="CD007961-sec-0082">Potential biases in the review process</h3> <p>This systematic review has many strengths regarding the review process: we adhered to the predefined objectives and study eligibility criteria; our literature search included an appropriate range of databases and sources, including relevant additional methods to identify relevant reports and retrieve as many eligible studies as possible; and we assessed all studies adequately for risk of bias. Two review authors independently screened the search results, selection of studies, and extraction of data. Intention‐to‐treat analysis was reported for all trials making incomplete data bias unlikely for this review. However, we had some concerns about publication bias. Publication bias is a possibility due to the limited number of trials for each comparison. Also, being an updated version, the review cannot be done blinded to the knowledge of the previous outcomes hence the potential to unconscious biasness. </p> </section> <section id="CD007961-sec-0083"> <h3 class="title" id="CD007961-sec-0083">Agreements and disagreements with other studies or reviews</h3> <p>Few systematic reviews have assessed the effectiveness of vaginal microbicides for for preventing STIs including HIV. There are four previous systematic reviews published on this topic (<a href="./references#CD007961-bbs2-0086" title="ObieroJ , MwetheraPG , HusseyGD , WiysongeCS . Vaginal microbicides for reducing the risk of sexual acquisition of HIV infection in women: systematic review and meta-analysis. BMC Infectious Diseases2012;12:1-8.">Obiero 2012b</a>; <a href="./references#CD007961-bbs2-0055" title="MusekiwaA , FernandoMB , AbarigaSA . Effectiveness of vaginal microbicides in preventing HIVtransmission. Tropical medicine and international health2020;25(7):790-802.">Musekiwa 2020</a>; <a href="./references#CD007961-bbs2-0081" title="WilkinsonD , RamjeeG , TholandiM , RutherfordG . Nonoxynol-9 for preventing vaginal acquisition of sexually transmitted infections by women from men. Cochrane Database of Systematic Reviews2002, Issue 1. Art. No: CD003939. [DOI: 10.1002/14651858.CD003939]">Wilkinson 2002a</a>; <a href="./references#CD007961-bbs2-0082" title="WilkinsonD , RamjeeG , TholandiM , RutherfordG . Nonoxynol-9 for preventing vaginal acquisition of HIV infection by women from men. Cochrane Database of Systematic Reviews2002, Issue 3. Art. No: CD003936. [DOI: 10.1002/14651858.CD003936]">Wilkinson 2002b</a>). . Evidence from two published systematic reviews (<a href="./references#CD007961-bbs2-0081" title="WilkinsonD , RamjeeG , TholandiM , RutherfordG . Nonoxynol-9 for preventing vaginal acquisition of sexually transmitted infections by women from men. Cochrane Database of Systematic Reviews2002, Issue 1. Art. No: CD003939. [DOI: 10.1002/14651858.CD003939]">Wilkinson 2002a</a>; <a href="./references#CD007961-bbs2-0082" title="WilkinsonD , RamjeeG , TholandiM , RutherfordG . Nonoxynol-9 for preventing vaginal acquisition of HIV infection by women from men. Cochrane Database of Systematic Reviews2002, Issue 3. Art. No: CD003936. [DOI: 10.1002/14651858.CD003936]">Wilkinson 2002b</a>) showed that one vaginal microbicide gel, nonoxynol‐9, may be harmful by increasing the risk of STI including HIV acquisition. In one systematic review, Musekiwa and colleagues searched two databases for studies published up to May 2019 on the effectiveness of microbicides to prevent HIV transmission (<a href="./references#CD007961-bbs2-0055" title="MusekiwaA , FernandoMB , AbarigaSA . Effectiveness of vaginal microbicides in preventing HIVtransmission. Tropical medicine and international health2020;25(7):790-802.">Musekiwa 2020</a>), and reported lack of effect of early non‐HIV‐specific microbicides. Our current findings are consistent with previously‐published reviews, that topical microbicide research has had disappointing outcomes over a long period (<a href="./references#CD007961-bbs2-0086" title="ObieroJ , MwetheraPG , HusseyGD , WiysongeCS . Vaginal microbicides for reducing the risk of sexual acquisition of HIV infection in women: systematic review and meta-analysis. BMC Infectious Diseases2012;12:1-8.">Obiero 2012b</a>). The authors of a recent systematic (<a href="./references#CD007961-bbs2-0055" title="MusekiwaA , FernandoMB , AbarigaSA . Effectiveness of vaginal microbicides in preventing HIVtransmission. Tropical medicine and international health2020;25(7):790-802.">Musekiwa 2020</a>) reported moderate certainty of evidence supporting effectiveness of the intravaginal ring containing dapivirine. Our review update supports these results; a vaginal microbicide ring that contains the non‐nucleoside reverse‐transcriptase inhibitor dapivirine was found to be effective in reducing the risk of HIV acquisition. To the best of our knowledge, our review is the most comprehensive synthesis of existing evidence on topical microbicides for prevention of HIV infection and other STIs. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD007961-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/urn:x-wiley:14651858:media:CD007961:CD007961-FIG-01" target="_blank"><b></b></a></p> </div><img alt="PRISMA diagram showing the search and selection of studies" data-id="CD007961-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/image_n/nCD007961-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/image_t/tCD007961-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA diagram showing the search and selection of studies</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/full#CD007961-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/image_n/nCD007961-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007961-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/urn:x-wiley:14651858:media:CD007961:CD007961-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD007961-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/image_n/nCD007961-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/image_t/tCD007961-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/full#CD007961-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/image_n/nCD007961-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007961-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/urn:x-wiley:14651858:media:CD007961:CD007961-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD007961-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/image_n/nCD007961-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/image_t/tCD007961-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/full#CD007961-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/image_n/nCD007961-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007961-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/urn:x-wiley:14651858:media:CD007961:CD007961-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Topical microbicide versus placebo ‐ dichotomous data, Outcome 1: HIV" data-id="CD007961-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/image_n/nCD007961-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/image_t/tCD007961-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Topical microbicide versus placebo ‐ dichotomous data, Outcome 1: HIV</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/references#CD007961-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/image_n/nCD007961-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007961-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/urn:x-wiley:14651858:media:CD007961:CD007961-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Topical microbicide versus placebo ‐ dichotomous data, Outcome 2: Herpes simplex" data-id="CD007961-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/image_n/nCD007961-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/image_t/tCD007961-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Topical microbicide versus placebo ‐ dichotomous data, Outcome 2: Herpes simplex </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/references#CD007961-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/image_n/nCD007961-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007961-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/urn:x-wiley:14651858:media:CD007961:CD007961-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Topical microbicide versus placebo ‐ dichotomous data, Outcome 3: Condyloma acuminatum" data-id="CD007961-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/image_n/nCD007961-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/image_t/tCD007961-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Topical microbicide versus placebo ‐ dichotomous data, Outcome 3: Condyloma acuminatum </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/references#CD007961-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/image_n/nCD007961-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007961-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/urn:x-wiley:14651858:media:CD007961:CD007961-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Topical microbicide versus placebo ‐ dichotomous data, Outcome 4: High‐risk HPV" data-id="CD007961-fig-0007" src="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/image_n/nCD007961-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/image_t/tCD007961-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Topical microbicide versus placebo ‐ dichotomous data, Outcome 4: High‐risk HPV </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/references#CD007961-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/image_n/nCD007961-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007961-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/urn:x-wiley:14651858:media:CD007961:CD007961-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Topical microbicide versus placebo ‐ dichotomous data, Outcome 5: Gonorrhoea" data-id="CD007961-fig-0008" src="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/image_n/nCD007961-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/image_t/tCD007961-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Topical microbicide versus placebo ‐ dichotomous data, Outcome 5: Gonorrhoea</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/references#CD007961-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/image_n/nCD007961-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007961-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/urn:x-wiley:14651858:media:CD007961:CD007961-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Topical microbicide versus placebo ‐ dichotomous data, Outcome 6: Chlamydia" data-id="CD007961-fig-0009" src="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/image_n/nCD007961-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/image_t/tCD007961-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Topical microbicide versus placebo ‐ dichotomous data, Outcome 6: Chlamydia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/references#CD007961-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/image_n/nCD007961-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007961-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/urn:x-wiley:14651858:media:CD007961:CD007961-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Topical microbicide versus placebo ‐ dichotomous data, Outcome 7: Syphilis" data-id="CD007961-fig-0010" src="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/image_n/nCD007961-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/image_t/tCD007961-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Topical microbicide versus placebo ‐ dichotomous data, Outcome 7: Syphilis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/references#CD007961-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/image_n/nCD007961-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007961-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/urn:x-wiley:14651858:media:CD007961:CD007961-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Topical microbicide versus placebo ‐ dichotomous data, Outcome 8: Trichomoniasis" data-id="CD007961-fig-0011" src="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/image_n/nCD007961-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/image_t/tCD007961-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Topical microbicide versus placebo ‐ dichotomous data, Outcome 8: Trichomoniasis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/references#CD007961-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/image_n/nCD007961-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007961-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/urn:x-wiley:14651858:media:CD007961:CD007961-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Topical microbicide versus placebo ‐ dichotomous data, Outcome 9: Serious Adverse Events" data-id="CD007961-fig-0012" src="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/image_n/nCD007961-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/image_t/tCD007961-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Topical microbicide versus placebo ‐ dichotomous data, Outcome 9: Serious Adverse Events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/references#CD007961-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/media/CDSR/CD007961/image_n/nCD007961-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD007961-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Dapivirine vaginal microbicide for preventing sexually transmitted infections</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Topical microbicides for preventing sexually transmitted infections</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Population:</b> heterosexual women<br/><b>Settings:</b> Local clinics and community based locations in Malawi, South Africa, Uganda, and Zimbabwe (1 study) and South Africa and Uganda (1 study)<br/><b>Intervention:</b> dapivirine vaginal microbicide rings<br/><b>Comparison:</b> identical placebo rings </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty </b>of the evidence<br/>(GRADE) </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Dapivirine</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HIV infection</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>78 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>55 per 1000</b> </p> <p>(44 to 69)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.71</b> </p> <p>(0.57 to 0.89)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4588<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Herpes simplex virus</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Data not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The dapivirine studies did not screen for herpes simplex virus</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gonorrhoea</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>153 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>153 per 1000</b> </p> <p>(133 to 175)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b> <br/>(0.87 to 1.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4588<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>1,2</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trichomoniasis</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>144 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>153 per 1000</b> </p> <p>(133 to 177)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.06</b> </p> <p>(0.92 to 1.23)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4588<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Chlamydia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>293 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>285 per 1000</b> </p> <p>(261 to 314)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.97</b> </p> <p>(0.89 to 1.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4588</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>moderate</b><sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Syphilis</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>8 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>13 per 1000</b> </p> <p>(5 to 35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.70</b> </p> <p>(0.63 to 4.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1956</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>low<sup>3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>110 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>123 per 1000</b> </p> <p>(103 to 145)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.12</b> </p> <p>(0.94 to 1.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4588<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceptability</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>No study reported this outcome in a form that could be put in a forest plot</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Minor adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>No study reported this outcome in a form that could be put in a forest plot</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the risk in the placebo group is the median risk across control groups of the included studies. The corresponding risk for dapivirine (and its 95% confidence interval) is based on the median risk in the dapivirine group and the risk ratio of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by one level for imprecision, due to lack of optimal information size.<br/><sup>2</sup> Downgraded by one level for inconsistency: I<sup>2</sup> = 62% (gonorrhoea), I<sup>2</sup> = 87% (serious adverse events)<br/><sup>3</sup> Downgraded by two levels for substantial imprecision. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Dapivirine vaginal microbicide for preventing sexually transmitted infections</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/full#CD007961-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007961-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Tenofovir vaginal microbicide for preventing sexually transmitted infections</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Topical microbicides for preventing sexually transmitted infections</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Population:</b> Heterosexual women<br/><b>Settings:</b> Community clinics in South Africa (2 studies), Uganda and Zimbabwe (1 study)<br/><b>Intervention:</b> Tenofovir vaginal microbicide gels<br/><b>Comparison:</b> Identical placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty </b>of the evidence<br/>(GRADE) </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Tenofovir</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HIV infection</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>78 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>64 per 1000</b> </p> <p>(53 to 79)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.83</b> </p> <p>(0.68 to 1.02)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4958<br/>(3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Herpes simplex virus</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>426 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>384 per 1000</b> </p> <p>(350 to 422)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.90</b> </p> <p>(0.82 to 0.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2439<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>low</b><sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Gonorrhoea</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>48 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>24 per 1000</b> </p> <p>(14 to 39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.66</b> </p> <p>(0.40 to 1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2010<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>low<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trichomoniasis</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>51 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>62 per 1000</b> </p> <p>(43 to 64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.21</b> </p> <p>(0.84, 1.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2010<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Chlamydia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>129 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>116 per 1000</b> </p> <p>(22 to 145)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.90</b> </p> <p>(0.71 to 1.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2010<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Syphilis</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>11 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>14 per 1000</b> </p> <p><b>(6 to 30)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.27</b> </p> <p>(0.58 to 2.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2010<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>63 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>63 per 1000</b> </p> <p>(51 to 78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.00</b> </p> <p>(0.81 to 1.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4958<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝</p> <p><b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceptability</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>No study reported this outcome in a form that could be put in a forest plot</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Minor adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>No study reported this outcome in a form that could be put in a forest plot</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the risk in the placebo group is the median risk across control groups of the included studies. The corresponding risk for tenofovir (and its 95% confidence interval) is based on the median risk in the tenofovir group and the risk ratio of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by two levels for substantial imprecision, due to lack of optimal information size.<br/><sup>2</sup> Downgraded by two levels for substantial inconsistency: I<sup>2</sup> = 85%. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Tenofovir vaginal microbicide for preventing sexually transmitted infections</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/full#CD007961-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007961-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Cellulose sulphate vaginal microbicide for preventing sexually transmitted infections</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Topical microbicide for preventing sexually transmitted infections</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> Heterosexual women </p> <p><b>Settings:</b> Community clinics Nigeria (1 study), South Africa, Uganda, Benin and India (1 study) </p> <p><b>Intervention:</b> Cellulose sulphate vaginal gel </p> <p><b>Comparison:</b> Identical placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty </b>of the evidence<br/>(GRADE) </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Cellulose sulphate</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>HIV Infection</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>19 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>23 per 1000</b> </p> <p>(14 to 37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.2</b> </p> <p>(0.74 to 1.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3069<br/>(2 studies </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>low<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Herpes simplex</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>11 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>11 per 1000</b><br/>(4 to 30) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.99</b> </p> <p>(0.37 to 2.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1425<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>low<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Gonorrhoea</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>66 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>59 per 1000</b><br/>(44 to 77) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.89</b> <br/>(0.67 to 1.17) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3069<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/><b>very low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trichomoniasis</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>55 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>53 per 1000</b><br/>(34 to 82) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.96</b> <br/>(0.62 to 1.49) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1425<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Chlamydia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>48 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>34 per 1000</b><br/>(24 to 48) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.70</b> <br/>(0.49 to 0.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3069<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>low<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Syphilis</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>14 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>10 per 1000</b><br/>(4 to 26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.69</b> <br/>(0.26 to 1.81) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1425<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>low<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>33 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>42 per 1000</b> </p> <p>(29 to 60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.25</b> </p> <p>(0.87 to 1.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3069<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceptability</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>No study reported this outcome in a form that could be put in a forest plot</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Minor adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>No study reported this outcome in a form that could be put in a forest plot</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the risk in the placebo group is the median risk across control groups of the included studies. The corresponding risk for cellulose sulphate (and its 95% confidence interval) is based on the median risk in the cellulose sulphate group and the risk ratio of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by two levels for substantial imprecision, due to lack of optimal information size<br/><sup>2</sup> Downgraded by one level for inconsistency: I<sup>2</sup> = 50% </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Cellulose sulphate vaginal microbicide for preventing sexually transmitted infections</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/full#CD007961-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007961-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary table with the description of included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Outcome</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD007961-bbs2-0001" title="Abdool KarimQ , Abdool KarimSS , FrohlichJA , GroblerAC , BaxterC , MansoorEL , et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science2010;329(5996):1168-74. Abdool KarimSS , Abdool KarimQ , KharsanyAB , BaxterC , GroblerAC , WernerL . Tenofovir gel for the prevention of herpes simplex virus type 2 infection. New England Journal of Medicine 20152015;373(6):530-9. KarimQA , KharsanyAB , FrohlichJA , BaxterC , YendeN , MansoorLE , et al. Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials2011;12:67. KellerDM . AIDS 2010, XVIII International AIDS Conference: Tenofovir vaginal gel first microbicide to prevent HIV, HSV infections. Medscape Medical News July 2010. "><b>Abdool Karim 2010</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>889 women</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tenofovir gel</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo gel</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV, HSV‐2, HPV, Adverse events</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD007961-bbs2-0002" title="Abdool KarimSS , RichardsonBA , RamjeeG , HoffmanIF , ChirenjeZM , TahaT , et al. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS2011;25(7):957-66. GuffeyMB , RichardsonB , HusnikM , MakananiB , ChilongoziD , YuE , et al. HPTN 035 Phase II/IIb Randomized safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in women. Sexually Transmitted Infections2014;90(5):1-15. "><b>Abdool Karim 2011</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3101 women</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Buffergel</p> <p>0.5% PRO 2000 gel</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo gel</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV, Chlamydia, Gonorrhoea, Trichomoniasis, HSV‐2</p> <p>Adverse events</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD007961-bbs2-0003" title="BaetenJM , Palanee-PhillipsT , BrownER , SchwartzK , Soto-TorresLE , GovenderV , et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. New England Journal of Medicine2016;375(22):2121-32. MTN 2016. Dapivirine vaginal ring helped protect women against HIV in ASPIRE Phase lll trial. Media release. "><b>Baeten 2016</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2629 women</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dapivirine ring</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo ring</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐1, Gonorrhoea, Trichomoniasis, Chlamydia, Adverse events</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD007961-bbs2-0005" title="FeldblumPJ , AdeigaA , BakareR , WevillS , LendvayA , ObadakiF , et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomised controlled trial in Nigeria. PLoS One2008;3(1):e1474. "><b>Feldblum 2008</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2153 women</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAVVY gel</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo gel</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV, Adverse events</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD007961-bbs2-0006" title="HalpernV , OgunsolaF , ObungeO , WangCH , OnyejepuN , OduyeboO , et al. Effectiveness of cellulose sulphate vaginal gel for the prevention of HIV infection: results of a phase III trial in Nigeria. PLoS One2008;3(11):e3784. "><b>Halpern 2008</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1644 women</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cellulose sulphate gel</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo gel</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV, Gonorrhoea, Chlamydia, Adverse events</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD007961-bbs2-0007" title="MarrazzoJM , RamjeeG , RichardsonBA , GomezK , MgodiN , NairG , et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. New England Journal of Medicine2015;372(6):509-17. "><b>Marrazzo 2015</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2010 women</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tenofovir gel</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo gel</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV, HSV, Gonorrhoea, Chlamydia, Syphilis, Trichomoniasis, Adverse events</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD007961-bbs2-0009" title="NelA , Van NiekerkN , KapigaS , BekkerLG , GamaC , GillK . Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. New England Journal of Medicine2016;375(22):2133-45. "><b>Nel 2016</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1959 women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dapivirine ring</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo ring</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HIV, Gonorrhoea, Chlamydia, Syphilis, Trichomoniasis, Adverse events</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD007961-bbs2-0008" title="McCormackS , RamjeeG , KamaliA , ReesH , CrookAM , GafosM , et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet2010;376(9749):1329-37. "><b>McCormack 2010</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9385 women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2% PRO 2000 gel</p> <p>0.5% PRO 2000 gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HIV, HSV, Gonorrhoea, Chlamydia</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD007961-bbs2-0010" title="PetersonL , NandaK , OpokuBK , AmpofoWK , Owusu-AmoakoM , BoakyeAY , et al. SAVVY (C31G) gel for prevention of HIV infection in women: a phase 3, double-blind, randomised, placebo-controlled trial in Ghana. PLoS One2007;2(12):e1312. "><b>Peterson 2007</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2142 women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SAVVY gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HIV, Adverse events</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD007961-bbs2-0004" title="Delany-MoretlweS , LombardC , BaronD , BekkerLG , NkalaB , Ahmed K et al. Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised,double-blind, placebo-controlled trial. The Lancet Infectious Diseases2018;18(11):1241-50. ReesHS , SineadA , Delany- MoretiwaS , BaronD , PachiaR , et al. In: FACTS 001 Phase III Trial of Pericoital Tenofovir 1% Gel for HIV Prevention in Women.The 22nd Conference on Retroviruses and Opportunistic Infections;2015 Feb 23-26; Seattle Washington. 2015. "><b>Delany‐Moretlwe 2018</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2059 women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tenofovir gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HIV, HSV, Adverse events</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD007961-bbs2-0011" title="MaraisD , GawareckiD , AllanB , AhmedK , AltiniL , CassimN , et al. The effectiveness of Carraguard, a vaginal microbicide, in protecting women against high-risk human papillomavirus infection. Antiviral Therapy2011;16(8):1219-26. Skoler-KarpoffS , RamjeeG , AhmedK , AltiniL , PlagianosMG , FriedlandB , et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9654):1977-87. "><b>Skoler‐Karpoff 2008</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6202 women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Carraguard gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HIV, Gonorrhoea, Chlamydia, Syphilis, Trichomoniasis, Adverse events</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD007961-bbs2-0012" title="Van DammeL , GovindenR , MirembeFM , GuédouF , SolomonS , BeckerML , et al. Lack of effectiveness of cellulose sulphate gel for the prevention of vaginal HIV transmission. New England Journal of Medicine2008;359(5):463-73. "><b>Van Damme 2008</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1428 women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cellulose sulphate gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HIV, HSV, Gonorrhoea, Chlamydia, Syphilis, Condyloma, Trichomoniasis</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary table with the description of included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/full#CD007961-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007961-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Topical microbicide versus placebo ‐ dichotomous data</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 HIV <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Herpes simplex <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Tenofovir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2439</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.82, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Cellulose sulphate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1425</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.37, 2.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 PRO 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6651</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.73, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Condyloma acuminatum <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Cellulose sulphate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 High‐risk HPV <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Gonorrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Carraguard</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.88, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Cellulose sulphate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3069</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.67, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.3 PRO 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.87, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.4 BufferGel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1546</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.51, 1.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.5 Tenofovir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.40, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.6 Dapivirine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4586</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.87, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Chlamydia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Cellulose sulphate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3069</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.49, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 BufferGel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1546</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.65, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.3 Carraguard</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.83, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.4 Dapirivine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4586</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.89, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.5 PRO 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.84, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.6 Tenofovir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.71, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Syphilis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Carraguard</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.75, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 Cellulose sulphate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1425</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.26, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.3 Dapivirine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1956</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [0.63, 4.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.4 Tenofovir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.58, 2.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Trichomoniasis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 Dapivirine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4588</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.92, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 BufferGel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1546</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.80, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.3 Carraguard</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.72, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.4 Cellulose sulphate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1425</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.62, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.5 PRO 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1546</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.99, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.6 Tenofovir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.84, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Serious Adverse Events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 Dapivirine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4588</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.94, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 Tenofovir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4958</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.81, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.3 BufferGel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1546</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.81, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.4 Carraguard</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.67, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.5 Cellulose sulphate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3069</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.87, 1.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.6 PRO 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.96, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.7 SAVVY</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.79, 2.35]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Topical microbicide versus placebo ‐ dichotomous data</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007961.pub3/references#CD007961-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD007961.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD007961-note-0013">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD007961-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD007961-note-0012">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD007961-note-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD007961-note-0009">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD007961-note-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD007961-note-0006">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD007961-note-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD007961-note-0005">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007961\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007961\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007961\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007961\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007961\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007961\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007961\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007961\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007961\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007961\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007961\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007961\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007961\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007961\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007961\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007961\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007961\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007961\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=kKvAiZoF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007961.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007961.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD007961.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD007961.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007961.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717556422"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007961.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717556426"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007961.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dbad05c889371',t:'MTc0MDcxNzU1Ny4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 